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Abstract 
This study compares the effectiveness of primary care interventions provided by 
general practitioners (GP) remunerated under the fee-for-service (FFS) or alternative 
payment plan (APP), using hospitalization rates for ambulatory care sensitive conditions 
(ACSC) in select Northern British Columbia (BC) communities. This study used BC 
Ministry of Health hospital separation data held at Population Data BC. Bivariate statistics 
were used to compare hospitalization rates for ACSC between both groups. The results 
indicate overall hospitalization rates of ACSC were higher in APP than FFS communities. 
Further, several ACSC showed varying hospitalization rates (asthma, pneumonia, COPD, 
diabetes, angina, gastroenteritis/dehydration and convulsion/epilepsy) and length of 
hospitalizations (convulsion/epilepsy and dental conditions) between both groups. In 
summary, this research informs policy on the effectiveness of GP remuneration adopted in 
Northern BC using hospitalization rates for ACSC. Further research is needed to further 
validate the findings of this study. 
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Chapter One: Introduction 
Universal access to medically necessary care remains one of the chief principles of a 
publicly funded health care system. In the Canadian health care system, the general 
practitioner (GP) acts as the gate keeper charged with coordinating and providing 
longitudinal relational care (Brown, Goldacre, Hicks Rourke, McMurray, Brown et al., 2001; 
Fleming, 1995). In Canada, the GP is the cornerstone of primary care and they work both 
independently and in group practices (Holden & Madore, 2002). This system has been 
practiced since the 1970s in most Canadian provinces (Health Canada, 2005). Currently 
however, the cost of this system is exceeding available resources (Fujisawa & Lafortune, 
2008; Lee et al., 1999). Escalating care costs and modes of remunerating physicians 
continues to be a key policy challenge in the Canadian health care system (Xu & Yu 2003). 
The primary care physician is an important component of the health care system in 
Canada. The payment of general practitioners (GPs) is one of the largest drivers of health 
service cost (Fujisawa & Lafortune, 2008). Hence, reforms of both GP practice approaches 
and payment schemes have occurred in several countries, (Scott & Hall, 1995). Despite 
these reforms, there is only modest empirical evidence about the impact of GP remuneration 
plans on GP performance, patient health outcomes and the overall cost of care. This evidence 
is paramount since it is an indicator of the effectiveness of the health care system (Scott & 
Hall, 1995). 
Over the past decade, several GP payment schemes have been adopted in Canada (Xu 
& Yu, 2003). The two most prominent payment schemes adopted for GPs are the alternative 
payment plan (APP), which is payment by contract, salary or capitation and the fee-for-
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service (FFS) plan, where GPs are compensated for each unit of service according to a 
provincially bargained fee schedule (Matthew & Lockhart 2003; Holden & Madore, 2002). 
The FFS payment is the most predominant form of payment for GP: the Canadian Institute 
for Health Information (CIHI) reported that approximately eighty percent of family 
physicians in 2004 received payment by FFS and approximately twenty percent received 
payment alternatively, i.e., salary, capitation, and contract (CIHI, 2005). Further, with the 
increasing criticism of the FFS remuneration for GP particularly with regards the objectives 
of the health care system such as improved outcomes for patients, improved provider 
satisfaction, and decreased costs (Berwick, Nolan & Whittington 2008; Beasley, 2009), 
health care policy makers in Canadian provinces have implemented several forms of 
alternative payment methods for GPs, such as salaries and mixed payment method (Wranik 
& Durier-Copp, 2010). Moreover, the government and policy makers seem to believe that 
having an alternative remuneration will tackle these challenges as well as encourage more 
GPs to become involved in primary health care reform (Martin & Hogg, 2004). 
The alternative remuneration schemes for GPs are also not devoid of criticisms, as 
several studies have highlighted their disadvantages, such as under servicing and loss of 
physician autonomy (Devlin & Sarma, 2008; Holden & Madore, 2002; Xu & Yu, 2003; Lee 
et al., 1999). Thus, an effective remuneration scheme for GP should be focused on improving 
access to care, quality, integration, health outcomes and decrease cost.. Additionally, 
reforming the method of payment could have a significant potential to modify the focus of 
primary health service delivery and potentially, patient outcomes. 
Opportune access to primary care is an important indicator for an effective health 
care system (Shah, Gunraj & Hux, 2003). The gauging of such access to care is dependent on 
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the individual or community health profile and the organization of health delivery system 
(Shah et al., 2003). One marker for gauging this access to care is to evaluate the 
hospitalizations for medical conditions that could have been prevented or effectively 
managed in an outpatient ambulatory setting. These medical conditions are known as 
ambulatory care sensitive conditions (ACSC), and consists of asthma, hypertension, diabetes, 
congestive heart failure, chronic obstructive pulmonary disease (COPD) etc (Shah et al., 
2003; Billings, Zeitel, Lukomnik, Carey, Blank & Newman, 1993; Pappas, Hadden, Korak 
& Fisher, 1997; Bindman, Grumbach, Osmond, Komaromy, Vranizan, Karen et al., 1995; 
Ansari, Laditka, Laditka, 2006; Rizza, Bianco, Pavia & Angelillo, 2007; Chen, Zhang, Sun 
& Mueller, 2009; Gao, Manns, Culleton, Tonelli, Quan, Crowshoe et al., 2008; Blustein, 
Hanson & Shea, 1998). Thus hospitalizations for these diagnoses that are best treated in 
primary health care settings are one indicator of access to or quality of care. 
Disparities in ACSC hospitalizations can be used to evaluate health system 
performance, quality of care and inform policy development (Brown et al., 2001; Ricketts, 
Randolph, Howard, Pathman, & Carey, 2001). Hospitalization for ACSC are considered as 
potentially avoidable, since because hospitalization may be prevented with timely and 
opportune access to primary care, however, less likely to be considered as 'inappropriate' 
since not all hospitalizations are avoidable (Brown et al., 2001; Lavoie, Forget, Prakash, 
Dahl, Martens & O'Neil, 2010; Starfield, Shi, Macinko, 2005; Parker, Simon, Parham, 
Teague & Li, 2005). 
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Conceptual Framework 
The purpose of this study was to explore the differences in rates of hospitalizations 
for ACSC in select communities where GPs are remunerated either by FFS or APP. I 
acknowledge that not all hospitalizations are avoidable (Starfield et al., 2005; Lavoie et al. 
2010), however, timely and effective access to and quality of primary care and intervention 
may prevent hospitalizations for these conditions (Lavoie et al., 2010). Thus, an effective GP 
remuneration plan can be defined conceptually as a remuneration plan that translates into 
better health outcomes, lower cost and improved physician satisfaction. Figure 1 below 
illustrates this correlation and outlines the conceptual model upon which this thesis is based. 
Research Objectives 
The purpose of this study was to explore the impact of two GP payment schemes 
(fee-for-service or alternative payment plans) on the quality of primary care interventions by 
comparing the rates of avoidable hospitalization for ACSC in eight communities (McBride, 
Fraser Lake, Valemount, Queen Charlotte, Prince Rupert, Stewart, Smithers, and Tumbler 
Ridge), where GPs are remunerated exclusively with FFS or APP. These communities were 
chosen because comparing ACSC hospitalization rates at a community level using GP 
remuneration was possible, since GPs are remunerated either by the FFS or APP. Moreover, 
research indicates that ACSC hospitalization rates are generally higher in individuals living 
in rural communities. Specifically, I will ascertain whether or not rates of avoidable 
hospitalization for ACSC are higher in communities where a GP is remunerated by FFS in 
comparison to communities where a GP receives payment through the APP. Additionally, the 
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study will also explore trends in rates of avoidable hospitalization for ACSC in either and 
both types of communities. 
Objective and Hypotheses 
The objective of this study was to test the following hypotheses: 
La To compare rates of avoidable hospitalization for ACSC between communities served by 
GPs remunerated on a FFS payment plan and APP. 
HI a: There is no difference in the rates of avoidable hospitalization for ACSC between 
communities with FFS payment plan and APP for the general practitioner. 
Lb To compare rates of hospitalization for diagnoses classified as ACSC between APP 
communities and FFS communities. 
Hlb: There is no difference in rates of hospitalization for diagnosis classified as ACSC in 
APP communities and FFS communities. 
2.a To examine (descriptive only) trends in rates of hospitalization for ACSC between 
communities served by GPs remunerated on a FFS payment plan and APP. 
H2a: There is no difference in trends in rates of avoidable hospitalization for ACSC between 
communities with FFS payment plan and APP for the general practitioner. 
3.a To compare length of hospitalization of diagnoses classified as ACSC between 
communities with FFS payment plan and APP plans for the general practitioner. 
H3a: There is no difference in length of hospitalizations of diagnoses classified as ACSC 
between communities with FFS payment plan and APP plans for the general practitioner. 
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Significance 
This study was poised to make a significant contribution to knowledge and policy. 
First, the study design is innovative and will bring evidence to an important question: how to 
best provide payment for GP services. Second, the result of the study will provide 
information relevant to curtailing the cost of hospitalization for conditions sensitive to the 
provision of effective PHC. Reducing the rate of ACSC hospitalization can improve patient 
outcomes, preserve health care dollars and improve service delivery in ambulatory setting. 
For example, Kruzikas and colleagues hypothesized that, "assuming that an average hospital 
stay costs $5,300 per admission, even a modest five percent decrease in hospitalizations for 
this ambulatory care sensitive conditions would save more than $1.3 billion in inpatient cost" 
(Kruzikas, Jiang, Remus, Barrett, Coffey & Andrews, 2004 ). Third, this study will 
contribute to the evaluation of access to and quality of primary care system and health care 
services in the communities studied (Chen et al., 2009). 
This thesis is organized into five chapters. The next section of the thesis reviews the 
existing literature on the GP remuneration plans and primary care intervention. The approach 
used to define ACSC is described and analysed. Findings related to GP remuneration and 
rates in avoidable hospitalization for ACSC and the overall hospitalization are summarized. 
This review of literature is followed by a description of the method used in analysis and a 
presentation of results from each GP remuneration plan at the community level. Finally a 
discussion of the research finding and implications will be described. 
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Payment Plan Characteristics 
Fee-For-Service 
- Increases physician autonomy 
- High service volume 
-Limited access for sicker less 
able patients 
-Encourage quick, frequent 
service 
- Over service 
Alternative Payment Plans 
- Increase physician patient 
relationship 
- Better cost control 
- Eliminate over service 
- Under servicing 
- Loss physician autonomy 
Lesson from Literature Innovation Measure of 
Performance 
\ 
f Quantity of service 
Cost 
I Quality of service A 
Avoidable 
hospitalization 
forACSC 
Is there a difference"? 
I Quantity of service 
t Saving 
1" Quality of service 
V Avoidable 
hospitalization 
for ACSC 
Figure J. Conceptual model for comparison of general practitioner remunerations. 
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Chapter Two: Literature Review 
The Canadian health care system continues to evolve in the range of health care 
services provided and user demands (Pfaff, Guerriero, Martalog, Arscott, Fontaine & 
Laforet, 2009). These changes have impacted GP practice as well as their perspectives on 
quality of care (Lepnurm, Dobson & Backman & Keegan, 2006). The primary care system 
has formed the bedrock of the Canadian health care system; a vibrant primary health system 
has been shown to correlate with a healthy and productive population (Katz, Soodeen, 
Bogdanovic, De Coster & Chateau, 2006). 
In Canada, the primary health care delivery system is built around the GP playing a 
central role as the front line practitioner within the health care system. The ageing 
population, together with the increasing rates of chronic disease, indicate that a growing 
number of patients are in need of a high level care provided in a more comprehensive, 
longitudinal and accessible setting. This generates an additional burden on the health care 
system, as demonstrated in the number of hospitalizations that are preventable (Sanchez, 
Vellanky, Herring, Liang & Jia, 2008). Thus, implementing adequate and effective incentives 
for GPs to be productive and provide quality care is pivotal to the challenges of the primary 
health care system. 
The literature review reported in this Chapter has been organized into three sections. 
First, I will discuss GP remuneration plans including advantages and disadvantages to the 
health care system. Second, I will discuss and outline the significance of primary care 
intervention to the health care system. Third, I will discuss researchers' efforts to clarify and 
define the concept of avoidable hospitalization for ambulatory care sensitive conditions. 
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A literature search was undertaken using CINAHL and Medline databases. CINAHL 
(1990 - July 2010) search terms included, "general practitioner remuneration plans", 
"primary care intervention", "ambulatory care sensitive conditions", "primary health care", 
"fee-for-service payment plan" and "alternative payment plan" and resulted in 853 articles. 
The MEDLINE (1996 - July 2009) search included the MESH terms "primary care 
intervention", "general practitioner remuneration plan" and "ambulatory care sensitive 
conditions" and resulted in 705 articles. All abstracts were reviewed and all articles with a 
declared focus on GP remuneration plans, ambulatory care sensitive conditions, and primary 
care intervention were retrieved. Published bibliographies and web sites of Canadian 
professional associations and organizations were also utilized to identify additional relevant 
work on GP remuneration plans, ambulatory care sensitive conditions, and primary care 
intervention. 
General Practitioner Remuneration and Incentives 
General practitioner remuneration schemes are central to the health care debate in 
Canada and around the world. Over the past decade, the escalating cost of health care 
services and the drive to sustain the publicly financed health care system (Devlin & Sarma, 
2008; Fujisawa & Lafortune, 2008), particularly with an aging population, has shifted the 
focus of policy makers to the general practitioner remuneration and practice style (Wright, 
1996; Lee, Cowie & Slobodian, 1999; Scott & Hall, 1995). In 2000, CIHI reported that 
approximately 13 billion was spent on physician services, reflecting 13.3% of the overall 
health care cost (CIHI, 2001). In spite of the significant reform initiatives and strategies that 
have been enacted, the question remains how GPs can be adequately reimbursed so it 
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translates into improved outcomes for patients, improved provider satisfaction, and decreased 
costs. 
The OECD countries have adopted a range of remuneration methods for their GPs in 
the private and public sectors. As a result, policy makers in several countries have modified 
their remuneration system for physicians, so as to encourage productivity, as well as to 
contain the cost of care (Simeons & Hurst, 2006). Some OECD countries (Greece, Portugal, 
Spain and Sweden), where health care is financed through taxation, hire GPs directly and 
remunerate by salary, while in others (such as in Australia, Norway, the United Kingdom, 
Denmark, and New Zealand), where GPs are freelance remuneration occurs through 
capitation/blended or salary or fee-for-service (Simeons & Hurst, 2006). GPs in countries 
with an insurance-based system are remunerated mainly through the fee-for-service method, 
such as in Austria, Belgium, France, Germany, Japan, Switzerland, the United States and 
Korea (Simeons & Hurst, 2006). 
Over the past decade, several GP payment schemes have been adopted in Canada (Xu 
& Yu, 2003). A summary of the alternative clinical payment types adopted by the Canadian 
provinces and territories is represented in Table 1, below. The most prominent form of GP 
remuneration in Canada is fee-for-service payments, where GPs are compensated for each 
unit for service according to the bargained fees (Wranik & Durier-Copp, 2010; Holden & 
Madore, 2002; Devlin & Sarma, 2008). There appears to be a move towards the alternative 
payment plans (APP) among physicians, government and regional health authorities as 
shown on Tables 2 and 3, below. Moreover, in British Columbia and Quebec, policy makers 
are increasingly remunerating GP through the alternative methods (Xu & Yu, 2003). CIHI 
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reported that in 2004\2005 approximately 80% of remuneration to family physician was on 
fee-for-service basis (Wranik & Durier-Copp, 2010). 
The other type of GP remuneration is the APP, which includes salary, sessional fees, 
capitation, and blended funding arrangement. Other less common APP payment mechanisms 
include service arrangement (utilized in recruitment and retention of general practitioners in 
rural areas, and may come as contractual payments or the blended payment, i.e., APP and 
FFS); and block funding, where annual budgets are negotiated for a group of general 
practitioners to provide all their medical services for a specific period of time at specific 
sites. This is mainly used in academic medical centre for clinical services, education and 
research (Martin & Hogg, 2004). 
In Canada, the APP remuneration plan accounts for approximately 20% of primary 
care physician's remuneration plan (CIHI, 2008). Regardless of the widespread utilization of 
fee-for service payment, recent assessments particularly among researchers and policy 
makers have shown that the fee-for-service payment is not the most efficient mode of GP 
payment (Wranik & Durier-Copp, 2010; Xu & Yu, 2003). Studies conducted in Ontario and 
Quebec have shown that salaried general practitioners practicing in community health 
centres provide more preventive services than their fee for service counterparts or colleagues. 
These findings are however debatable because they are based on personal perception and a 
low response rates (Lee et al., 1999). 
Several studies have shown that the methods of payment for GPs influences their 
behaviour, the mode of service delivery, quality and cost of health care provided (Gosden, 
Pedersen & Torgerson, 1999; Scott & Hall, 1995). Further, given that efficiency, equity and 
quality are greatly dependent on workers' incentive, an adequate understanding of 
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determinants of physician behavior is essential, in order to carve out appropriate policy to 
guide allocation and incentive (financial) decisions that may improve quality and access to 
care. Thus, an adequate evaluation of GP remuneration on health care service delivery should 
be based on the performance measured in terms of patient health outcomes, patient and 
provider satisfaction, decrease cost and quality of primary physician services. Additionally, 
the quality of primary physician services plays an important role in the utilization and 
effectiveness of specialized health services (Hogg et al. 2007). 
To date, there has been a paucity of research on the influence of the various GP 
remuneration plans with regard to how it translates into better delivery of in primary care 
(Devlin & Sarma, 2008), particularly in Canada where GP remuneration reforms are still in 
their infancy. Hence, this study will be relevant for policy on efficient and effective 
physician remuneration. In the next section will discuss the various GP payment methods 
adopted in Canada. 
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Table 1 
Summary of Alternative Clinical Payment Type by Province and Territory, 2005-2006 
CIHI, 2008 
N.W.T. Y.T. B.C. AB. SASK. MB. ONT. QUE. N.B. N.S. P.E.I. N.L. 
Alternative Payment Types 
Salary Yes - Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes 
Sessional Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes 
Capitation - - - Yes - Yes - - - - -
Block Funding - - - Yes - Yes Yes - Yes - Yes 
Blended - - Yes Yes Yes - Yes - - Yes 
Emergency and on Call - - - Yes - Yes 
Contract/unspecified - Yes Yes Yes Yes - Yes - Yes Yes 
Information collection Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes 
Others - - Yes - - - Yes . . . 
Note. The blank space represents year that data were not submitted. Further, most of the provinces may not have reported on a 
particular payment type/s because the amount of physician receiving remuneration under the plan may be insignificant. 
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Fee-for service (FFS) 
The FFS payment scheme remunerates GPs based on a negotiated rate for each 
individual service they provide to a given patient (Drossos, 2002; Matthew & Lockhart 
2003). Thus the GP makes claims for each unit of service provided to patients from the 
provincial or territorial health insurance plan (Xu & Yu, 2003; Holden & Madore, 2002). 
The general practitioners' gross annual income will be dependent on the number of hours 
worked, patients treated and the varieties of health service provided (Drossos, 2002; Holden 
& Madore, 2002). The FFS payment scheme is implemented in whole or part in several 
OECD member countries. In countries like Japan, Australia, Germany, and Belgium 
physicians are remunerated exclusively under the FFS. Others like Norway and the United 
States have incorporated portions of the FFS scheme in reimbursing physicians (Fujisawa & 
Lafortune, 2008; Holden & Madore, 2002). 
In 2005-2006 fiscal years, the CIHI reported that the "total in-province" FFS payment 
(without payments for services like radiology, laboratory and anaesthesia, as well as 
anaesthesia specialty) to physicians were approximately $10.2 billion, in addition to $248 
million for standardized service delivered (CIHI, 2008). Further, of this $10.2 billion; 
approximately $4.9 billion (48%) and $5.3 billion (52%) accounted for FFS payments to 
general practitioners and specialist respectively. Additionally, of the $248 million for 
standardized services, the general practitioners and specialist received approximately $161 
million (65%) and $87 million (35%) (CIHI, 2008). Furthermore, of the overall $10.2 billion 
for fee-for-service remuneration, Ontario reported $4.3 billion (42%) while combine FFS 
payment of $4.5 billion (44%) was reported in provinces of Alberta, British Columbia and 
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Quebec (CIHI, 2008). Also, consultation and visits accounted for 86.2% of the claims and 
payment to FFS family physician, which is 81.1% of the services provided (CIHI, 2008). 
Table 2 presents a summary FFS remuneration for physicians' method as a 
percentage to all physicians. In British Columbia (BC) 87.5% of physicians, 72.9 in 
Manitoba (MB), 91.5 in Ontario (ONT), 72.1 in Nova Scotia (NS), 81.9 in Prince Edward 
Island (PEI), 97.2 in Alberta (AB), and 80.8 in Quebec (QUE) were remunerated under the 
FFS method in 2000-2001 fiscal year. Conversely, in 2005-2006 fiscal year, 79.6% of 
physicians in BC, 68.7 in MB, 81.6 in ONT, 57.2 in NS, 64.2 in PEI, 87.7 in AB, and 75.9 in 
QUE were remunerated under the fee-for-service method in 2000-2001 fiscal year (CIHI, 
2008). This decline in FFS remuneration for physician in Canadian provinces and territories 
reflects a gradual shift to alternative forms of remuneration for physician. 
There is considerable empirical evidence documenting the merits and the demerits of 
utilizing the FFS approach in remunerating general practitioners. The intrinsic worth of FFS 
will be highlighted in relation to improved patients' outcome and improved provider 
satisfaction, and decreased costs. First, under the FFS, several studies have shown that 
patients cared for under FFS GPs have better access to health care services in comparison to 
patients under the care of a GPs paid under an alternative remuneration (Xu & Yu, 2003; 
Holden & Madore, 2002; Drossos, 2002). Second, several studies have documented that, 
under the FFS, GPs are being paid according to the number of patients treated. Thus the 
amount of patients treated will equate to the amount of income. Consequently, this makes the 
FFS remuneration scheme more enticing to primary care physicians because they tend to 
have control over their net revenue (Holden & Madore, 2002; Drossos, 2002). Third, as 
mentioned previously, GPs under FFS are remunerated based on the number of patients seen 
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and treated. Thus, this creates a compelling incentive for the GPs to provide health care 
services in a more economic and efficient fashion (Holden & Madore, 2002), thereby 
benefiting the healthcare system economically. Finally, the FFS scheme makes it easier for 
government to initiate targeted FFS codes like, health promotion, disease-prevention 
services, and chronic disease management programs (Xu &Yu, 2003). 
On the other hand, the demerits of FFS remuneration for the general practitioner are 
also well documented in the literature. Firstly, GPs are remunerated according the number of 
patients treated. Thus this may provide GPs with a financial incentive to opt for procedure-
oriented specialty and reject engaging in non-billable services, such as using fewer expensive 
sources of care and patients consultation (Matthew & Lockhart 2003). These conclusions 
were echoed by Holden and Madore (2002) who reported that GPs under the FFS 
remuneration scheme over-strain the health care system with unnecessarily expensive 
procedures on the grounds that they have the propensity to pay better. The fees may also 
vary depending on the kind of service delivered; thus, there is an incentive to deliver more 
services so as to increase income (Gosden et al 2001; Devlin & Sarma, 2008; Xu & Yu, 
2003; Holden & Madore, 2002). As a result, incentive-driven services may result in 'supplier 
induced demand' (SID), where patients are over treated (Gosden et al., 2001; Drossos, 2002), 
hence, increasing the overall health care cost (Xu & Yu, 2003). 
Consequently, uncontrolled health care cost as a result of GPs budgetary cost has 
made it difficult for health authorities to curb the overall cost of health care and the impact 
on the health system (Holden & Madore, 2002). In Canada, the uncontrollable FFS 
expenditure has resulted in five Canadian provinces (British Columbia, Manitoba, Ontario, 
Quebec and Saskatchewan) incorporating some cost containment strategies like placing a 
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ceiling on the maximum number and kind of services a FFS physician can claim in a fiscal 
year (Xu & Yu, 2003). Similarly, this same cost containment strategy is being implemented 
in Germany and has been proven effective (Fujisawa & Lafortune, 2008). 
Another demerit of the FFS payment plan documented in the literature is that, given 
visit-time limitations, GPs under the FFS are remunerated on the basis of the number of 
patients seen or treated, i.e., incentivized to provide a more frequent and quicker services 
(Holden & Madore, 2002). Thus patients have insufficient visit-time with the GP, 
particularly among elderly patients with complex morbidities. As a result, elderly and sicker 
patients may be discriminated against or denied access to quality care (Xu & Yu, 2003; 
Drossos, 2002). 
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Table 2 
Physicians' Fee-for-service Remuneration Method as a percentage of all Payment to all Physicians 
CIHI, 2008 
N.W.T. Y.T. B.C. AB. SASK. MB. ONT. QUE. N.B. N.S. P.E.I. N.L. 
Fiscal Year 
2000-2001 - - 87.5 97.2 78 72.9 91.5 80.8 83.5 72.1 81.9 67.6 
2001-2002 - 95.3 82.5 93.2 75.8 72 88.1 78.7 82 69.8 81.9 60.7 
2002-2003 - 92 80.8 91.3 72.9 70.5 88.5 78.1 81.5 68.4 75 57.8 
2003-2004 2.6 88.5 80.3 90.9 74.1 70.1 84.0 77 77.9 64.3 69.5 58.2 
2004-2005 5.6 83.7 80.1 89.2 73.6 70.4 83.2 76.1 76.3 58.5 66.9 58.8 
2005-2006 3.9 84 79.6 87.7 74.1 68.7 81.6 75.9 74.7 57.2 64.2 62 
Note. The blank space represents year that data were not submitted. Further, most of the provinces may not have reported on a 
particular payment type/s because the amount of physician receiving remuneration under the plan may be insignificant. 
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Table 3 
Physicians' Alternative Remuneration Method as a percentage of all Payment to all Physicians 
CIHI, 2008 
N.W.T. Y.T. B.C. AB. SASK. MB. ONT. QUE. N.B. N.S. P.E.I. N.L. 
Fiscal Year 
2000-2001 
2001-2002 
2002-2003 
2003-2004 
2004-2005 
2005-2006 
4.7 
97.4 8 
94.4 11.5 
94.4 16.3 
96.1 16 
12.5 2.8 
17.5 6.8 
19.2 8.7 
19.7 9.1 
19.9 10.8 
20.4 12.3 
22 27.1 
24.2 28 
27.1 29.5 
25.9 29.9 
26.4 29.6 
25.9 31.3 
8.5 19.1 
11.9 21.3 
11.5 21.9 
16 23 
16.8 23.9 
18.4 24.1 
16.5 27.9 
18 30.2 
18.5 31.6 
22.1 35.7 
23.7 41.5 
25.3 42.8 
18.1 32.3 
18.1 39.3 
25 42.2 
30.5 41.8 
33.1 41.2 
35.8 38 
Note. The blank space represents year that data were not submitted. Further, most of the provinces may not have reported on a 
particular payment type/s because the amount of physician receiving remuneration under the plan may be insignificant. 
Alternative payment plan (APP) 
The escalating health care cost and the increasing aging population creates a 
significant challenge to the sustainability of the health care delivery system, particularly the 
publicly funded system (Delvin & Sarma, 2008; Hurst, Forde, Reiter-Theil, Slowther, Perrier 
& Pegoraro et al., 2007). Consequently, several industrialized countries have reformed or are 
in the process of reforming, their health care delivery system as a result of budgetary 
constraints (Delvin & Sarma, 2008), focusing particularly on the mode of physician 
remuneration. In contrast to the fee-for-service, the most predominant mechanism of 
payment for general practitioners, quite a number of alternative payment mechanisms are 
also being employed. In 2005-2006, CIHI reported that the overall payments made to 
physician through the alternative payment mechanism was approximately $2.98 billion, 
representative of 21.3% of the overall payments made to physicians for clinical services in 
Canada (CIHI, 2008). Further, over the previous six years the overall expenditure for 
alternative payments to physician for clinical services increased significantly, from $1.31 
billion (13.0%) in 2000-2001 to $2.98 billion (20.3%) in 2005-2006 (CIHI, 2008). 
From Table 3, a summary of physicians' alternative remuneration method as a 
percentage of all payment to all physicians showed that, 12.5% of physicians in BC, 27.1 in 
MB, 8.5 in ONT, 27.9 in NS, 18.1 in PEI, 2.8 in AB, and 19.1 in QUE were remunerated 
under the alternative method in 2000-2001 fiscal year. Conversely, in 2005-2006 fiscal year, 
the proportion of alternative payment mechanism varied substantially across province in 
Canada, ranging from 96.1% in Northwest Territories to 42.8% in NS, 38.0% in NL, 35.8% 
in PEI, 31.3% in MB to 25.9% in SASK, 25.3% in NB, 24.1% in QUE, 20.4% in BC, 18.4% 
in ONT, 16.0% in the YT and 12.3% in AB (CIHI, 2008). 
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A review of academic and grey literature on alternative remuneration plans for GPs 
demonstrated that there are merits and demerits of remunerating physicians through this 
mechanism. Thus, in evaluating Alternative Payment Plans, I will focus on four most widely 
used alternative remuneration plans, i.e., salary, capitation, sessional fees and blended 
remuneration mechanism. 
Salary remuneration mechanism. 
The salary remuneration mechanism is a defined payment to the GPs negotiated 
annually between the physician and the government, regardless of the volume of services 
executed (Wranik & Durier-Copp, 2010; Xu & Yu, 2003; Fujisawa & Lafortune, 2008; 
Holden & Madore, 2002). Thus, under the salary remuneration mechanism, services are 
impartial since it is independent of the amount or cost of services provided (Xu & Yu, 2003). 
Moreover, GPs negotiate their salaries and enjoy certain additional benefits (Wranik & 
Durier-Copp, 2010), that can be adjusted based on seniority and promotions (Holden & 
Madore, 2002). The salary is a predominant form of remuneration for GP in a number of 
OECD countries, including Iceland, Finland (Fujisawa & Lafortune, 2008), Sweden and 
France (Holden & Madore, 2002). This is due to the fact that GPs in these countries are 
employees of the public health authority, giving the public sector a significant role (Fujisawa 
& Lafortune, 2008; Holden & Madore, 2002). Traditionally, most GPs under the salary 
remuneration mechanism signed a contract with the ministry or health authority (Wranik & 
Durier-Copp, 2010) and are required to work a specific number of hours per week and most 
often a specific geographical location or population (Wranik & Durier-Copp, 2010). 
The salary remuneration mechanism is operational in all Canadian jurisdictions with 
an intention of curbing the cost of care increasing quantity of services, and improving GP 
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recruitment and retention (Wranik & Durier-Copp, 2010). However, recruitment and 
retention of GPs in rural and remote communities has been difficult (Wranik & Durier-Copp, 
2010). This may be as a result of the inadequate availability of social amenities and general 
living conditions in rural and remote communities (Wranik & Durier-Copp, 2010). Further, 
remunerating GPs practicing in rural and remote via salary rather through capitation or FFS 
plan will boost their retention, since a "low patient base" and sparse population of the rural 
and remote communities may be a major determinant. Therefore APP provides a stable, 
predictable and high income for GPs working in remote and rural communities (Wranik & 
Durier-Copp, 2010). 
There are several advantages associated with the salary remuneration mechanism for 
general practitioners. First, as a corollary to salary remuneration, general practitioners have 
no reason to over-service, prescribe avoidable treatments or visits irrespective of the type or 
level of services provided, contrary to the FFSs mechanism that rewards GP for such 
behaviour (Holden & Madore, 2002; Xu & Yu, 2003). Thus, APP is more likely to result in 
consistency and sureness of services and procedures performed (Holden & Madore, 2002). 
Secondly, the salary remuneration mechanism eradicates any form of financial penalties 
associated with lengthy patient visits under the FFS. Thus, GPs have the liberty to have a 
thorough consultation, thereby promoting more preventive care resulting in improved health 
care outcomes (Holden & Madore, 2002). Third, the salary remuneration mechanism has the 
potential to induce a more efficient use of health care resources (Holden & Madore, 2002; 
Devlin & Sarma, 2008). Since salaried GPs are associated with larger primary care centres 
that utilize a variety of health care providers, health care centres and authorities have the 
potential to effectively distribute patients and responsibilities to their employees in a more 
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efficient and cost-effective approach (Holden & Madore, 2002). Further, this eliminates the 
propensity of'cream-skimming'1 associated with capitation mechanisms and a subjective 
selection with the FFS remuneration mechanism (Xu & Yu, 2003). APP also allows for 
increased consultation with the interdisciplinary team resulting in more comprehensive care 
to patients. 
On the other hand, several studies have identified a number of demerits associated 
with salary remuneration mechanisms for GPs. First, salaried GPs have little incentive to see 
more patients, since salary remuneration is independent to the level of service provided, 
whereas, the FFS remuneration is dependent on the level of services provided (Lee et al., 
1999; Holden & Madore, 2002; Xu & Yu, 2003; Devlin & Sarma, 2008). Many studies have 
demonstrated that salaried practitioners provide fewer services in comparison to GP under 
the FFS remuneration (Xu & Yu, 2003). This may be due to the fact that salaried GP are 
more likely to be working in underserviced or high-need population where comprehensive 
care and more consultation time are required per patient (Tu, Cauch-Dudek & Chen, 2009; 
Delvin, Sarma & Hogg, 2006). Second, salaried GPs have little incentive to retain steady 
patient populations, hence posing a significant challenge for patient-physician relationship 
and continuity of care (Xu & Yu, 2003; Holden & Madore, 2002). This is more prevalent in 
urban areas than rural and remote areas. Third, GPs under the salary remuneration 
1
 'Cream skimming' is a term that refers to "choosing patients for some characteristic(s) 
other than their need for care, which enhances the profitability or reputation of the provider" 
(Friesner & Rosenman, 2009). 
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mechanism may have diminished satisfaction with the health care system, since physician 
autonomy is reduced as a result of more governmental control (Xu & Yu, 2003). Fourth, 
under the salary remuneration mechanism, the supply of medical services and physicians are 
independent of the costs, thus an increase in demand of medical services may result in 
increased wait times (Devlin & Sarma, 2008) and a reduction in the number of patient visits 
may result in increasing the cost of care, i.e., hiring more GPs (Holden & Madore, 2002). 
Finally, under the salary remuneration mechanism, patients may slip through the health care 
system particularly those at the margin, because the hours of operation under the contractual 
arrangement may not correspond with the timing or access the high-need population 
requiring care (Holden & Madore, 2002). 
Capitation remuneration mechanism 
The capitation remuneration mechanism, also known as 'rostering' (Xu & Yu, 2003; 
The College of Family Physician of Canada (CFPC), 2007), is the flat payment to the GP for 
each patient enrolled with them, in return for a commitment that they will provide a basket of 
services to their patients or practice population over a period of time (Fujisawa & Lafortune, 
2008; CFPC, 2007; Gosden, Forland, Kristiansen, Sutton, Leese, Giuffrida et al., 2006; Xu & 
Yu, 2003; Drossos, 2002, Holden & Madore, 2002). This implies that the remuneration of 
GPs is dependent on the number of patients on their list and the level of care provided per 
patient, which is typically negotiated between the health care providers and funders. The 
capitation fee per patient amount is adjusted according to sex, age, and geographical location 
(Fujisawa& Lafortune, 2008; Drossos, 2002; Holden & Madore, 2002). The efficiency of the 
capitation mechanism is dependent on the patients' commitment, meaning that patients must 
be committed to seeking primary care services from a pre-determined GP or group practice 
24 
(Holden & Madore, 2002). This commitment on the patient's part can be done in two ways: 
through a voluntary patient enrolment or propinquity-based registration where patients are 
automatically enlisted or assigned to a particular practice in their region (the latter is 
predominant in rural and remote area) (Holden & Madore, 2002). 
In many industrialized countries like Italy, New Zealand and the Netherlands, 
capitation is the most prominent form of remunerating GPs. In 2007 the College of Family 
Physician of Canada (CFPC) reported that the capitation remuneration mechanism is 
increasingly becoming the preferred mechanism of GP remuneration in Canada. Moreover, 
several health authorities have been directed by provincial and territorial governments to take 
up the responsibility to remunerating general practitioners for the services provided to local 
population. Further, the escalating cost for health care associated with physician 
remuneration has motivated health authorities to seek means of containing the cost of health 
care by budgeting general practitioners remuneration in a rather predictable manner (CFPC, 
2007). Capitation is particularly interesting to health authorities, because health care funding 
is based on need rather than entirely on service utilization (2007). Hence, the capitation is a 
rising method for remunerating general practitioners (Tu et al., 2009; Fujisawa & Lafortune, 
2008). Moreover, newer capitation mechanisms in Canada include financial incentives for 
reaching certain goals for preventive care (Tu et al., 2009). This contributes to better care of 
chronic diseases. 
Several potential advantages of capitation remuneration for general practitioners have 
being highlighted in the literature. First, GPs remunerated by capitation have incentives to 
contain costs and financial risk, due to the predetermined payments to the GPs for the care of 
their enrolees (Gosden et al, 2006; Xu & Yu, 2003). Further, this offers fiscal predictability 
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to the payer, as well as relative income predictability for the GP (CFPC, 2007). Second, there 
is less incentive for GPs under capitation to over-service or provide unnecessary care, since, 
revenue received and the number of services provided are negatively correlated (Xu & Yu, 
2003; Holden & Madore, 2002). Third, the capitation mechanism offers a long term 
relationship or longitudinal relationship between the patient and physician or a specific 
population and the physician. This aligns patients with a suitable GP, encouraging continuity, 
preventive and completeness of care. Thus GPs are remunerated for affirmative health 
outcome of their patients rather than for the amount services of provided as in the fee-for-
service (CFPC, 2007; Xu & Yu, 2003; Holden & Madore, 2002; Drossos, 2002). Fourth, GPs 
under the capitation mechanism are remunerated based on the number of patients enrolled 
with them; hence, this provides a strong incentive to GPs to offer services that resonate with 
the needs of their patients, thereby promoting and sustaining strong patient satisfaction 
(Holden & Madore, 2002). 
There are several problems associated with the capitation remuneration mechanism 
that health care experts have identified. First, the capitation mechanisms as mentioned 
previously incentivizes GPs to provide health care services in a practical, cost-effective 
manner, thereby providing only that care which is appropriate. On one hand, this may result 
in GPs providing fewer services (fewer examination, attention and shorter consultation time) 
than the population may actually need, since the GP is required to roster a large number of 
patient in other to stay within the capitated amount negotiated (CFPC, 2007; Gosden et al., 
2006; Xu & Yu, 2003; Drossos, 2002; Holden & Madore, 2002). Second, several empirical 
studies have argued that GPs under the capitation remuneration have the potential to "cherry 
pick" patients that are easier to care for rather than those who have with complex morbidities 
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because of their health status, particularly in cases where rostering is by recruitment and 
alternatives are limited (CFPC, 2007; Gosden et al., 2006; Xu & Yu, 2003; Holden & 
Madore, 2002). Third, in rural and remote communities with an inadequate number of GPs, 
patients under a GP paid with the capitation mechanism have limited freedom of choice, 
since recruitment is by geographic rostering (Holden & Madore, 2002). 
Blended remuneration mechanism 
An effective remuneration for GPs should translate into an effective delivery of care 
that is in compliance with overarching objectives of the health care system (cost control, 
quality of care and good patients' access to care). However, the outstanding question 
remains, how best can general practitioners be remunerated thereby actualizing these 
objectives (Xu & Yu, 2003)? Several empirical studies have suggested that the blended 
remuneration mechanism may be central to this goal, since the blended remuneration is not 
only a specific mechanism of remuneration but a combination of several remuneration types 
(Xu & Yu, 2003; Holden & Madore, 2002). Further, the policy shift of the GP to a blended 
capitation model as promoted by the Canadian Primary Health Care Transition Fund 
(PHCTF)2 is focused on improving access to health care, health outcome, quality and cost 
efficiency (Martin & Hogg, 2004). The two prominent blended remuneration types 
documented in the literature particular to the Canadian health care system are blended 
capitation model and the blended complement model. 
The 'blended capitation model', also known as the Family Health Network (Glazier, 
Klein-Geltink, Kopp & Sibley, 2009), makes a based payment to a GP per patient in return 
2
 The PHCTF was established in 2000, with $800 million fund setup to support efforts of 
provinces and territories to develop and implement transitional primary health care renewal 
initiatives (Health Canada, 2004). 
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for the provision of comprehensive care, in addition to incentives for the provision of 
specific primary care services (Ontario Ministry of Health and Long-Term Care, 2009). 
Second, the 'blended complement model' provides compensation based on the number of 
physicians within the group. Thus general practitioners are offered a base payment for the 
provision of comprehensive care, in addition to incentives for provision of specific primary 
health care services, as well as funding for emergency service (Ontario Ministry of Health 
and Long-Term Care, 2009). 
There are several empirical advantages and disadvantages that have been identified 
with the blended remuneration mechanism for GPs. The advantages of remunerating GPs 
include minimizing the tendency to under-service and 'cherry-pick' patients, as well as 
curbing the overall health care cost (Ontario Ministry of Health and Long-Term Care, 2009; 
Xu & Yu, 2003; Holden & Madore, 2002). On the other hand, the disadvantages of blended 
payment include difficulties in setting or developing combination proportions, since blended 
remuneration is a combination of two or more payment types (Xu & Yu, 2003). Furthermore, 
the blended remuneration attenuates the advantages of the "pure" remuneration scheme 
(Holden & Madore, 2002). Moreover, the blended remuneration requires maintaining 
different payment schedules, thus may increase the administrative burden and cost (Holden 
& Madore, 2002). 
In sum, the fee-for services remains the most prominent form of remunerating GPs in 
Canada with exception of the territories. Provincial and territorial governments negotiate the 
fee schedule with the health care providers. The Canada Health Act prohibits provinces from 
allowing private billing for publicly insured services by physicians, otherwise they are 
penalized financially. In most provinces, budget cap was introduced for fee-for-services 
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payments to GPs. The essence of this ceiling was to curb the increasing cost of care. The 
advantages and disadvantages of the fee-for service remuneration for general practitioners 
are itemized on Table 4. 
In recent years, all Canadian jurisdictions have developed one form of alternative 
remuneration for GPs, such as salary, mixed payment method, and blending FFS with the 
salary or capitation model. This shift towards an alternative payment is an attempt to control 
the cost of care and also to transfer some of fiscal the responsibility from funders to 
providers, like in the capitation-based models in primary health care. The merits and 
demerits of the alternative are also itemized on Table 4. In 2004, approximately 20% of 
physicians (including both GPs and specialists) received a form of alternative remuneration 
other than FFS (Fujisawa & Lafortune, 2008). In Alberta and British Columbia, physicians 
are either paid by contract, session or salary; in Ontario50 % of general practitioner are 
remunerated with the alternative model other than fee-for-service (Fujisawa & Lafortune, 
2008). Alternative forms of remuneration also exist in most other provinces in Canada. 
Remuneration of health professional remains one of the largest drivers of cost of 
provision of health services. Thus making remuneration a pivotal concern for policy makers 
endeavouring to improve efficiency, access and quality of care provided while curbing the 
escalating cost of care, particularly in the primary health care. 
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Table 4 
Evaluating Physician Remuneration Methods 
Remuneration 
Type 
Fee-for-service 
Salary 
Capitation 
Blended 
Advantages 
i. Better accessibility 
ii. Target income 
iii. Better Physician autonomy 
iv. High volume driven 
v. Incentives for health 
promotion 
i. No incentive to over service 
ii. Reduces cream-skimming 
iii. Increased budget certainty 
iv. More efficient use of 
resources 
v. Consistency and sureness of 
service provided 
i. Improved budget certainty 
ii. Better patient-physician 
relationship 
iii. services resonant with patient 
needs 
iv. Less incentive to over-service 
v. Income predictability for 
physicians 
i. Reduces under-servicing 
ii. Reduces cream-skimming 
iii. Curbs health care cost 
Disadvantages 
i. Incentives to over service 
ii. Limited for sicker less capable patients 
iii. Promotes quicker and frequent services 
iv. Short visit and consultation with GP 
v. Unpredictable budget 
i. No incentive to see more patient 
ii. No incentive for continuity of care 
iii. Reduced Physician autonomy 
iv. Inadequate services for vulnerable 
population 
i. Reduced Physician autonomy 
ii. Cream-skimming in recruitment 
iii. Providing only necessary care 
iv. Incentives to over service 
i. Difficulty in developing combination 
proportion 
ii. Increased administrative burden and cost 
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Primary Health Care 
In this era of shrinking health care resources and budgetary constraints, the capacity 
of health care providers to respond to the need of the increasing ageing population and those 
with chronic diseases has become severely limited. Hence, recent cost reduction strategies 
have resulted in the need to identify where and how health care resources might be 
effectively invested and monitored to yield the desirable goal of efficient care delivery 
(World Health Organization, 1996; Roos, Walld, Uhanova & Bond, 2005). It is generally 
accepted that an integrated primary health care (PHC) sector plays a key role in delivering 
preventive services, diagnosis, in long term disease management, and in the coordinating of 
specialized care (Shah et al., 2003). Thus, exploring the relevance of an effective primary 
health care system to health service utilization delivered in ambulatory care settings is 
important is important to curbing health care cost and improved patient outcome. Further, 
high rates of hospitalization for ACSCs may provide indirect evidence of problems 
associated with patient access to primary care. 
In the Canadian context, a commonly used definition from the Canadian Health 
Services Research Foundation (CHSRF) is: "primary health care is defined as a set of 
universally accessible first-level services that promote health, prevent disease, and provide 
diagnostic, curative, rehabilitative, supportive and palliative services" (Lamarche, Beaulieu, 
Pineault, Contandriopoulos, Denis & Haggerty, 2003, pp. 2). Primary care according to 
Starfield (1998), is "that level of a health service system that provides entry into the system 
for all new needs and problems, provides person-focused (not disease-oriented) care over 
time, provides care for all but very uncommon or unusual conditions, and co-ordinates or 
integrates care provided elsewhere by others." (pp. 8-9). This implies that primary care is an 
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integral part health care system or primary health care, since primary care focuses on health 
care services that include health promotion, diagnosis, prevention and treatment of illness 
and injury (Health Canada, 2006). The 1978 Declaration of Alma-Ata defined primary health 
care as: 
...essential health care based on practical, scientifically sound and socially acceptable 
methods and technology made universally accessible to individuals and families in 
the community, through their full participation and at a cost that the community can 
afford to maintain at every stage of their development in the spirit of self-reliance and 
self-determination. It forms an integral part both of the country's health system, of 
which it is the central function and main focus, and of the overall social and 
economic development of the community. It is the first level of contact of 
individuals, the family and the community with the national health system, bringing 
health care as close as possible to where people live and work, and constitutes the 
first element of a continuing health care process (World Health Organization, 1978, 
pp. 1-2). 
Primary health care provides a two-fold function in the health care system. First, primary 
health care provides direct first-contact services with the health care system via providers 
like general practitioner, pharmacist, nurse practitioners, and telephone counseling services. 
Second, primary health care coordinates services to maintain continuity of care, as well as 
easy movement within the system. This enables care to be integrated when patients require 
specialized care from specialist (Health Canada, 2006). 
According to Lamarche et al. (2003), the six broad outcomes the primary health care 
system should produce are effectiveness (ability to improve or maintain health); productivity 
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(the cost, type, nature of service for health concern); accessibility (easy accessing general 
practitioner, specialized and diagnostic services); continuity (extent to which care is provided 
as a consistent progression of episode); quality (appropriateness of care as perceived patient 
and provider); and responsiveness (accommodation for the expectation and preference of 
patient and provider). Further, with the ageing population and the increasing rate of chronic 
illnesses, the approach to treatment has to be modified as well. Thus primary health care 
plays an integral role in education, promotion and prevention of chronic diseases, since the 
major goal of primary health care is to enable patient to take responsibility for their own care 
(Khan, Mcintosh, Sanmartin, Watson & Leeb, 2008). This was echoed by the WHO in a 
statement that: 
The service delivery reforms advocated by the PHC [Primary Health Care] movement 
aim to put people at the centre of health care, so as to make services more effective, 
efficient and equitable. Health services that do this start from a close and direct 
relationship between individuals and communities and their caregivers. This, then, 
provides the basis for person-centredness, continuity, comprehensiveness and 
integration, which constitute the distinctive features of primary care (WHO, 2008, pp. 
43). 
Consequently, timely access to primary health care is an essential quality indicator of the 
performance of the overall health care system. One instrument for measuring access to PHC 
is to examine the rate of health service utilization for ambulatory care sensitive conditions, 
ACSC, (Shah et al 2003; Billings et al., 1993; Pappas et al., 1997; Bindman et al., 1995; 
Ansari et al, 2006; Rizza et al., 2007; Chen et al., 2009, Gao et al., 2008; Blustein et al., 
1998). 
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Ambulatory Care Sensitive Conditions 
In the Canadian health care system access to care is universal, thus everyone has 
access to care regardless of their economic status. The Canadian Health Act 1984 specifies 
that health care services must be publicly administered, universal, accessible, portable and 
comprehensive (Madore, 2005). Thus, considering this provision in the Canadian Health Act, 
one may presume all hospitalizations are appropriate, particularly in a scenario where 
resources are inadequate and the population is ageing. However, in principle, it is well 
documented in the literature that many hospital resources are used inappropriately, whether 
by providing services that do not translate into health benefit, or providing services that 
would have been provided at a different organizational level utilizing lesser resources (CIHI, 
2008). This reflects the deficit in preventive care leading up to hospitalizations for conditions 
sensitive to the primary health care settings. 
One indirect measure used in defining preventable hospitalizations or the overall 
performance of the health care system is to identify those conditions for which 
hospitalizations are generally considered preventable i.e. ambulatory care sensitive 
conditions (ACSC) (Brown et al, 2001; Shah et al., 2003). The hypothetical concept of 
ACSC was developed by Billings et al. (1993), and refers to conditions for which 
hospitalization might be avoided with timely and effective outpatient care, that either 
prevents the onset of the condition, assists in managing a chronic condition, or helps 
controlling acute periodic condition (Roos et al. 2005; Caminal, Starfield, Sanchez, 
Casanova & Morales, 2004; Parker et al., 2005; Rizza et al., 2007; Flores, Abreu, Chaisson 
& Sun, 2003). The ACSC diagnosis lists generally include the following conditions: asthma, 
diabetes, chronic obstructive pulmonary disease (COPD), angina pectoris, cellulitis, 
34 
congestive heart failure (CHF), dehydration, dental conditions, diabetes, gastroenteritis, 
seizure disorders, hypertension, hypoglycaemia, vaccine-preventable conditions, urinary tract 
infection, pneumonia, severe ear/nose/throat infection, tuberculosis, nutritional deficiency 
(Billings, Anderson & Newman, 1996). 
Hospitalization rates for ACSC conditions have been linked with the absence or 
presence of adequate and effective principal or preventive care (Roos et al 2005; Billings et 
al., 1993; Chen et al., 2009). Comparing rates of hospitalization for ACSC across populations 
or communities can therefore provide insight into the quality of care in the ambulatory care 
settings of these populations or communities. Further, it is assumed that the disproportionate 
rates of hospitalization for ACSC in a given population or community indicates delay in 
diagnosis or treatment of these conditions because of insufficient access to PHC. Moreover, 
reducing ACSC hospitalization is a cost restraining mechanism that will enhance patients' 
quality of life and efficient use of the health care delivery system (Clancy, 2005; Chen et al., 
2009). 
In 2001 the Agency for Healthcare Research and Quality (AHRQ) published 
Preventive Quality Indicators (PQIs) as an instrument to measure rates of ACSC 
hospitalization, with the presumption that access to primary care could be improved (AHRQ, 
2001). The concept of ACSC has been widely researched in several western countries 
including Canada, Australia and the U.S. (Rizza et al., 2007; Ansari et al., 2006), as well as 
many European countries (Rizza et al., 2007). Hospitalization rates for ACSC have been 
widely used as a measure of access to care. However, these rates varies by populations 
(Billings et al., 1993), with higher rates being documented for Aboriginal people in Canada 
(Shah et al., 2003; Lavoie et al. 2010) and geographical location, with higher rates in 
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communities with a lower aggregate income level (Billings et al., 1993). Furthermore, other 
factors that influence rates in ACSC hospitalizations are inadequate access to primary care 
(Rizza et al., 2007; Bindman et al., 1995); and greater supply of hospital bed (Rizza et al., 
2007), as well as socioeconomic indicators, with higher rates among uninsured individuals 
particularly in the U.S. (Billings et al., 1993). 
Further, hospitalization for ACSC is higher among rural residents in comparison to 
the urban counterparts, because rural residents have lower health status and shortage of 
primary care facilities and physician when compared to their urban counterpart (Chen et al., 
2009). This disparity in ACSC rates between rural residents and urban residents may also be 
as a result of people traveling longer distances for care and are often admitted so as to 
precipitate care or supports might be inadequate; hence people get admitted into so call 
"social admissions". Moreover, Billings and colleagues (1996) found that Canadians from 
low income communities were 40% more likely to be at risk for avoidable hospitalizations in 
comparison to their counterparts in high income communities (Blustein et al., 1998). In 2010, 
Lavoie and colleagues used a full range of ACSC diagnosis (chronic, acute and vaccine-
preventable) to explore the relationship between of community controlled health services and 
local access to primary health care services for Aboriginal people in Manitoba. Their study 
demonstrated that Aboriginal communities with improved access to primary health care at 
the local level (such as nursing stations) had lesser rates of hospitalization for ACSC, in 
contrast to communities with limited access to primary health care at local level, where rates 
hospitalization for ACSC were higher (Lavoie et al., 2010). 
The Canadian Institute for Health Information (CIHI) identified a significant 
downward trend in rate of ACSC hospitalization for the Canadian population younger than 
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age 75 (exclude Quebec); however, Canadians aged 64 to 74 accounted for 50% of all ACSC 
hospitalization (CIHI, 2009). This study explored trends in ACSC hospitalization rates for 
seven conditions (angina, asthma, COPD, diabetes, epilepsy, heart failure and pulmonary 
edema, and hypertension). They estimated that about 1 in 8 (13%) medical hospitalizations in 
Canada for patients younger than 75 years of age were for ACSC (CIHI, 2008). Further, 
ACSC admission rates ranged from a low of 281 per 100,000 in British Columbia population 
to a high of 1,298 per 100,000 in Nunavut (CIHI, 2009). The same studies found that ACSC 
hospitalization rates were 60% higher in rural communities (510 per 100,000 population) in 
comparison to urban communities (318 per 100,000 population) (CIHI, 2008). Moreover, the 
rates for ACSC hospitalization increased as income level decreased, since those living in less 
affluent areas were 2.6 times more likely to be hospitalized for ACSC than those living in an 
affluent area (CIHI, 2009). 
Despite the fact that the ACSC lists generally include a core diagnoses group, in most 
cases the conditions have been modified and selected to align with the population of interest. 
For instance, Weissman and colleagues excluded pulmonary emboli and stroke in their list of 
ACSC because avoidable hospitalizations for these conditions were considered to be 
arguable (Pappas et al., 1997). Furthermore several other researchers have excluded 
congestive heart failure and pneumonia in their study of older populations because these 
conditions are viewed as an unavoidable trajectory for elderly people, even though these two 
conditions are the most common cause hospitalization for elderly people (Bindman et al., 
1995; Pappas et al., 1997). 
One reason for measuring ACSC hospitalization rates was the assumption that these 
conditions are sensitive to care in the primary health care system. While this method is 
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widely used in the literature, no studies were found that have examined the relationship of 
GP payment schemes and avoidable hospitalization for ACSC. Hence, this study is 
innovative and timely, particularly with the changing demographics care should be delivered 
smartly so it translates into lower cost, improved patient outcome and providers' satisfaction. 
Additionally, economic incentives for GPs are widely adopted by health care policy-maker to 
improve allocative effectiveness and quality in primary care (Lippi Bruni et al 2009). In spite 
of the evidence that incentive-based remuneration can have an influence on GP behavior, 
there is yet limited evidence to relate the impact of this policy on health outcomes with 
respect to hospitalization for ACSC (Lippi Bruni et al., 2009). 
Summary 
There is a robust body of knowledge in the literature on general practitioner (GP) 
remuneration, ambulatory care sensitive conditions (ACSC) and primary health care. Several 
studies have explored the effectiveness of general GP remunerations on the health care 
system; however no studies were found that have employed health services utilization for 
ACSC. The literature is consistent in stating that the primary health care system is the 
bedrock of the health care system, hence adequate access to GPs is central, particularly in 
countries like Canada where they are the first point of contact with the health care system. 
One way of measuring access or quality of care is to capture those hospitalizations that could 
be avoided with high preventive care in the primary care settings. The literature has been 
inconsistent with the definition of ACSC conditions, as well as their predictors. This is the 
gap in the literature that this study proposes to address. 
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Chapter Three: Methods 
This Chapter provides an overview of the methods used in this study. This study was 
an analysis of health services utilization administrative data in order to examine rates and 
predictors of hospitalization, as well as trends in hospitalization for ambulatory care sensitive 
conditions (ACSC). This study employed administrative health utilization data on 
hospitalizations from the BC Ministry of Health Hospital Separations dataset, housed in 
Population Data BC for selected communities. 
Research Design 
This is a population-based database study. A retrospective cohort analysis of all 
hospitalizations classified as ACSC from 1992/1993 onward was conducted to compare 
trends and patterns of hospitalizations for ACSC in select communities with fee-for-service 
(FFS) and alternative payment plans (APP) for GPs. Descriptive statistics on selected 
communities were used to predict hospitalization rates for ACSC among selected 
communities that are matched based on their community and individual level characteristics. 
I also examined the data for relationships between GP payment schemes and rates of 
hospitalization for ACSC. 
Study populations 
In this study, aggregate-level hospitalization data was used to identify all individuals 
under 65 years of age on March 31, 2008, who were admitted to hospital for selected 
conditions classified as ACSC (see Appendix A for list of ICD-9 and ICD-10-CA codes) 
between April 1, 1992 to March 31, 2008 while living in selected communities (as shown in 
Appendix B). This study includes northern communities served by GPs remunerated with 
APP (McBride, Dunster, Fraser Lake, Valemount & Robson; Haida Gwaii (Queen Charlotte 
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& Sandspit) and Stewart) and FFS (Prince Rupert, Tumbler Ridge, Smithers and Telkwa) GP 
payment plans. Communities with APP and FFS are listed in Appendix B. Postal codes in the 
database were used to identify all patients in the selected communities hospitalized for 
ACSC; however, postal codes were not released to the researcher. Geographic information 
was provided as flags, i.e. ACSC hospitalizations from APP and FFS communities were 
flagged as APP and FFS respectively; ACSC hospitalizations from postal codes not listed 
were flagged as NA (see Appendix B). 
Community profile. 
A community profile for each community by demographic characteristics was 
extracted from the 2006 census data as well as Northern Health. This study is intended to 
investigate the quality of and access to primary care physicians for selected communities. 
These parameters were measured using the hospitalization for ACSC in five Northwest 
communities (Prince Rupert, Stewart, Queen Charlotte, and Smithers), three Northern 
interior communities (Valemount, McBride, and Fraser Lake) and one Northeast community 
(Tumbler Ridge). The profiles of these communities are discussed based on the demographic 
characteristics, health status, and health facilities in this community. Of the Northern Interior 
communities, the population of McBride was approximately 655, with 49.6% male and 
50.4%o female; Fraser Lake was approximately 1115, with 51.6% male and 48.4%> female; 
Valemount was approximately 1020, with 51%> male and 49%> female (see Table 5). Of the 
Northwest communities, the population of Queen Charlotte with approximately 945, with 
51.9%o male and 48.1% female; Stewart was approximately 495, with 49.5%> male and 50.5%> 
female; Prince Rupert was approximately 12,815, with 49.5%> male and 50.5%> female; 
Smithers was approximately 5,220, with 48.5%> males and 51.5% female (see Table 5). The 
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population of the Northeast community (Tumbler Ridge) was approximately 2,455 with 53% 
male and 47% female (see Table 5). 
The communities in this study have a relatively young population, with the average 
ranging from 36.1 years in Smithers to 42.9 years in Stewart. The average age for McBride, 
Prince Rupert, Fraser Lake, Queen Charlotte, Valemount, and Tumbler Ridge are 37.1, 38.5, 
39.2, 41.1, 42.2 and 42.3 years respectively (see Table 5). The average age for McBride, 
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Prince Rupert, Fraser Lake, Queen Charlotte, Valemount, and Tumbler Ridge are 37.1, 38.5, 
39.2, 41.1, 42.2 and 42.3 years respectively (see Table 5). The annual number of births for 
women of childbearing age is approximately 15, 15 -20, 8-10, 48, and 175 in McBride, 
Fraser Lake, Valemount, Queen Charlotte and Prince Rupert respectively. On the other hand, 
the annual death rate is 15, 12-15, 12, 30, and 116 in McBride, Fraser Lake, Valemount, 
Queen Charlotte and Prince Rupert respectively. The average life expectancy for residents in 
McBride, Fraser Lake, Valemount, and Prince Rupert is 78.5, 76.9 - 77.7, 78.5, and 78.9 
years respectively (see Table 5). 
In Canada, chronic diseases and the risk factors associated with them remain a 
significant public health concern, since a significant portion of morbidity and mortality 
among Canadians are attributable to chronic disease (Patra, Popova, Rehm, Bondy, Flint & 
Giesbrecht, 2007). The four prevalent chronic diseases in McBride, Fraser Lake, Valemount, 
Queen Charlotte and Prince Rupert include hypertension; asthma, diabetes, and 
cardiovascular disease (see Table 5). 
As illustrated on Table 5, all communities have one or more health care facilities that 
provide primary care services to their residents. In the Northern Interior Health Service 
Delivery Area (HSDA), the number of primary health care physician per 100,000 population 
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is 104 in 2004/2005 fiscal year, while in the Northwest and Northeast Health Service 
Delivery Area the number primary health care physician per 100,000 population in 
2004/2005 fiscal year was 116 and 79 respectively (Watson et al., 2009). The percentages of 
individuals age 12 and older that have a regular family physician in Northern Interior, and 
Northwest/Northeast HSDA are 90% and 88% respectively (Watson et al., 2009). 
Furthermore, 41% of individuals age 12 and older in both Northern Interior, 
Northwest/Northeast HSDA have visited a family physician at least 3 times in the past year, 
in contrast to 10% and 13% respectively, who have consulted a nurse in the past year 
(Watson et al., 2009). 
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Table 5 
Selected Characteristics of Study Population 
Characteristics 
Alternative Payment Plan 
McBride 
Number 
Fraser Lake 
Number 
Valemount 
Number 
Queen Charlotte 
(Haida Gwaii) 
Number 
Stewart 
Number 
Fee-for-service 
Prince 
Rupert 
Number 
Tumbler 
Ridge 
Number 
Smithers 
Number 
Gender33 
Male 
Female 
325 
330 
575 
540 
520 
500 
490 
455 
245 
250 
6,345 
6,470 
1,300 
1,155 
2,530 
2,690 
Age Groups (Yrs)3a 
0-19 
20-39 
40-64 
65+ 
Median Age 
180 
175 
225 
80 
37 
320 
265 
410 
125 
39 
250 
240 
385 
145 
42 
255 
220 
405 
80 
41 
120 
125 
205 
60 
43 
3,690 
3,015 
4,785 
1,355 
39 
595 
550 
1,040 
275 
42 
1,580 
1,335 
1,720 
585 
36 
Ethnicity33 
Visible Minority 
Aboriginal Population 
Rest of the population 
35 
60 
565 
15 
200 
895 
20 
75 
925 
40 
135 
760 
10 
55 
430 
1,369 
4,475 
6,911 
15 
220 
2,215 
260 
765 
4,120 
Health Status3b 
Annual average birth 
rate 
Annual average death 
rate 
Average life 
expectancy 
15 
15 
79 
15-20 
12-15 
77-78 
8-10 
12 
79 
48 
30 
175 
116 
79 
Estimated Prevalence (existing cases) of selected chronic conditions313'a 
Hypertension 111(8) 176(11) 175(13) 712 (68) - 2,765 (189) - -
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Asthma 
Diabetes 
Ischemic Heart Disease 
Congestive Heart 
Failure 
Cardiovascular Disease 
Stroke 
Chronic Kidney 
Disease 
COPD 
61(4) 
45(3) 
20(2) 
12(2) 
29(3) 
6(1) 
11(2) 
13(2) 
83(6) 
61(6) 
28(2) 
25(4) 
52(5) 
12(2) 
15(3) 
26(3) 
96(6) 
70(5) 
31(3) 
19(3) 
45(5) 
10(1) 
17(3) 
21(2) 
279 (27) 
63(9) 
92 (14) 
228 (22) 
58(6) 
49 (10) 
89 (10) 
-
-
. 
-
-
-
-
1,275 (72) 
1,063 (79) 
476 (23) 
335 (41) 
726 (47) 
168(21) 
190(37) 
280 (36) 
-
-
-
-
-
-
-
-
-
-
-
-
Health care Facility 
Health Facility type 
Emergency room visit 
District 
Hospital 
2,035 
Community 
Health 
Centre 
5,349 
Community 
Health 
Centre 
4,401 
General hospital, 
Community 
health centre, 
medical clinic, 
city health centre 
3,184 
Health 
centre 
808 
Regional 
hospital, 
community 
health 
centre 
24,662 
Community 
health 
centre, 
health unit 
-
District 
hospital, 
Community 
health 
centre 
13,701 
Note. Cells with hyphen indicate that data not available at the time of compilation 
a
 The numbers in parenthesis are the incident rates of the chronic condition per year. Also, the health status data used for Queen Charlotte covers all 
diagnosis for select chronic conditions in Queen Charlotte Local Health Area. 
3a Statistics Canada, 2010 
3b Northern Health, (n.d) 
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Estimation of Study population 
I conducted a retrospective population-base study to assess hospitalization rates for 
ACSC in five APP communities and three FFS communities. Based on Table 5, the total 
population of the FFS communities is approximately five times that of the APP communities. 
These significant variations in population size for APP and FFS make it improper to compare 
the number of hospitalizations for ACSC between both sets of communities. In order to 
suitably compare ACSC hospitalization in communities under the FFS remuneration versus 
the APP remuneration, community populations from census data within the study period 
were processed in order to obtain for each considered community a standard population and 
single calendar year from 1992 - 2008. Linear interpolation procedure was used to predict 
the population of calendar years 1992 - 2006. As shown in Table 6, the APP communities 
showed a positive growth in population between 1991 and 1996 census data; and a negative 
growth in population between 1996 and 2001, as well as 2001 and 2006 census data, i.e., 
0.23%, 0.28% and 0.14% respectively. This implies 0.05%, 0.06% and 0.03% changes per 
year between 1991, 1996, 2001, and 2006 census year respectively. On the other hand, the 
FFS communities showed negative growth in population between 1991, 1996, 2001, and 
2006 census year data, i.e., 0.01%, 0.17% and 0.09% respectively. This implies 0.00%, 
0.03% and 0.02% changes per year between 1991, 1996, 2001, and 2006 census year 
respectively. I assumed there was no change in the population for calendar year 2007 and 
2008 since the last census during the period of study was in 2006 (see Table 7). 
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Table 6 
Population per Census Year in APP and FFS Communities 
Population Under 65yrs by census year 
APP 
FFS 
percentage change 1991-2006 
APP 
FFS 
1991 
4860 
25830 
0 (0%) 
0 (0%) 
1996 
6175 
25710 
0.23(23%) 
0.01 (1%) 
2001 
4430 
21385 
0.28 (28%) 
0.17(17%) 
2006 
3820 
19495 
0.14(14%) 
0.09 (9%) 
percentage change per year by census 
year 
APP 0(0%) 0.05(5%) 0.06(6%) 0.03(3%) 
FFS 0(0%) 0.00(0%) 0.03(3%) 0.02(2%) 
Table 7 
Estimation of Community Population 
APP 
FFS 
1991 
4860 
25830 
1992 
5123 
25806 
1993 
5386 
25782 
1994 
5649 
25758 
1995 
5912 
25734 
1996 
6175 
25710 
1997 
5826 
24845 
1998 
5477 
23980 
1999 
5128 
23115 
APP 
FFS 
2000 
4779 
22250 
2001 
4430 
21385 
2002 
4308 
21007 
2003 
4186 
20629 
2004 
4064 
20251 
2005 
3942 
19873 
2006 
3820 
19495 
2007 
3820 
19495 
2008 
3820 
19495 
Note. Census year and data are in boldface. 
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Selection of ACSC hospitalizations. 
Ambulatory Care Sensitive Conditions include conditions that can be prevented via 
vaccination and/or PHC intervention (Ansari et al., 2006). Previous studies have identified 
hospitalization for ACSC, by focusing on principal diagnosis at hospital discharge abstract 
(Steiner, Braun, Melinkovich, Glazner, Chandramouli, LeBaron & Davidson, 2003; Falik, 
Needleman, Wells & Korb, 2001). Data from these abstracts are stored in the Hospital 
Separation Database (HSD). 
For this study I adapted the list of ACSC conditions developed by Lavoie et al. 
(2010). The definition of ACSC by Lavoie and colleagues includes three main categories: 
chronic conditions, vaccines preventable conditions, acute conditions and their 
corresponding ICD-9 and 10 codes (International Classification of Disease, 9th and 10th 
Revision) (see Table 8). This classification is consistent with the widely used definition of 
ACSC by Billings et al. (1993). Conditions classified as chronic conditions may require 
partial medical management and episodic office visits (Falik et al., 2001). Conditions 
classified as acute most likely require timely intervention and care to prevent hospitalization. 
Furthermore, acute conditions can develop into chronic conditions if preventive measures are 
not timely. Conditions classified as vaccine preventable conditions could be averted if timely 
and appropriate vaccination was administered. It is worth noting that the selected conditions 
were developed to monitor hospitalizations principally in populations under age 65, since 
some diseases are presented differently in the elderly (Blustein et al., 1998; Billings et al., 
1993;Bindmanetal., 1995). 
The hospital separation abstract is based on the primary diagnosis such as asthma, 
COPD, congestive heart failure, diabetes mellitus, and hypertension. 
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Table 8 
Definition of Ambulatory Care Sensitive Conditions 
List of ACSC adapted from Lavoie et al. (2010) 
Chronic Conditions 
Vaccine Preventable 
Conditions 
Acute Conditions 
Asthma 
Angina 
Heart Failure and pulmonary edema 
Convulsion & Epilepsy 
Diabetes with complications 
Diptheria 
Hemophilus Influenza type B 
Hepatitis A 
Hepatitis B 
Influenza 
Measles 
Meningococcal disease (meningitis) 
Dental Conditions 
Cellulitis 
Pelvic Inflammatory Disease 
Hypertension 
COPD 
Pneumonia 
Acute Bronchitis 
Iron deficiency anemia 
Mumps 
Pertussis 
Pneumococcal 
Poliomyelitis 
Tuberculosis 
Rubella 
Tetanus 
Gastroenteritis & Dehydration 
Severe ENT infections 
However, asthma and COPD are also classified as secondary diagnosis so long as the 
primary diagnosis is either pneumonia or acute bronchitis. Thus the selected conditions are 
believed to reflect adult chronic conditions that should have benefited from timely outpatient 
primary care. Consequently, for the purpose of this study, ICD-9 and 10 codes are used in 
identifying a potential ACSC hospitalization provided the codes were reported as the 
principal diagnosis for any hospitalization as shown in Appendix C. 
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Data sources 
The administrative health data used for this study is from the BC Ministry of Health 
and is held at Population Data BC. The Population Data BC maintains a comprehensive, 
longitudinal, population-based administrative database comprised of core data from health 
service utilization and physician billings files and hospitalization for residents of BC. The 
data obtained reflects population-based health service utilization because the health care 
delivery system in BC is universal. The hospital separation database for population data BC 
is comprehensive on health service utilization in BC, regardless of where the hospitalization 
took place. Hence, hospitalization data is an essential part of this study. 
The Population Data BC have the authority to hold individual-level personal 
information based on the information sharing agreements with provincial ministries and 
other public body data providers. They are permitted to disclose anonymized personal health 
information without consent for the purposes of evaluating and monitoring health system 
performance (Population Data BC, 2010). Population Data BC also accepts the responsibility 
of maintaining the confidentiality of the health information it receives. The protocol for this 
project was reviewed by the Population Data BC Privacy Officer to ensure that it met the 
criteria for privacy and confidentiality of data outlined in Population Data BC Privacy 
Policies and Procedures (Population Data BC, 2010). Overall, the use of administrative data 
for research brings strengths and limitations to the research project. These are more 
completely described in Chapter 5: Discussion. 
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Ethics Approval 
Ethics approval to collect the data related to this study was granted from the 
University of Northern British Columbia Research Ethics Committee. 
Data Analysis 
Hospitalization and ACSC hospitalization rates 
The community population was used as standard population and was estimated using 
figures from 1991, 1996, 2001 and 2006 censuses. Overall annual hospitalization rates were 
calculated as the number of hospitalizations per 1000 population in each fiscal year between 
April 1, 1992 and March 31, 2008 to examine trends over time. The overall hospitalization 
rates were first calculated to minimize the impact of rehospitalizations on the rates. In 
calculation of the rate, the numerator data consisted of the total number of hospitalization of 
ACSC for each calendar year of the principal and primary diagnoses. Denominator data was 
derived from estimated annual census data for each community as provided on Table 7. The 
annual census population estimates for each community were derived through linear 
interpolation. The incidence rates described above were also calculated for ACSC 
hospitalization specifically. 
Data analysis was performed using the Statistical Package for Social Sciences (SPSS) 
for Windows version 11.5. Descriptive statistics using nonparametric test were used to 
compare the difference in rate of hospitalization for ACSC in communities with FFS and 
APP physician remuneration scheme. For all of the analysis, alpha was set at .10, i.e., p <.10. 
A more liberal alpha (a) was used for this analysis, since it decreases likelihood of making a 
Type II Error (i.e., saying there is no difference in the population when there is) and the rigor 
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of the test. Moreover, the data for this study consist of yearly rates over 17 years, hence the 
number of data points is quite small, i.e., 17. This would suggest the probability of high Type 
II error if a = .05. However, the likelihood of making Type I error increases (i.e., saying 
there is a difference in the population that might not exist). Furthermore, oc-level of .10 
increases power, thereby there is a greater chance of accepting the alternative if it is true (i.e., 
power) and, consequently the likelihood of rejecting the null hypothesis will be increased. 
The subsequent chapters present and discuss the results of this study. 
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Chapter Four: Results 
This chapter outlines the results from the data analyzed for this thesis. The chapter is 
arranged as follows. First, a descriptive analysis of both payment plans is presented using 
rates of ACSC hospitalization. Second, statistical difference between ACSC rates in APP and 
FFS Communities are described in some detail. Third, the lengths of stay in hospital for both 
plans are presented. This is followed by statistical testing for significance differences 
between plans. The population used throughout this analysis were taken from the described 
procedure as shown on Tables 6 and 7 in methodology chapter. 
Preliminary Data Analysis 
I decided not to adjust the rates of ACSC hospitalization by age and gender in both 
APP and FFS communities, since the gender ratio and age 95% CI split by gender indicates 
that there is no difference between the populations (APP and FFS). Further, the median and 
mean age split by gender in both communities also indicated that the populations were fairly 
homogenous (see Table 9 below). Thus, there was no concern to adjust rates of ACSC 
hospitalizations in these important characteristics that might influence reported proportions 
of health event rates or physician visits in the APP or FFS communities. 
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Table 9 
Age and Gender Proportion of ACSC Hospitalization in APP and FFS Communities 
Gender 
Female 
Male 
Gender 
Female 
Male 
n 
505 
446 
n 
2110 
1877 
M 
34.81 
33.46 
M 
36.11 
33.03 
SD 
18.99 
20.55 
SD 
18.67 
20.03 
Mdn 
37 
31 
Mdn 
39 
30 
APP 
95% CI 
[33.15,36.47] 
[31.55,35.37] 
FFS 
95% CI 
[35.31,36.91] 
[32.12,33.94] 
Gender Ratio 
1.13 
1 
Gender Ratio 
1.12 
1 
Hospitalization Rates for ACSC 
The hospitalization rates for ACSC discussed includes hospitalization rates for 
chronic, acute and vaccine preventable conditions. Between 1992- 2008 there were 2,887 
ACSC hospitalizations in the APP communities and 12, 270 ACSC hospitalizations in FFS 
communities. The mean hospitalization rates for all ACSC per 1,000 population in APP 
communities was 36.94 per 1000 person, in comparison to FFS communities where the mean 
hospitalization rate was 32.03 per 1000 person (see Table 10). The hospitalization rates in the 
APP community were lower than the FFS until 1997/98 when they even out. In 2005/06 
there was a significant spike in the rates of hospitalization for ACSC in both communities, 
although the most significant spikes occurred in the APP communities (see Figure 2). The 
rates of ACSC hospitalizations in the APP communities ranged from a low of 20.57 per 
1,000 population in 1996/97 to a high of 68.06 per 1,000 population in 2007/08. The 
hospitalization rates for ACSC in the FFS communities range from a low of 25.03 per 1,000 
population to a high of 44.93 per 1,000 population (see Figure 2). 
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Figure 2. Rates of ACSC hospitalizations in APP and FFS communities. 
The second highest rate of ACSC hospitalization in the APP communities was 60.47 
per 1,000 population in 2006/07, in comparison to 44.32 per 1,000 population in the FFS 
communities. ACSC hospitalization rates appear higher in FFS communities in comparison 
to APP communities. Additionally, the slopes of the APP and FFS communities appears 
significantly dissimilar as the hospitalization rate for ACSC in the APP communities grew at 
a rate of 2.1 cases per 1000 persons per year, whereas the FFS communities grew slightly at 
0.2 cases per 1000 person per year (see Figure 2). The results are summarized on Table 10. 
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Table 10 
Rates of ACSC Hospitalizations in APP andFFS Communities, 1992/93-2008/09 
Total ACSC Hospitalizations 
APP 
1992/93 
1993/94 
1994/95 
1995/96 
1996/97 
1997/98 
1998/99 
1999/00 
2000/01 
2001/02 
2002/03 
2003/04 
2004/05 
2005/06 
2006/07 
2007/08 
2008/09 
Number of 
hospitalizations 
138 
139 
132 
137 
127 
176 
159 
225 
204 
140 
173 
144 
144 
181 
231 
260 
177 
Rates per 
1,000 
26.94 
25.81 
23.37 
23.17 
20.57 
30.21 
29.03 
43.88 
42.69 
31.60 
40.16 
34.40 
35.43 
45.92 
60.47 
68.06 
46.34 
FFS 
Number of 
hospitalizations 
920 
923 
823 
756 
767 
757 
624 
703 
666 
539 
590 
676 
651 
647 
876 
864 
488 
Rates per 
1,000 
35.65 
35.80 
31.95 
29.38 
29.83 
30.47 
26.02 
30.41 
29.93 
25.20 
28.09 
32.77 
32.15 
32.56 
44.93 
44.32 
25.03 
Rates of hospitalizations for chronic ACSC conditions 
Chronic ACSC evaluated in this study include hospitalizations for asthma, angina 
pectoris, heart failure, bronchitis, hypertension, convulsion and epilepsy, diabetes, COPD, 
pneumonia, and anemia. These chronic conditions were analyzed in groups of related 
conditions, similar data pattern and dissimilar data pattern. 
Hospitalization rates for chronic ACSC with similar patterns in the FFS and APP 
data. 
The ACSC chronic conditions classified as having similar data pattern include, 
asthma, bronchitis epilepsy, pneumonia, COPD, hypertension and diabetes. The trend lines 
of these chronic conditions illustrated similar directional data pattern, which is either 
increasing or decrease in both APP and FFS communities. 
The mean hospitalization rates per 1,000 population and the 95% confidence intervals 
for asthma, bronchitis epilepsy, pneumonia, COPD, hypertension and diabetes in the APP 
communities were 3.40 [3.22, 3.58], 0.82 [0.66, 0.98], 2.18 [2.03, 2.34], 2.94 [2.62, 3.27], 
1.06 [0.78, 1.35], 4.23 [3.85, 4.61] and 3.60 [2.65, 4.54], respectively while the FFS 
communities had a mean hospitalization rates of 2.55 [2.64, 2.46], 0.79 [0.72, 0.87], 2.82 
[2.77, 2.86], 1.65 [1.57, 1.74], 0.49 [0.42, 0.56], 4.49 [4.35, 4.62], and 1.64 [1.36, 1.91], 
respectively (see Table 11). 
From Figures 3, 4, and 5, the rates of hospitalization for asthma, bronchitis and 
epilepsy from 1992/93 - 2008/09 in the APP communities are similar to that of the FFS 
communities. Also, all three conditions appear to show a downward trend in their 
hospitalization rates (see Figures 3, 4, and 5). Further, the slopes of the APP and FFS 
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Table 11 
Rates for Chronic ACSC Hospitalizations inAPP Communities, 95% Confidence Intervals, 
1992/93-2008/09 
Asthma 
Angina Pectoralis 
Convulsion & Epilepsy 
Hypertension 
Bronchitis 
Pneumonia 
Heart Failure and Pulmonary Edema 
Anemia 
Diabetes with complications 
COPD and Allied conditions 
APP 
n M SD 95% CI 
282 3.40 1.55 [3.22,3.58] 
181 2.34 1.36 [2.14,2.54] 
182 2.18 1.07 [2.03,2.34] 
313 4.23 3.41 [3.85,4.61] 
70 0.82 0.67 [0.66,0.98] 
219 2.94 2.43 [2.62,3.27] 
33 0.42 0.34 [0.30,0.54] 
66 0.84 0.54 [0.71,0.98] 
239 3.60 7.44 [2.65,4.54] 
74 1.06 1.27 [0.78, 1.35] 
FFS 
n M SD 95% CI 
1040 2.55 1.54 [2.64,2.46] 
355 0.90 0.35 [0.86,0.93] 
1106 2.82 0.73 [2.77,2.86] 
1644 4.49 2.73 [4.35,4.62] 
330 0.79 0.69 [0.72,0.87] 
598 1.65 1.08 [1.57,1.74] 
203 0.53 0.12 [0.51,0.54] 
353 0.90 0.38 [0.86,0.94] 
554 1.64 3.31 [1.36, 1.91] 
175 0.49 0.47 [0.42,0.56] 
Note. M= mean rate per 1,000 persons. 
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communities in all three conditions appear to have a similar pattern. The hospitalization rate 
for asthma in the APP communities decreased at a rate of 0.17 per 1000 persons per year, in 
comparison to 0.29 per 1000 persons per year in FFS communities (see Figure 3). Likewise 
the hospitalization rate for bronchitis in the APP communities decreased at a rate of 0.05 per 
1000 persons per year, in comparison to 0.12 per 1000 persons per year in FFS communities 
(see Figure 4). The hospitalization rate for convulsion and epilepsy in the APP communities 
decreased at a rate of 0.03 per 1000 persons per year, in comparison to 0.11 per 1000 persons 
per year in FFS communities (see Figure 5). There were slight spikes in hospitalization rates 
in both types of communities for asthma, bronchitis and epilepsy, but it was very noticeable 
in the APP communities in comparison to the FFS communities (see Figures 3, 4 and 5). 
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Figure 3. Rates of hospitalization for asthma, 1992/93 - 2008/09. 
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Rates of Bronchitis Per 1000 Persons 
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Figure 4. Rates of hospitalization for bronchitis, 1992/93 - 2008/09. 
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Figure 5. Rates of hospitalization for convulsion and epilepsy, 1992/93 - 2008/09. 
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Based on Figures 6, 7, and 8, the rates of hospitalization for pneumonia, COPD and 
hypertension from 1992/93 - 2008/09 in the APP communities are appeared similar to that of 
the FFS communities, since all three conditions appear to show an upward trend in their 
hospitalization rates. Further, the slopes of these conditions in the APP and FFS communities 
appear to have a similar pattern. The hospitalization rate for pneumonia in the APP 
communities increased at a rate of 0.32 per 1000 persons per year, in comparison to 0.18 per 
1000 persons per year in FFS communities (see Figure 6). Likewise the hospitalization rate 
for COPD in the APP communities decreased at a rate of 0.21 per 1000 persons per year, in 
comparison to 0.07 per 1000 persons per year in FFS communities (see Figure 7). The 
hospitalization rate for hypertension in the APP communities decreased at a rate of 0.56 per 
1000 persons per year, in comparison to 0.40 per 1000 persons per year in FFS communities 
(see Figure 5). There were significant spikes in hospitalization rates in both types of 
communities, but it was very noticeable in the APP communities in comparison to the FFS 
communities, particularly of pneumonia. Also, the hospitalization rates for hypertension and 
COPD in the APP communities had significant spikes in 2007/2008 for the (see Figures 6, 7 
and 8). 
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Figure 6. Rates of hospitalization for pneumonia, 1992/93 - 2008/09. 
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Figure 7. Rates of hospitalization for COPD, 1992/93 - 2008/09. 
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Rates of Hypertension per 1000 Persons 
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Figure 8. Rates of hospitalization for hypertensions, 1992/93 - 2008/09. 
Interestingly, the hospitalization rates for diabetes in the APP and FFS communities 
were both flat and near zero until 2005/2006 - 2008/2009, when there was a sudden jump in 
hospitalization rates for diabetes. This sudden jump in hospitalization rate for diabetes may 
have being as a result of changes in reporting perhaps. Thus, the slope in both APP and FFS 
communities appears useless since, hospitalization data are inconsistent. However, in 
analyzing this rapid three year jump, both communities indicated similar pattern i.e., rising 
(2005/06 - 2007/08) and falling (2008/09). The APP indicated a higher rate in comparison to 
their FFS counterpart as shown in Figure 9. 
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25.00 -i 
Rates on Diabetes Per 1000 Persons 
Figure 9. Rates of hospitalization for diabetes and allied conditions, 1992/93 - 2008/09. 
Hospitalization rates for chronic ACSC with dissimilar patterns in the FFS and 
APP data. 
The ACSC chronic conditions classified as having dissimilar data pattern include 
angina pectoris, heart failure and anemia. The trend lines of these chronic conditions 
illustrated dissimilar directional data pattern, which may indicated change pattern between 
both payment plans. 
The mean hospitalization rates per 1,000 population and the 95% confidence intervals 
for angina pectoris, heart failure and anemia in the APP communities were 2.34 [2.14, 2.54], 
0.42 [0.30, 0.54] and 0.84 [0.30, 0.54] respectively whereas the FFS communities had a 
mean hospitalization rates of 0.90 [0.86, 0.93], 0.53 [0.51, 0.54], and 0.90 [0.86, 0.94] 
respectively (see Table 11). 
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From Figures 10, 11, and 12, the rates of hospitalization for angina pectoris, heart 
failure and anemia from 1992/93 - 2008/09 in the APP communities are dissimilar to that of 
the FFS communities, since all three conditions appear to show an upward trend in their 
hospitalization rates in the APP communities and a somewhat flat hospitalization rates in 
their FFS counterpart. The hospitalization rate for angina pectoris in the APP communities 
increased at a rate of 0.13 per 1000 persons per year, in comparison to a somewhat flat rate 
of 0.04 per 1000 persons per year in FFS communities (see Figure 10). Similarly, the 
hospitalization rate for heart failure in the APP communities indicated a slight upward trend 
of 0.02 per 1000 persons per year, in comparison to a somewhat fiat rate of O.OOlper 1000 
persons per year in FFS communities (see Figure 11). The hospitalization rate for anemia 
indicated a similar pattern, in the APP communities was slightly up at a rate of 0.04 per 1000 
persons per year, in comparison to a decline of 0.04 per 1000 persons per year in FFS 
communities (see Figure 12). There were significant spikes in hospitalization rates in both 
types of communities, but it was very noticeable in the APP communities in comparison to 
the FFS communities, particularly of anemia (see Figures 10, 11 and 12). 
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Figure 10. Rates of hospitalization for angina pectoris, 1992/93 - 2008/09. 
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Figure 11. Rates of hospitalization for heart failure and pulmonary edema, 1992/93 
2008/09. 
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Figure 12. Rates of hospitalization for anemia, 1992/93 - 2008/09. 
Rates of hospitalizations for acute ACSC conditions 
Acute ACSC evaluated in this study include hospitalizations for dental conditions 
cellulitis, pelvic inflammatory disease, gastroenteritis and dehydration and severe ear, nose 
and throat infections (ENT). The acute conditions were analyzed in groups of related 
conditions and similar pattern. Of these acute conditions, pelvic inflammatory disease, ENT 
and dehydration all indicated similar patterns in rates of hospitalizations, which are either 
increasing or decreasing rates in hospitalizations in both APP and FFS communities. On the 
other hand, hospitalization rates for dental conditions and cellulitis indicated change pattern 
between both payment plans. 
The mean rate of hospitalizations per 1,000 population for dental conditions, 
cellulitis, pelvic inflammatory disease, gastroenteritis and dehydration and ENT in the APP 
communities are 4.98 [4.83, 5.13], 1.55 [1.45, 1.65], 2.12 [1.94, 2.29], 2.70 [2.48, 2.92] and 
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2.61 [2.51, 2.70] respectively, while the FFS communities had mean hospitalizations rates of 
4.68 [4.63, 4.73], 1.47 [1.43, 1.51], 1.79 [1.73, 1.85], 3.59 [3.48, 3.70] and 2.64 [2.55, 2.72] 
per 1000 population for dental conditions, cellulitis, pelvic inflammatory disease, 
gastroenteritis and dehydration and ENT respectively (see Table 12). 
From Figures 13 and 14, the rates of hospitalization for pelvic inflammatory disease 
and ENT from 1992/93 - 2008/09 in the APP communities are similar to that of the FFS 
communities, since both conditions appear to show a downward trend in their hospitalization 
rates. Further, the slopes of the APP and FFS communities in both conditions appear to be 
similar. The hospitalization rate for pelvic inflammatory disease in the APP communities 
decreased at a rate of 0.14 per 1000 persons per year, in comparison to 0.14 per 1000 persons 
per year in FFS communities (see Figure 13). Likewise the hospitalization rate for ENT in 
the APP communities decreased at a rate of 0.07 per 1000 persons per year, in comparison to 
0.25 per 1000 persons per year in FFS communities (see Figure 14). Although the 
hospitalization rates for pelvic inflammatory disease are unidirectional, the decline in ENT 
appears steeper. There were slight spikes in hospitalization rates in both types of 
communities for pelvic inflammatory disease and ENT, but it was very noticeable in the APP 
communities in comparison to the FFS communities (see Figures 13 and 14). 
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Table 12 
Rates for Acute ACSC Hospitalizations in FFS Communities, 95% Confidence Intervals, 
1992/93-2008/09 
Dental conditions 
Cellulitis 
Pelvic inflammatory disease 
Gastroenteritis & Dehydration 
Severe Ear, Nose and Throat 
(ENT) infection 
APP 
n M SD 95% CI 
403 4.98 1.51 [4.83,5.13] 
126 1.55 0.60 [1.45,1.65] 
179 2.12 1.19 [1.94,2.29] 
204 2.70 1.61 [2.48,2.92] 
216 2.61 0.71 [2.51,2.70] 
FFS 
n M SD 95% CI 
1795 4.68 1.09 [4.63,4.73] 
575 1.47 0.48 [1.43,1.51] 
715 1.79 0.83 [1.73, 1.85] 
1313 3.59 2.00 [3.48,3.70] 
1063 2.64 1.40 [2.55,2.72] 
Note. M= mean rate per 1,000 persons. 
Based on Figure 15, the rates of hospitalization for dehydration from 1992/93 -
2008/09 in the APP communities are appeared similar to that of the FFS communities, since 
both communities showed an upward trend in their hospitalization rates. Further, the slopes 
of both APP and FFS communities appear to have a similar directional pattern. The 
hospitalization rate for dehydration in the APP communities increased at a rate of 0.28 per 
1000 persons per year, in comparison to 0.31 per 1000 persons per year in FFS communities 
(see Figure 15). Both the APP and FFS communities had several fluctuations in the rates of 
hospitalization of these conditions; however it was noticeable in the APP communities 
particular in 2006/07 calendar year (see Figure 15). 
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Figure 13. Rates of hospitalization for pelvic inflammatory disease, 1992/93 - 2008/09. 
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Rates on Severe Ear, Nose and Throat (ENT) Infections Per 1000 Persons 
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Figure 14. Rates of hospitalization for severe ENT infections, 1992/93 -2008/09. 
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Figure 15. Rates of hospitalization for gastroenteritis and dehydration, 1992/93 - 2008/09. 
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From Figures 16 and 17, the rates of hospitalization for dental conditions and 
cellulitis from 1992/93 - 2008/09 in the APP communities are dissimilar to that of the FFS 
communities, since both conditions appear to show an upward trend in their hospitalization 
rates in the APP communities and a somewhat flat hospitalization rates in their FFS 
counterpart. The hospitalization rate for dental conditions in the APP communities increased 
at a rate of 0.10 per 1000 persons per year, in comparison to a somewhat flat rate of 0.001 
per 1000 persons per year in FFS communities (see Figure 16). Similarly, the hospitalization 
rate for cellulitis in the APP communities indicated a slight upward trend of 0.003 per 1000 
persons per year, in comparison to a slight downward rate of 0.05 per 1000 persons per year 
in FFS communities (see Figure 17). 
The hospitalization rate for dental conditions in the APP communities showed a 
significant spike in 2000/01 and 2001/02, as well as a sharp fall in both communities in 
2007/08., In Figure 17, the rates in hospitalization for cellulitis in the APP communities was 
less in comparison to their FFS counterpart in 1992/93, afterwards the rates fluctuated in 
both communities until 2001/02 when the APP communities had a sharp spike and the FFS 
communities had a moderated fall in same year. Interestingly, in 2007/08 both APP and FFS 
communities had a sharp decline in hospitalization rates for cellulitis (see Figures 16 and 17). 
This decline may have been as a result of changes in practice or reporting. 
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Figure 16. Rates of hospitalization for dental conditions, 1992/93 - 2008/09. 
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Rates of Cellulitis Per 1000 Persons 
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Figure 17. Rates of hospitalization for cellulitis, 1992/93 - 2008/09. 
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Rates of hospitalizations for vaccine preventable ACSC conditions 
The conditions shown in Figures 18-29 all have erratic patterns and sudden spikes in 
data that appear then disappear. Comparison of these conditions, slopes and any statistical 
inference would not be useful. Simple description of these conditions follows. The results for 
the vaccine preventable conditions include hospitalizations for diphtheria, hemophilus 
influenza type B, hepatitis A, hepatitis B, mumps, influenza, measles, meningococcal disease 
(meningitis), pertussis, pneumococcal, poliomyelitis, tuberculosis, rubella and tetanus. 
During the period of study, 1992/93 - 2008/09, there was no hospitalization for tetanus and 
poliomyelitis in either of the communities either. Further, there were no hospitalizations for 
hepatitis B and diphtheria in the APP communities as well. The mean rate of hospitalizations 
per 1,000 population for these conditions are summarized in Table 13 
The hospitalization rates for vaccine preventable conditions vary throughout the study 
years for both APP and FFS communities. As illustrated in Figures 18 and 19, the rates of 
hospitalization for influenza and rubella from 1992/93 - 2008/09 in the FFS indicated erratic 
spikes in APP communities and a slight spike in their FFS counterpart. Also, their trend lines 
in both the APP and FFS communities indicate a downward movement and the slope of the 
trend lines is somewhat similar in both plans (see Figure 18 and 19). The hospitalization rate 
for pneumococcal from 1992/93 - 2008/09 in the APP communities had a sudden spike 
whereas their FFS counterpart was somewhat flat. Interestingly, there was a sudden spike in 
2000/01 in the APP communities for influenza, rubella and pneumococcal. This sudden spike 
in hospitalization rates may be as a result of a reporting issue or a systemic glitch, as well as 
an epidemic outbreak. Their trend lines appear to be declining as well (see Figures 18, 19 and 
20 respectively). 
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Table 13 
Rates for Vaccine Preventable Conditions ACSC Hospitalizations in APP Communities, 95% Confidence Intervals, 
1992/93-2008/09 
Influenza 
Hemophilus Influenza Type B 
Mumps 
Rubella 
Pneumococcal 
Pertussis 
Measles 
Pulmonary / other Tuberculosis 
Hepatitis A 
Meningococcal Disease (Meningitis) 
Hepatitis B 
Diphtheria 
APP 
n M SD 95% CI 
27 0.32 0.27 [0.22,0.42] 
1 0.01 0.05 [-0.08,0.10] 
2 0.02 0.07 [-0.07,0.12] 
26 0.29 0.50 [0.09,0.48] 
16 0.19 0.19 [-0.06,0.44] 
2 0.02 0.02 [-0.10,0.14] 
22 0.26 0.26 [-0.05,0.57] 
2 0.03 0.03 [-0.08,0.13] 
1 0.01 0.01 [-0.08,0.10] 
1 0.01 0.01 [-0.08,0.10] 
0 0 
FFS 
n M SD 95% CI 
93 0.23 0.18 [0.19,0.26] 
4 0.01 0.02 [-0.01,0.03] 
8 0.02 0.03 [0.00,0.04] 
72 0.17 0.20 [0.12,0.22] 
105 0.25 0.27 [0.20,0.31] 
12 0.03 0.05 [0.00,0.06] 
87 0.23 0.63 [0.09,0.36] 
11 0.03 0.06 [0.00,0.07] 
13 0.03 0.04 [0.01,0.05] 
18 0.04 0.06 [0.02,0.07] 
27 0.07 0.08 [0.04,0.10] 
1 0.00 0.01 [-0.02,0.02] 
Note. M= mean rate per 1,000 persons. 
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The hospitalization rates for pertussis, hemophilus influenza type B and hepatitis A in 
the APP communities had significant spikes 1998/99, 1993/92 and 1999/00 respectively, 
whereas in 1995/96 and 1997/98 there was a spike in rates of hospitalization for hepatitis B 
and diphtheria respectively in the FFS communities (see Figure 21, 22 and 23). This spike in 
hospitalization rates in APP communities in same study period may have been as a result 
changes in reporting or an outbreak, particular in remote and rural communities where few 
cases double the incidence of the disease. The hospitalization rates (per 1,000 population) of 
mumps, measles, meningitis and tuberculosis are shown on figures 26, 27, 28 and 29 below. 
Rates of Influenza Per 1000 Persons 
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Linear (APP) 
Linear (FFS) 
y = -0.0251X + 0.5423 
R2 = 0.2283 
y = -0.0316x +0.5099 
R2 = 0.7926 
Figure 18. Rates of hospitalization for influenza, 1992/93 - 2008/09. 
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Rates on Rubella Per 1000 Persons 
Figure 19. Rates of hospitalization for rubella, 1992/93 - 2008/09. 
Rates on Pneumococcal Per 1000 Persons 
Figure 20. Rates of hospitalization for pneumococcal, 1992/93 - 2008/09. 
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Rates on Pertussis Per 1000 Persons 
Figure 21. Rates of hospitalization for pertussis, 1992/93 - 2008/09. 
Figure 22. Rates of hospitalization for hemophilus influenza type B, 1992/93 - 2008/09. 
Linear (FFS) 
y = -0.0018X + 0.0376 
R2 = 0.0104 
y = -0.0027X + 0.0535 
R2 = 0.0663 
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Linear (APP) 
Linear (FFS) 
y = -0.0005X + 0.0158 
R2 = 0.0026 
y = -0 0021x + 0 0518 
R2 = 0.0873 
Figure 23. Rates of hospitalization for hepatitis A, 1992/93 - 2008/09. 
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Rates on Hepatitis B Per 1000 Persons 
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Figure 24. Rates of hospitalization for hepatitis B, 1992/93 - 2008/09. 
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Figure 25. Rates of hospitalization for diphtheria, 1992/93 - 2008/09. 
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Figure 26. Rates of hospitalization for mumps, 1992/93 - 2008/09. 
Rates on Measles Per 1000 Persons 
Figure 27. Rates of hospitalization for measles, 1992/93 - 2008/09. 
Rates on Meningococcal Diease (Meningitis) Per 1000 Persons 
Figure 28. Rates of hospitalization for meningitis, 1992/93 - 2008/09. 
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Rates on Pulmonary / other Tuberculosis Per 1000 Persons 
0.30 T 
Figure 29. Rates of hospitalization for pulmonary/other tuberculosis, 1992/93 - 2008/09. 
Statistical Difference between APP and FFS Communities 
Table 14 indicates that the two remunerations plans for GPs (APP and FFS) are 
different with regards to mean hospitalization rates for ACSC per 1,000 population. The 
mean hospitalizations rates per 1,000 population in the APP communities was 36.94 (13.21) 
whereas the FFS communities had a mean hospitalizations rates of 32.02 (5.67) per 1,000 
population for all ACSC. Further, there was a statistical difference in hospitalization rates for 
ACSC between plans, with the APP showing higher rates in hospitalization for ACSC (/(16) 
= 1.83, p = .08, d= 0.48). Note however, that the APP rates appear to be trending upwards as 
shown in Figure 2. This finding demonstrates the importance of my chosen ec-level; since a-
level of .05 would not have seen any difference in population even when the effect size 
(0.48) was small almost medium (see Table 14). 
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From Figure 2, the hospitalization rates for all conditions suggested to be ACSC 
showed a statistically difference in the means hospitalization rates of both APP and FFS 
population. 
Table 14 
Overall Analysis of ACSC Hospitalizations Rates per 1000 Population in APP and FFS 
Communities 
APP 
FFS 
M 
36.94 
32.03 
SD 
13.21 
5.67 
/(16) 
1.83 
P 
.08 
Cohen's d 
0.48 
Analysis of hospitalization rates for ACSC specific conditions 
Based on figures 22, 23, 24, 25, 26, 27, 28 and 29 a t-test analysis is improper in my 
opinion. In these cases trend lines are either having irregular ACSC hospitalizations pattern 
(see Figures 22, 23, 26, 27, 28 and 29) or having a condition show up in one community and 
not the other (see Figures 24 and 25). Further, the actual number of cases is so low as to 
make any further analysis meaningless. 
Chronic ACSC hospitalizations 
Table 15 clearly indicates that there were statistically significant differences found in 
hospitalization rates for chronic ACSC with asthma, pneumonia, COPD, diabetes, angina 
pectoris, convulsion and epilepsy showing a statistical difference in both payment plans. 
There is overwhelming evidence showing that the mean hospitalization rates for these 
conditions above are higher in the APP communities in comparison to their FFS counterpart. 
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It is also worth noting that the difference in the hospitalization rates for diabetes with a 
significant level ofp = (.07) would not have been detected if the alpha level was .05, 
particularly when the effect size was small (0.34). This reinforces the importance of an alpha 
level .10. 
The hospitalization rates for asthma showed a downward trend of 0.29 and 0.17 per 
year per 1000 for the APP and FFS plans respectively, while convulsion and epilepsy 
showed downward trends of 0.03 and 0.11 respectively (see Figure 3 and 10). Whereas the 
hospitalization rate for pneumonia and COPD showed an upward trend of 0.32 and 0.18 per 
year per 1000 population for the APP and FFS plans respectively, while COPD had an 
upward trend of 0.21 and 0.07 per year over 1000 population respectively (Figure 4 and 5). 
Interestingly, the hospitalization rate for angina shows an upward trend of 0.13 per year per 
1000 population in the APP communities and a downward in the FFS communities, 0.04 per 
year per 1000 population (Figure 7). Other chronic conditions (not statistically significant) 
such as hypertension and diabetes showed upward trends; anemia and heart failure showed 
both showed an upward trend for APP and a downward trend for FFS ; bronchitis showed a 
downward trend for APP and an upward trend for FFS. The summary of the means and 
standard deviations can be found on Table 15. 
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Table 15 
Contrast of APP Communities with FFS Communities in Hospitalization for Chronic ACSC 
ACSC conditions 
Asthma 
Bronchitis 
Pneumonia 
COPD 
Hypertension 
Heart Failure 
Angina Pectoris 
Anemia 
Diabetes 
Convulsion/Epilepsy 
i 
M 
3.40 
0.82 
2.94 
1.06 
4.23 
0.42 
2.34 
0.84 
3.60 
2.18 
\PP 
SD 
1.55 
0.67 
2.43 
1.27 
3.41 
0.34 
1.36 
0.55 
7.44 
1.07 
M 
2.55 
0.79 
1.65 
0.49 
4.49 
0.53 
0.90 
0.90 
1.64 
2.82 
FFS 
SD 
1.54 
0.69 
1.08 
0.47 
2.73 
0.12 
0.35 
0.39 
3.31 
0.73 
t(l6) 
2.29 
0.16 
3.46 
2.53 
-0.66 
-1.37 
3.87 
-0.32 
1.92 
-2.38 
P 
.03 
.88 
.00 
.02 
.52 
.19 
.00 
.75 
.07 
.03 
Cohen's 
d 
0.55 
0.04 
0.69 
0.60 
-0.08 
-0.43 
1.45 
-0.13 
0.34 
-0.70 
Acute A CSC hospitalization 
The mean hospitalization rates for gastroenteritis and dehydration were found to be 
statistically significant with FFS plan showing a higher rate in hospitalization in comparison 
to APP plan (t(16) = -4.34, p = .00, d = 0.49) (see Table 16). The other acute conditions did 
not show statistical significant difference in either remuneration plans. The summary of the 
means and standard deviations can be found on Table 16. 
The hospitalization rates for gastroenteritis and dehydration showed an upward trend 
of 0.28 and 0.31 per year per 1000 persons for the APP and FFS plans respectively, Other 
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acute conditions (not statistically significant) dental conditions, cellulitis showed upward 
trend; anemia and heart failure showed both showed upward trend for APP and a downward 
trend for FFS; bronchitis showed a downward trend for APP and an upward trend for FFS. 
Table 16 
Contrast of APP Communities with FFS Communities in Hospitalization for Acute ACSC 
ACSC conditions 
Dental Condition 
Pelvic inflammatory disease 
Gastroenteritis & Dehydration 
Severe ENT infection 
Cellulitis 
APP 
M 
4.98 
2.12 
2.70 
2.61 
1.55 
SD 
1.51 
1.19 
1.61 
0.71 
0.6 
FFS 
M 
4.68 
1.79 
3.59 
2.64 
1.47 
SD 
1.09 
0.83 
2.00 
1.40 
0.48 
>(16) 
1.25 
1.67 
-4.34 
-0.11 
0.37 
P 
.23 
.11 
.00 
.91 
.71 
Cohen's 
d 
0.23 
0.32 
-0.49 
-0.03 
0.15 
Vaccine preventable ACSC hospitalization 
There was no statistical significant difference in the hospitalization rates for vaccine 
preventable conditions, as shown on Table 17. The summary of the means and standard 
deviations can be found on Table 17. All vaccine preventable conditions had a downward 
trend in hospitalization for ACSC, with the exception of tuberculosis. 
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Table 17 
Contrast ofAPP Communities with FFS Communities in Hospitalization for Vaccine 
Preventable ACSC 
APP FFS Cohen's 
ACSC conditions M SD M SD t(\6) P D 
Influenza 032 027 023 018 L40 18 0.39 
Pneumococcal 0.19 0.51 0.25 0.27 -0.63 .54 -0.15 
Rubella 0.29 0.50 0.17 0.20 1.04 .31 0.32 
Length of Hospital Stay in APP and FFS Communities 
The length of stay involves the total number of days a patient was hospitalized for a 
particular condition. The conditions not reported in this analysis are conditions that have 
irregular data patterns. These conditions include heart failure, diphtheria, hemophilus 
influenza Type B, hepatitis A, hepatitis B, measles, meningitis, mumps, pertussis, 
pneumococcal, poliomyelitis, tuberculosis, and tetanus. A difference in length of 
hospitalization may indicate systemic or administrative default as well as difficulty in 
discharge planning, coordination of primary care providers, comorbidites and late diagnosis. 
Length of hospital stay in APP and FFS communities for chronic ACSC 
Table 18 summarizes the mean length of hospitalizations for various chronic ACSC 
in 1992/93 - 2008/09. The mean length of hospitalization varied in each payment plans and 
conditions during the period of study. Of all chronic ACSC hospitalization, convulsion and 
epilepsy is the only condition with a statistical significant difference in the length of 
hospitalization (/(16) = -4.34, p = .00), with Cohen d = 0.49; mean of 1.77 (0.55) and 2.29 
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(1.01) for APP and FFS plan respectively. Thus, the length of hospitalization for convulsion 
and epilepsy is higher under the FFS plan in comparison to the APP plan. 
Table 18 
Contrast of APP Communities with FFS Communities in Length of Hospital Stay for c^vv^.-.^ 
ACSC 
Asthma 
Cohen's 
M SD 95% CI f(16) p d 
-1.14 .27 -0.41 APP 
FFS 
319 
1360 
1.90 
2.25 
Convulsion and Epilepsy 
APP 
FFS 
Hypertension 
APP 
FFS 
Bronchitis* 
APP 
FFS 
Pneumonia 
APP 
FFS 
COPD 
APP 
FFS 
Diabetes* 
APP 
FFS 
221 
1417 
50 
140 
232 
701 
646 
1570 
149 
266 
97 
329 
Angina Pectoris 
APP 
FFS 
Anemia* 
APP 
FFS 
245 
322 
13 
53 
1.77 
2.29 
1.36 
2.13 
2.61 
2.31 
4.12 
4.45 
2.77 
3.49 
3.14 
5.95 
2.06 
2.27 
0.79 
2.03 
1.08 
0.59 
0.55 
1.01 
2.37 
1.42 
1.95 
1.18 
2.99 
1.38 
2.93 
3.26 
1.15 
2.12 
1.28 
0.72 
1.16 
2.72 
[1.78,2.01] 
[2.22, 2.28] 
[1.69, 1.84] 
[2.23, 2.34] 
[0.64, 1.92] 
[1.76,2.25] 
[2.36, 2.86] 
[2.22, 2.40] 
[3.89, 4.35] 
[4.38, 4.52] 
[1.98,2.91] 
[2.69, 3.47] 
[2.91,3.37] 
[5.72,6.18] 
[1.90,2.22] 
[2.19,2.35] 
[0.16, 1.42] 
[1.29,2.76] 
-2.17 .05 -0.64 
•1.11 .28 -0.39 
1.48 .16 0.18 
-0.37 .71 -0.14 
-0.85 .40 -0.23 
•1.10 .12 -1.64 
-0.53 .60 -0.20 
-1.56 .15 -0.59 
Note: The degree of freedom for bronchitis, diabetes & anemia are 15, 4 and 11 respectively. 
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Length of hospital stays in APP and FFS communities for acute ACSC 
Table 19 summarizes the mean length of hospitalizations for various acute ACSC in 
1992/93 - 2008/09. The mean length of hospitalization varied in each payment plans and 
conditions during the period of study. Of all acute ACSC, dental conditions is the only 
condition with a statistically significant difference in the length of hospitalization (t (16) = 
2.31, p = .03), with Cohen d = 0.64; mean of 0.31 (0.34) and 0.14 (0.16) for APP and FFS 
plan respectively. Thus, this evidence suggests that a patients length of hospitalization for a 
dental condition is higher under the APP plan in comparison to the FFS plan. This disparity 
in length of hospitalization between the APP and FFS communities may be as a result of the 
lack of dental care in remote and rural areas. 
Table 19 
Contrast of APP Communities with FFS Communities in Length of Hospital Stay for Acute 
ACSC 
Cohen's 
N M SD 95% CI t(l6) p d 
Dental conditions 
APP 105 0.31 
FFS 200 0.14 
Pelvic inflammatory disease 
APP 195 1.54 
FFS 456 1.63 
Dehydration 
APP 214 2.00 
FFS 645 1.95 
Severe ENT Infection 
APP 151 1.79 
FFS 591 1.28 
Cellulitis 
APP 287 3.67 
FFS 1154 3.63 
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0.34 [0.24,0.37] 2.31 .03 0.64 
0.16 [0.12,0.16] 
1.11 [1.39.1.70] -0.24 .81 -0.08 
0.87 [1.55,1.71] 
1.61 [1.78,2.21] 0.11 .92 0.04 
0.94 [1.87,2.02] 
1.75 [1.51,2.07] 1.15 .27 0.40 
0.44 [1.25, 1.32] 
2.10 [3.43,3.92] 0.07 .94 0.03 
1.12 [3.56,3.69] 
Length of hospital stays in APP and FFS communities for vaccine preventable 
ACSC 
Table 20 summarizes the mean length of hospitalizations for various vaccine 
preventable ACSC in 1992/93 - 2008/09. The mean length of hospitalization varied in each 
payment plans and ACSC conditions during the period of study. There were no statistical 
differences in the length of hospitalization for vaccine preventable conditions in APP and 
FFS plans with an exception of influenza and rubella as shown on Table 20 below. 
Table 20 
Contrast of APP Communities with FFS Communities in Length of Hospital Stay for 
Vaccine ACSC 
Cohen's 
M SD 95% CI t(\6) p d 
Influenza 
APP 1.23 
FFS 1.63 
Rubella 
APP 1.60 
FFS 3.68 
Summary of Finding. 
Overall, the APP communities showed higher rates of hospitalization for ACSC (t = 
1.83, df= 16, p = .08), with Cohen's d = 0.48. Chronic conditions such as asthma, 
pneumonia, COPD, diabetes, and angina showed a higher rate hospitalization in APP 
communities, while epilepsy and convulsion, and dehydration showed a higher ration of 
hospitalization in the FFS communities in comparison to their counterparts. Some conditions 
such as diphtheria, hepatitis A, hepatitis B, and tuberculosis were unsuitable for statistical 
testing because of irregular data patterns and very low incidence. The hospitalization rates 
89 
1.27 [0.81, 1.64] -1.43 .08 -0.35 
1.03 [1.47, 1.80] 
1.64 [1.02, 1.83] -2.30 .04 -1.31 
1.52 [2.14, 1.32] 
for all vaccine preventable and acute conditions, with the exception of dehydration, were 
statistically non-significant in both APP and FFS communities. Furthermore, the length of 
hospitalization for most chronic, acute and vaccine preventable conditions in APP and FFS 
plans were not different. Notable exceptions included convulsion and epilepsy, dental 
conditions, influenza and rubella which indicated statistically significant differences between 
APP and FFS. The APP had a higher longer hospital stay for dental conditions in comparison 
to the FFS plan, whereas the FFS had a longer hospital stay for convulsion and epilepsy, 
influenza and rubella in comparison to the APP plan. 
Table 21 
Summary of Finding 
APP FFS 
Overall ACSC rate t 1 
ACSC Specific Condition 
Chronic ACSC 
Asthma 
Pneumonia 
COPD 
Angina Pectoris 
Diabetes 
Convulsion & Epilepsy 
Acute ACSC 
Gastroenteritis & Dehydration 
Length of Hospitalization 
Chronic ACSC 
Convulsion & Epilepsy 
Acute ACSC 
Dental Conditions 
Vaccine Preventable ACSC 
Influenza 
Rubella 
T 
T 
t 
T 
T 
4 
i 
i 
t 
t 
t 
4 
I 
i 
i 
i 
T 
T 
I 
4 
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Chapter Five: Discussion 
Key Findings and Contribution 
This study is the first to compare the rates in hospitalization of ambulatory care 
sensitive conditions for persons accessing the care of a general practitioner remunerated 
under the alternative payment plan and fee-for-service remuneration in Northern British 
Columbia, Canada. Improving access to primary care is one principal objective of healthcare 
policy makers to improve the health of Canadians, since access to primary care is widely 
considered to be a necessary building block of an effective health care delivery system. 
However the literature is inconsistent as to any one measure of access as the best possible 
indicator of system performance in the primary care settings (Ricketts et al., 2001). Over the 
past decade, one tool established for analyzing access to care, has been hospitalization rates 
for ACSC. The findings from ACSC hospitalization rates has being significant, as it provides 
a practical way of evaluating care delivered in the primary care settings, as well as 
identifying appropriate areas for improving access and quality of care. 
The decision to use alpha at .10 in this study, was to ensure no possible difference 
was missed. While this admittably increases the likelihood of more Type I errors (claims of 
difference that might not exist), I was more concerned about lessening the Type II errors 
(capturing all possible differences). Furthermore, having a small sample size (df= 16) poses 
problems with Type I and II errors. For this study, we included 17 years of data. Increasing 
the sample size to other communities was not practical. This is one limitation of using an 
administrative data since analysis is limited to what is provided. Hence, a particular strength 
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of this study is to use alpha-level of .10 for statistical testing, so as to capture all differences 
that may not have been identified with alpha-level of .05. 
The analysis applied an interpolation and extrapolation procedure to estimate 
population size in between census years. This allowed me to complete a population based 
analysis of ACSC, a widely used indicator for measuring of access and quality of primary 
care (Ansari et al. 2006; Caminal et al. 2004; Pappas et al., 1997). The definition of ACSC 
used for this study was adapted from Lavoie et al. (2010), using ten chronic conditions 
(asthma, angina pectoris, heart failure, convulsion and epilepsy, diabetes, hypertension, 
COPD, pneumonia, bronchitis and anemia); five acute conditions (dental condition, cellulitis, 
pelvic inflammatory disease, gastroenteritis and dehydration, severe ENT infections); and 
fourteen vaccine preventable conditions (diphtheria, hemophilus influenza type B, hepatitis 
A, hepatitis B, influenza, measles, meningitis, mumps, pertussis, pneumococcal, 
poliomyelitis, tuberculosis, rubella and tetanus). The major contribution of the study is to 
provide some insights into how different modes of GPs remuneration can translate into better 
outcomes for patients, and presumably improve provider satisfaction, as well as decrease 
costs. 
Hospitalization rates are often associated with several factors that include personal 
income and the relative wealth of a person's community, healthcare coverage, race, region, 
and gender, as well as the correlation among those factors and incidence of the underlying 
disease (Ricketts et al., 2001). Variations in hospitalization rates for ACSC conditions over 
time among the APP and FFS communities could prompt further studies as to why these 
discrepancies occurred. Variation may arise due to changes in reporting or method of 
delivery care, systemic problems and several confounding factors like physician supply, 
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'social admission', where patient travel longer distance for care and are often hospitalized to 
precipitate care, hospital bed supply, etc. The reason for the discrepancies as to why certain 
conditions will be reported in certain calendar year under a particular payment option and not 
in the following year, are unknown. Possibilities include, for example, an epidemic or mild 
flu season in one community versus the other. Variations for chronic conditions require 
further investigation. Other determinants of these variations could be improved vaccination 
coverage or better recruitment of health professional in one community in comparison to the 
other. The overarching importance of the ACSC is to showcase these conditions that are 
thought to be avoidable if patients have timely care. Factors associated with preventable 
hospitalization or ACSC rates have specifically been examined by a number of researchers 
(Billings et al., 1993; Pappas et al., 1997; Ricketts et al., 2001). 
This study is not intended to address the appropriateness of hospitalization or quality 
of care. This is because diagnoses are not certain until discharge from hospital and abstracts 
are completed. The assertion remains one of the primary limitations of using administrative 
hospitalization data to ascertain appropriateness of care. 
Rates of hospitalization and ACSC 
Overall there was a statistical significant difference between the two the payment plan 
(7(16) = 1.83, p = .08), with Cohen's d = 0.48, particularly in four chronic conditions 
(asthma, COPD, pneumonia and convulsion and epilepsy) and one acute condition 
(gastroenteritis and dehydration). This is an important addition to the literature, as no study 
has examined the effectiveness of the GPs payment plans using hospitalization for ACSC. 
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In Table 12, the mean and standard deviation of all hospitalization for ACSC in FFS and 
APP communities are shown. The figure indicates that the rates of hospitalization for ACSC 
were higher among the APP communities in comparison to their FFS counterpart, 
particularly among chronic conditions. Previously the prevalence of hospitalization for 
conditions thought to be avoidable was calculated and compared between the two groups and 
the findings recorded in Tables 10 - 15. For the chronic conditions asthma, pneumonia, and 
COPD, there were statistically significant differences found, with the APP showing a higher 
rate of hospitalization in comparison to the FFS plans. Also important was higher rates of 
hospitalization for convulsion and epilepsy, gastroenteritis and dehydration in the FFS 
community in comparison to the APP communities. 
For chronic conditions of hypertension, bronchitis, diabetes, heart failure, and anemia 
there was no statistically significant difference between the two payment plans. In the larger 
part, this speaks to management of these chronic conditions. In part, several environmental 
factors like tobacco smoke, allergens, occupational and indoor pollutants may have also 
contributed to these differences in hospitalization rates for asthma, pneumonia, COPD, 
angina, diabetes and convulsion in both payment plans. In addition, I could not control for 
prevalence of diseases in certain communities. 
For acute conditions of dental conditions, cellulitis, pelvic inflammatory disease, and 
severe ENT infections there were no statistically significant differences in the hospitalization 
rates between two payment plans. For vaccine preventable conditions there was no 
statistically significant difference between the two plan options. This is not surprising 
following the innovations and health promotion and education around vaccinations. 
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One possible explanation of the difference reported here is that only those diagnoses 
confirmed by GPs and do not include individual with certain symptoms still to be diagnosed. 
Thus, the rates of ACSC may have being underestimated. Although there is no significant 
difference in hospitalizations for several conditions thought to be avoidable between the two 
payment options, it is noteworthy that the prevalence of certain conditions is dependent on 
the demographic composition of the population. Thus a community with younger or older 
population may influence the prevalence of the certain conditions classified as ACSC. 
Statistical analysis 
Overall, the mean rates in hospitalization for conditions classified as ACSC were found 
to have statistically important differences between APP and FFS communities. The APP 
communities had an increasing rate of 2.13 per year per 1000 population while the FFS had a 
slight increase of 0.20 per year per 1000 population. These findings suggest that the rate of 
ACSC hospitalization in the APP communities is significantly higher in comparison to the 
FFS communities. Further, from Table 15, five chronic conditions showed significant 
differential trends in hospitalization for ACSC include asthma, convulsion, pneumonia, 
angina pectoris and COPD. Gastroenteritis and dehydration also showed differential 
statistical trend in rate of hospitalizations. 
The overarching objective of exploring rates of hospitalization for ACSC has been that 
increased rates of these conditions thought to be avoidable via timely access to care may 
indicate potential problems with the health delivery system. This study compares the rate of 
ACSC for communities under GPs remunerated with either APP or FFS payment schemes. 
Specifically, I compared GP remuneration plans using hospitalization for ACSC. The 
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findings from this study showed statistical differences in hospitalization rate for ACSC 
between both remuneration plans with the higher rate leaning toward the APP plan as 
compared to the FFS community. The statistical analysis focuses on conditions that had the 
trend lines running in both the same direction and opposite direction as shown on Figures 2 -
21. Conditions that had trend lines for only one conditions or irregular pattern were excluded 
from statistical analysis as shown on Tables 15-17. 
Length of hospital stay 
There was no significant difference in length of stay for conditions classified as ACSC 
in this study. However, there were statistical differences in length of hospitalization for 
convulsion and epilepsy with the FFS plan showing a longer stay in comparison to the APP 
plan (see Table 16); and dental conditions where the length of hospitalization was longer 
under the APP plan as compared to the FFS plan (see Table 17). The literature suggests that 
several factors have been responsible for prolonged length of stay for ACSC. One such 
contributor includes re-hospitalization as related to access to care barriers and post discharge 
follow-up (Porter, Herring, Lacroix, & Levinton, 2007). While not all re-hospitalizations are 
avoidable, certain factors contribute to repeated admissions among patients hospitalized for 
ACSC. These factors include discharge planning, non-compliance with treatment, family 
history (nature causes), coordination of primary care professionals (Porter et al., 2007). 
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Chapter Six: Conclusion 
Hospitalization rates for ambulatory care sensitive conditions (ACSC) are widely 
used as an indicator of access and the quality of primary care delivered. This study examines 
the effectiveness of primary care interventions provided by general practitioners (GP) 
remunerated under the fee-for-service (FFS) or alternative payment plan (APP), using health 
service utilization data for ACSC. The main goal of this study was to examine how GP 
remuneration and incentive contribute to the core objective of a public funded health system 
like Canada's; i.e., reduce cost of care, improve patient outcome and providers' satisfaction 
(Berwick et al., 2008; Beasley, 2009). The hospital separation data used for this study was 
provided by BC Ministry of Health, held at Population Data BC. The Population Data BC 
maintains comprehensive, longitudinal, population-based administrative database containing 
all physician billings files and hospitalization also required in this study. 
The result of this study illustrates the importance of physician remuneration, 
particularly with regard to hospitalization for ACSC. Increase rates in hospitalization for 
ACSCs are correlated with inadequate access and delivery of primary care, which leads to 
deterioration of health conditions and to over utilization of hospitals (Delvin & Sarma, 
2008), since proactive utilization health care services is thought to be better use of health 
care. This study is timely particularly for development of initiatives that will improve access, 
reduce cost, and improve patients' outcome and providers' satisfaction. 
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Returning to the Conceptual Model 
In the introduction, a conceptual model was proposed regarding the difference in 
rates of hospitalizations for ACSC in select communities where general practitioners are 
remunerated by FFS or APP. This model appeared as follows: 
Payment Plan Characteristics 
Fee-For-Service 
- Increases physician 
autonomy 
- High service volume 
-Limited access for sicker less 
able patients 
-Encourage quick, frequent 
service 
- Over service 
Alternative Payment Plans 
- Increase physician patient 
relationship 
- Better cost control 
- Eliminate over service 
- Under servicing 
- Loss physician autonomy 
Lesson from Literature 
Innovation: Measure of 
Performance 
t Quantity of 
service 
TCost 
| Quality of service 
Is there a difference? 
t Quality of service 
t Saving 
J. Quantity of 
service 
Avoidable 
hospitalization 
for ACSC 
Avoidable 
hospitalization 
for ACSC 
Figure 30. Conceptual model for comparison of general practitioner remunerations. 
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In this thesis, administrative data were analysed to examine the difference in health 
service utilization for ACSC in select Northern BC communities served by GP under the FFS 
and APP remuneration. In doing so, this thesis has informed the conceptual model and has 
provided insights into the difference in hospitalization rates for ACSC in both APP and FFS 
communities. At the conclusion of this thesis the below were the hypothesis results. 
Hypothesis results. 
The hypothesis HI a, that there no difference in the rates of avoidable hospitalization 
forACSC between communities with FFS payment plan and APP for the general practitioner 
is not supported as there are differences in rate of hospitalization for ACSC in APP and FFS 
communities. Likewise, the hypothesis Hlb, that there is no difference in rates of 
hospitalization for diagnosis classified as ACSC in APP communities and FFS communities 
is not supported for the chronic conditions of asthma, pneumonia, convulsion and epilepsy, 
angina pectoris, and chronic obstructive pulmonary disease (COPD), and acute condition 
gastroenteritis and dehydration. Based on the findings in this study, there are significant 
differences in hospitalization rates for the above mentioned chronic conditions in the APP 
and FFS communities. 
The hypothesis H2a, that there is no difference in trends in rates of hospitalization 
for ACSC between communities with FFS payment plan and APP for the general 
practitioner. Based on data erratic patterns rate of change analysis is not useful. 
The hypothesis H3, that there is no difference in length of hospitalizations of 
diagnoses classified as ACSC between communities with FFS payment plan and APP plans 
for the general practitioner is not supported as there are statistical differences in length of 
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hospitalization rate for chronic and acute conditions of convulsion and epilepsy and dental 
conditions respectively. 
In sum, the results from this study include the following; first, overall hospitalization 
rates for ACSC were significantly different between remuneration plans, with the APP plan 
showing a higher rate of hospitalization for ACSC in comparison to the FFS plan. 
Furthermore, rates in hospitalization for most chronic conditions (asthma, convulsion and 
epilepsy, angina pectoris, pneumonia, COPD) and acute conditions (gastroenteritis and 
dehydration) were found to be different in the two payment plans with the asthma, angina 
pectoris, pneumonia and COPD showing higher rates of hospitalization in the APP 
communities compared to FFS communities, while (convulsion and epilepsy) and 
(gastroenteritis and dehydration) showed higher rates of hospitalization in the FFS 
communities than APP communities. 
Second, overall trends in hospitalization rates for ACSC appear to show important 
differences for between remuneration plans, with the APP plan showing an upward trend in 
rate of hospitalization for ACSC in comparison to the FFS plan. Furthermore, rates of 
hospitalization for most chronic condition (asthma, convulsion and epilepsy, angina pectoris, 
pneumonia, COPD) and acute condition (gastroenteritis and dehydration) were found to be 
statistically different in both payment plans with the asthma, angina pectoris, pneumonia and 
COPD showing higher rates of hospitalization in the APP communities than FFS 
communities, while (convulsion and epilepsy) and (gastroenteritis and dehydration) showed 
higher rates in hospitalization in the FFS communities than APP communities. 
Third the length of hospitalization was different in one chronic (convulsion and 
epilepsy) and acute (dental conditions) conditions. The hospitalization for convulsion and 
epilepsy was found to be longer for the FFS communities in comparison to APP 
communities, while there was more lengthy stay for dental condition in the APP 
communities in comparison to FFS communities. 
Study limitations. 
First, this study only examined people aged 65 years and younger. It is possible to 
arrive at different conclusions when all age groups are examined. However, the under 65 
population is an interesting one for the purposes of studying ACSC as the entire population is 
insured, which reduces insurance as a reason for problems with access to care. 
Second, this study used administrative health data mandated by the Government of 
British Columbia for monitoring and financial purposes. One potential limitation of using 
these data is that they are collected for non-research purposes, and thus may result in possible 
lack of modification of the variables, missing information and coding errors. However the 
importance of using administrative data is that they require fewer resources than primary 
data collection, as well as allow for longitudinal follow-up of individuals. Still, the benefits 
of using administrative data for specific project outweigh the limitations since using readily 
available data to measure ACSC is a pragmatic strategy for assessing the performance of the 
primary care system. 
Third, in assessing the validity and characteristic of the ACSC measure, this study 
was restricted by the content of the administrative data available. Using the hospital 
separation data, I have not control on physician practices and availability, local health 
practices, severity of illness, area of residence and other social and economic factors that 
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could be responsible for differential rates. Subsequent studies will be required to address 
these limitations. 
Fourth, this is an ecological study, in which the unit of analysis is population based 
rather than individual member of the population. One limitation of this study design is the 
potential for leakages, where patients from FFS communities receive services from APP GPs 
and vice versa. Moreover, registry records on patients' may not have been updated at the 
point of hospitalization However, I will assume the two groups are separate that there were 
no diffusions across communities, since six digits postal codes for both communities were 
used in tracking hospitalizations. Further, I reasonable assume that the leakage is on biased in 
one group than the other. 
Fifth, this study used the linear interpolation technique to estimate the study 
population of calendar years 1992 - 2006 and assumed that the community groups were 
equal for calendar years 2007-2008. Thus the hospitalization rates for ACSC and community 
population may have been underestimated or overestimated. In spite of this, the bias was not 
in one community than the other. 
Sixth, the APP was established in rural and remote communities as a recruitment and 
retention tool for GPs. However, obtaining data on when the APP was implemented in the 
APP communities was challenging, as it varied per community. Hence, the study assumed 
that all GPs in the APP communities were paid under the APP during the period. This may 
have resulted in a 'mix bag' where GPs may have being remunerated under the FFS plan 
during the period of study in the APP communities. While possible, this remains unlikely as 
GPs funded under the APP model were provided with this opportunity because recruitment 
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of GPs under FFS was challenging, leaving the same communities with no local access to 
GPs. 
Seventh, my analysis, I used aggregate measures, thereby introducing potential 
limitations in the analysis of long-term practical use of measures as well as contributing to 
aggregation bias. However, comparison of rates also focused on individual ACSC conditions, 
which is very beneficial for targeted interventions and policy making. Finally, this study 
measured hospitalizations for a population with higher rates ACSC along with an equivalent 
risk of hospitalization per person; as such the rate of hospitalization will appear greater for 
those rural communities. 
Implication of this study 
Further research. 
This study is based on data from individual hospitalized for conditions that are thought 
to be sensitive to primary care to draw an inference about quality of preventive care, 
management of chronic conditions and access to care. However, further research in this area 
is required to further validate of the findings of this study by exploring the effect of all 
confounding factors that may have contributed to the differences in hospitalization rates for 
ACSC found in both payment plans. The most pressing need for future research in this area 
is to further validate the odds that a person be hospitalized for ACSC under the APP or FFS 
remuneration plans. 
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Policy and practice. 
Hospitalization rates can be used to examine health system performance, evaluate 
policy changes, as well as assessment of quality preventive care (Lavoie et al., 2010). This 
study is focused on flagging potential barriers to accessing quality preventive care in primary 
care settings using physician remuneration plan. This study is based on the assumption that 
physician remuneration plans and its embedded incentives have an influence on their output. 
Hence the results of this study are beneficial to stakeholder and policy makers as to the most 
effective way of remunerating and incentivizing general practitioners so the core goals the 
health system (reduce cost, improve patient and provider satisfaction) can be achieved. 
Further, this study explored the rates in hospitalization for individual ACSC hospitalizations, 
which is very beneficial for targeted interventions and policy making. 
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Appendix A: Conditions Suggesting Potentially Avoidable Hospitalizations, with 
Corresponding ICD-9 and ICD-10-CA Codes 
Chronic Conditions 
i 
ANEMIAS 280 IRON DEFICIENCY 
ANAEMIAS 
280.0 SECONDARY TO BLOOD 
LOSS (CHRONIC) 
280.1 SECONDARY TO 
INADEQUATE DIETARY IRON 
INTAKE 
280.8 OTHER SPECIFIED IRON 
DEFICIENCY ANEMIAS 
280.9 IRON DEFICIENCY 
ANEMIA, UNSPECIFIED 
281 OTHER DEFICIENCY 
ANAEMIAS 
281.0 PERNICIOUS ANAEMIA 
281.1 OTHER VITAMIN-'B 12'-
DEFICIENCY ANAEMIA 
281.2 FOLATE-DEFICIENCY 
ANAEMIA 
281.3 OTHER SPECIFIED 
MEGALOBLASTIC ANAEMIAS, 
NOT ELSEWHERE CLASSIFIED 
281.4 PROTEIN-DEFICIENCY 
ANAEMIA 
281.8 ANAEMIA ASSOCIATED 
WITH OTHER SPECIFIED 
NUTRITIONAL DEFICIENCY 
281.9 UNSPECIFIED 
ANGINA PECTORIS 411.1 INTERMED CORONARY 
SYND 
411.8 ACUTE COR OCCLSN 
W/OMI 
AC ISCHEMIC HRT DIS NEC 
413 ANGINA DECUBITUS 
PRINZMETAL ANGINA 
ANGINA PECTORIS NEC/NOS 
D50 IRON DEFICIENCY ANAEMIA 
D50.0 IRON DEFICIENCY ANAEMIA 
SECONDARY TO BLOOD LOSS 
(CHRONIC) 
D50.1 SIDEROPENIC DYSPHAGIA 
D50.8 OTHER IRON DEFICIENCY 
ANAEMIAS 
D50.9 IRON DEFICIENCY ANAEMIA, 
UNSPECIFIED 
120 ANGINA PECTORIS 
120.0 UNSTABLE ANGINA 
120.1 ANGINA PECTORIS WITH 
DOCUMENTED SPASM 
120.8 OTHER FORMS OF ANGINA 
PECTORIS 
120.80 ATYPICAL ANGINA 
120.88 OTHER FORMS OF ANGINA 
PECTORIS 
120.9 ANGINA PECTORIS, UNSPECIFIED 
123.82 POSTMYOCARDIAL 
INFARCTION ANGINA AS CURRENT 
COMPLICATION FOLLOWING ACUTE 
MYOCARDIAL INFARCTION 
124.0 CORONARY THROMBOSIS NOT 
RESULTING IN MYOCARDIAL 
INFARCTION 
124.8 OTHER FORMS OF ACUTE 
ISCHAEMIC HEART DISEASE 
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124.9 ACUTE ISCHAEMIC HEART 
DISEASE, UNSPECIFIED 
J45 ASTHMA 
J45.0 PREDOMINANTLY ALLERGIC 
ASTHMA 
J45.00 PREDOMINANTLY ALLERGIC 
ASTHMA WITHOUT STATED STATUS 
ASTHMATICUS 
J45.01 PREDOMINANTLY ALLERGIC 
ASTHMA WITH STATED STATUS 
ASTHMATICUS 
J45.1 NONALLERGIC ASTHMA 
J45.10 NONALLERGIC ASTHMA 
WITHOUT STATED STATUS 
ASTHMATICUS 
J45.ll NONALLERGIC ASTHMA WITH 
STATED STATUS ASTHMATICUS 
J45.8 MIXED ASTHMA 
J45.80 MIXED ASTHMA WITHOUT 
STATED STATUS ASTHMATICUS 
J45.81 MIXED ASTHMA WITH STATED 
STATUS ASTHMATICUS 
J45.9 ASTHMA, UNSPECIFIED 
J45.90 ASTHMA, UNSPECIFIED, 
WITHOUT STATED STATUS 
ASTHMATICUS 
J45.91 ASTHMA, UNSPECIFIED, WITH 
STATED STATUS ASTHMATICUS 
BRONCHITIS 466 ACUTE BRONCHITIS AND J20 ACUTE BRONCHITIS 
BRONCHIOLITIS J20.0 ACUTE BRONCHITIS DUE TO 
466.0 ACUTE BRONCHITIS MYCOPLASMA PNEUMONIAE 
466.1 ACUTE BRONCHIOLITIS J20.1 ACUTE BRONCHITIS DUE TO 
HAEMOPHILUS INFLUENZAE 
J20.2 ACUTE BRONCHITIS DUE TO 
STREPTOCOCCUS 
J20.3 ACUTE BRONCHITIS DUE TO 
COXSACKIEVIRUS 
J20.4 ACUTE BRONCHITIS DUE TO 
PARAINFLUENZA VIRUS 
J20.5 ACUTE BRONCHITIS DUE TO 
RESPIRATORY SYNCYTIAL VIRUS 
J20.6 ACUTE BRONCHITIS DUE TO 
RHINOVIRUS 
J20.7 ACUTE BRONCHITIS DUE TO 
ECHOVIRUS 
J20.8 ACUTE BRONCHITIS DUE TO 
OTHER SPECIFIED ORGANISMS 
J20.80 ACUTE BRONCHITIS DUE TO 
HUMAN METAPNEUMOVIRUS 
J20.88 ACUTE BRONCHITIS DUE TO 
OTHER SPECIFIED ORGANISMS 
J20.9 ACUTE BRONCHITIS, 
ASTHMA 493 ASTHMA 
493.0 EXTRINSIC ASTHMA 
493.1 INTRINSIC ASTHMA 
493.9 ASTHMA, UNSPECIFIED 
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UNSPECIFIED 
CONVULSION & 
EPILEPSY 
345 EPILEPSY 
345.0 GENERALIZED 
NONCONVULSIVE EPILEPSY 
345.1 GENERALIZED 
CONVULSIVE EPILEPSY 
345.2 PETIT MAL STATUS 
345.3 GRAND MAL STATUS 
345.4 PARTIAL EPILEPSY, 
WITH IMPAIRMENT OF 
CONSCIOUSNESS 
345.5 PARTIAL EPILEPSY, 
WITHOUT MENTION OF 
IMPAIRMENT OF 
CONSCIOUSNESS 
345.6 INFANTILE SPASMS 
345.7 EPILEPSIA PARTIALIS 
CONTINUA 
345.8 OTHER 
345.9 UNSPECIFIED 
780.3 CONVULSIONS 
642.6 ECLAMPSIA 
G40 EPILEPSY 
G40.0 LOCALIZATION-RELATED 
(FOCAL)(PARTIAL) IDIOPATHIC 
EPILEPSY AND EPILEPTIC 
SYNDROMES WITH SEIZURES 
OF LOCALIZED ONSET 
G40.00 LOCALIZATION-RELATED 
(FOCAL) (PARTIAL) IDIOPATHIC 
EPILEPSY AND EPILEPTIC 
SYNDROMES WITH SEIZURES 
OF LOCALIZED ONSET, NOT STATED 
AS INTRACTABLE 
G40.01 LOCALIZATION-RELATED 
(FOCAL) (PARTIAL) IDIOPATHIC 
EPILEPSY AND EPILEPTIC 
SYNDROMES WITH SEIZURES 
OF LOCALIZED ONSET, INTRACTABLE 
G40.1 LOCALIZATION-RELATED 
(FOCAL)(PARTIAL) SYMPTOMATIC 
EPILEPSY AND EPILEPTIC 
SYNDROMES WITH 
SIMPLE PARTIAL SEIZURES 
G40.10 LOCALIZATION-RELATED 
(FOCAL) (PARTIAL) SYMPTOMATIC 
EPILEPSY AND EPILEPTIC 
SYNDROMES WITH 
SIMPLE PARTIAL SEIZURES, NOT 
STATED AS INTRACTABLE 
G40.ll LOCALIZATION-RELATED 
(FOCAL) (PARTIAL) SYMPTOMATIC 
EPILEPSY AND EPILEPTIC 
SYNDROMES WITH 
SIMPLE PARTIAL SEIZURES, 
INTRACTABLE 
G40.2 LOCALIZATION-RELATED 
(FOCAL)(PARTIAL) SYMPTOMATIC 
EPILEPSY AND EPILEPTIC 
SYNDROMES WITH 
COMPLEX PARTIAL SEIZURES 
G40.20 LOCALIZATION-RELATED 
(FOCAL) (PARTIAL) SYMPTOMATIC 
EPILEPSY AND EPILEPTIC 
SYNDROMES WITH 
COMPLEX PARTIAL SEIZURES, NOT 
STATED AS INTRACTABLE 
G40.21 LOCALIZATION-RELATED 
(FOCAL) (PARTIAL) SYMPTOMATIC 
EPILEPSY AND EPILEPTIC 
SYNDROMES WITH 
COMPLEX PARTIAL SEIZURES, 
INTRACTABLE 
G40.3 GENERALIZED IDIOPATHIC 
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EPILEPSY AND EPILEPTIC 
SYNDROMESG40.30O 
G40.30 GENERALIZED IDIOPATHIC 
EPILEPSY AND EPILEPTIC 
SYNDROMES, NOT STATED AS 
INTRACTABLE 
G40.31 GENERALIZED IDIOPATHIC 
EPILEPSY AND EPILEPTIC 
SYNDROMES, INTRACTABLE 
G40.4 OTHER GENERALIZED EPILEPSY 
AND EPILEPTIC SYNDROMES 
G40.40 OTHER GENERALIZED 
IDIOPATHIC EPILEPSY AND EPILEPTIC 
SYNDROMES, NOT STATED AS 
INTRACTABLE 
G40.41 OTHER GENERALIZED 
IDIOPATHIC EPILEPSY AND EPILEPTIC 
SYNDROMES, INTRACTABLE 
G40.5 SPECIAL EPILEPTIC 
SYNDROMES 
G40.50 SPECIAL EPILEPTIC 
SYNDROMES, NOT STATED AS 
INTRACTABLE 
G40.51 SPECIAL EPILEPTIC 
SYNDROMES, INTRACTABLE 
G40.6 GRAND MAL SEIZURES, 
UNSPECIFIED (WITH OR WITHOUT 
PETIT MAL) 
G40.60 GRAND MAL SEIZURES, 
UNSPECIFIED (WITH OR WITHOUT 
PETIT MAL), NOT STATED AS 
INTRACTABLE 
G40.61 GRAND MAL SEIZURES, 
UNSPECIFIED (WITH OR WITHOUT 
PETIT MAL), INTRACTABLE 
G40.7 PETIT MAL, UNSPECIFIED, 
WITHOUT GRAND MAL SEIZURES 
G40.70 PETIT MAL, UNSPECIFIED, 
WITHOUT GRAND MAL SEIZURES, 
NOT STATED AS INTRACTABLE 
G40.71 PETIT MAL, UNSPECIFIED, 
WITHOUT GRAND MAL SEIZURES, 
INTRACTABLE 
G40.8 OTHER EPILEPSY 
G40.80 OTHER EPILEPSY, NOT STATED 
AS INTRACTABLE 
G40.81 OTHER EPILEPSY, 
INTRACTABLE 
G40.9 EPILEPSY, UNSPECIFIED 
G40.90 EPILEPSY, UNSPECIFIED, NOT 
STATED AS INTRACTABLE 
G40.91 EPILEPSY, UNSPECIFIED, 
INTRACTABLE 
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CHRONIC 
OBSTRUCTIVE 
PULMONARY 
DISEASE (COPD) AND 
ALLIED CONDITIONS 
490 BRONCHITIS, NOT 
SPECIFIED AS ACUTE OR 
CHRONIC 
491 CHRONIC BRONCHITIS 
491.0 SIMPLE CHRONIC 
BRONCHITIS 
491.1 MUCOPURULENT 
CHRONIC BRONCHITIS 
491.2 OBSTRUCTIVE CHRONIC 
BRONCHITIS 
491.8 OTHER CHRONIC 
BRONCHITIS 
491.9 UNSPECIFIED 
492 EMPHYSEMA 
494 BRONCHIECTASIS 
496 CHRONIC AIRWAYS 
OBSTRUCTION, NOT 
ELSEWHERE CLASSIFIED 
G41 STATUS EPILEPTICUS 
G41.0 GRAND MAL STATUS 
EPILEPTICUS 
G41.1 PETIT MAL STATUS 
EPILEPTICUS 
G41.2 COMPLEX PARTIAL STATUS 
EPILEPTICUS 
G41.8 OTHER STATUS EPILEPTICUS 
G41.9 STATUS EPILEPTICUS, 
UNSPECIFIED 
R56 CONVULSIONS, NOT ELSEWHERE 
CLASSIFIED 
R56.0 FEBRILE CONVULSIONS 
R56.01 COMPLEX FEBRILE 
CONVULSIONS 
R56.09 FEBRILE CONVULSIONS, 
UNSPECIFIED 
R56.8 OTHER AND UNSPECIFIED 
CONVULSIONS 
R56.80 SEIZURE DISORDER, SO 
DESCRIBED 
R56.88 OTHER AND UNSPECIFIED 
CONVULSIONS 
015 ECLAMPSIA 
O15.0 ECLAMPSIA IN PREGNANCY 
015.1 ECLAMPSIA IN LABOUR 
015.2 ECLAMPSIA IN THE 
PUERPERIUM 
015.9 ECLAMPSIA, UNSPECIFIED AS 
TO TIME PERIOD 
J41 SIMPLE AND MUCOPURULENT 
CHRONIC BRONCHITIS 
J41.0 SIMPLE CHRONIC BRONCHITIS 
J41.1 MUCOPURULENT CHRONIC 
BRONCHITIS 
J41.8 MIXED SIMPLE AND 
MUCOPURULENT CHRONIC 
BRONCHITIS 
J42 UNSPECIFIED CHRONIC 
BRONCHITIS 
J43 EMPHYSEMA 
J43.0 MACLEOD'S SYNDROME 
J43.1 PANLOBULAR EMPHYSEMA 
J43.2 CENTRILOBULAR EMPHYSEMA 
J43.8 OTHER EMPHYSEMA 
J43.9 EMPHYSEMA, UNSPECIFIED 
J44 OTHER CHRONIC OBSTRUCTIVE 
PULMONARY DISEASE 
J44.0 CHRONIC OBSTRUCTIVE 
PULMONARY DISEASE WITH ACUTE 
LOWER RESPIRATORY INFECTION 
J44.1 CHRONIC OBSTRUCTIVE 
PULMONARY DISEASE WITH ACUTE 
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EXACERBATION, UNSPECIFIED 
J44.8 OTHER SPECIFIED CHRONIC 
OBSTRUCTIVE PULMONARY DISEASE 
J44.9 CHRONIC OBSTRUCTIVE 
PULMONARY DISEASE, UNSPECIFIED 
J47 BRONCHIECTASIS 
DIABETES WITH 
COMPLICATIONS 
250 DIABETES MELLITUS 
250.0 DIABETES MELLITUS 
WITHOUT MENTION OF 
COMPLICATION 
250.1 DIABETES WITH 
KETOACIDOSIS 
250.2 DIABETES WITH COMA 
250.3 DIABETES WITH RENAL 
MANIFESTATIONS 
250.4 DIABETES WITH 
OPHTHALMIC 
MANIFESTATIONS 
250.5 DIABETES WITH 
NEUROLOGICAL 
MANIFESTATIONS 
250.50 DIABETES WITH 
OCULAR INVOLVMENT, 
ADULT 
250.51 DIABETES WITH 
OCULAR INVOLVMENT, 
JUVENILE 
250.6 DIABETES WITH 
PERIPHERAL CIRCULATORY 
DISORDERS 
250.7 DIABETES WITH OTHER 
SPECIFIED MANIFESTATIONS 
250.8 DIABETES WITH OTHER 
SPECIFIED MANIFESTATIONS 
250.9 DIABETES WITH 
UNSPECIFIED 
COMPLICATIONS 
E10 TYPE 1 DIABETES MELLITUS 
E10.1 TYPE 1 DIABETES MELLITUS 
WITH ACIDOSIS 
E10.10 TYPE 1 DIABETES MELLITUS 
WITH KETOACIDOSIS 
E10.ll TYPE 1 DIABETES MELLITUS 
WITH LACTIC ACIDOSIS 
E10.12 TYPE 1 DIABETES MELLITUS 
WITH KETOACIDOSIS WITH LACTIC 
ACIDOSIS 
E10.6 TYPE 1 DIABETES MELLITUS 
WITH OTHER SPECIFIED 
COMPLICATIONS 
El 0.60 TYPE 1 DIABETES MELLITUS 
WITH MUSCULOSKELETAL AND 
CONNECTIVE TISSUE COMPLICATION 
E10.61 TYPE 1 DIABETES MELLITUS 
WITH SKIN AND SUBCUTANEOUS 
TISSUE COMPLICATION 
E10.62 TYPE 1 DIABETES MELLITUS 
WITH PERIODONTAL COMPLICATION 
E10.63 TYPE 1 DIABETES MELLITUS 
WITH HYPOGLYCAEMIA 
E10.64 TYPE 1 DIABETES MELLITUS 
WITH POOR CONTROL, SO DESCRIBED 
E10.68 TYPE 1 DIABETES MELLITUS 
WITH OTHER SPECIFIED 
COMPLICATION, NOT ELSEWHERE 
CLASSIFIED 
E10.7 TYPE 1 DIABETES MELLITUS 
WITH MULTIPLE COMPLICATIONS 
E10.70 TYPE 1 DIABETES MELLITUS 
WITH FOOT ULCER (ANGIOPATHIC) 
(NEUROPATHIC) 
E10.71 TYPE 1 DIABETES MELLITUS 
WITH FOOT ULCER (ANGIOPATHIC) 
(NEUROPATHIC) WITH GANGRENE 
E10.78 TYPE 1 DIABETES MELLITUS 
WITH MULTIPLE OTHER 
COMPLICATIONS 
E10.9 TYPE 1 DIABETES MELLITUS 
WITHOUT (MENTION OF) 
COMPLICATION 
El l TYPE 2 DIABETES MELLITUS 
E11.0 TYPE 2 DIABETES MELLITUS 
WITH COMA 
El 1.1 TYPE 2 DIABETES MELLITUS 
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WITH ACIDOSIS 
E11.10 TYPE 2 DIABETES MELLITUS 
WITH KETOACIDOSIS 
Ell.11 TYPE 2 DIABETES MELLITUS 
WITH LACTIC ACIDOSIS 
E11.12 TYPE 2 DIABETES MELLITUS 
WITH KETOACIDOSIS WITH LACTIC 
ACIDOSIS 
E11.6 TYPE 2 DIABETES MELLITUS 
WITH OTHER SPECIFIED 
COMPLICATIONS 
El 1.60 TYPE 2 DIABETES MELLITUS 
WITH MUSCULOSKELETAL AND 
CONNECTIVE TISSUE COMPLICATION 
E11.61 TYPE 2 DIABETES MELLITUS 
WITH SKIN AND SUBCUTANEOUS 
TISSUE COMPLICATIONE11.9 
El 1.62 TYPE 2 DIABETES MELLITUS 
WITH PERIODONTAL COMPLICATION 
El 1.63 TYPE 2 DIABETES MELLITUS 
WITH HYPOGLYCAEMIA 
El 1.64 TYPE 2 DIABETES MELLITUS 
WITH POOR CONTROL, SO DESCRIBED 
E11.68 TYPE 2 DIABETES MELLITUS 
WITH OTHER SPECIFIED 
COMPLICATION, NOT ELSEWHERE 
CLASSIFIED 
E11.7 TYPE 2 DIABETES MELLITUS 
WITH MULTIPLE COMPLICATIONS 
E11.70 TYPE 2 DIABETES MELLITUS 
WITH FOOT ULCER 
(ANGIOPATHIC)(NEUROPATHIC) 
El 1.71 TYPE 2 DIABETES MELLITUS 
WITH FOOT ULCER (ANGIOPATHIC) 
(NEUROPATHIC) WITH GANGRENE 
E11.78 TYPE 2 DIABETES MELLITUS 
WITH MULTIPLE OTHER 
COMPLICATIONS 
E11.9 TYPE 2 DIABETES MELLITUS 
WITHOUT (MENTION OF) 
COMPLICATIONS 
E13 OTHER SPECIFIED DIABETES 
MELLITUS 
E13.0 OTHER SPECIFIED DIABETES 
MELLITUS WITH COMA 
E13.1 OTHER SPECIFIED DIABETES 
MELLITUS WITH ACIDOSIS 
E13.10 OTHER SPECIFIED DIABETES 
MELLITUS WITH KETOACIDOSIS 
E13.ll OTHER SPECIFIED DIABETES 
MELLITUS WITH LACTIC ACIDOSIS 
E13.12 OTHER SPECIFIED DIABETES 
MELLITUS WITH KETOACIDOSIS WITH 
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LACTIC ACIDOSISE13.7 
E13.6 OTHER SPECIFIED DIABETES 
MELLITUS WITH OTHER SPECIFIED 
COMPLICATIONS 
E13.60 OTHER SPECIFIED DIABETES 
MELLITUS WITH MUSCULOSKELETAL 
AND CONNECTIVE TISSUE 
COMPLICATION 
E13.61 OTHER SPECIFIED DIABETES 
MELLITUS WITH SKIN AND 
SUBCUTANEOUS TISSUE 
COMPLICATION 
E13.62 OTHER SPECIFIED DIABETES 
MELLITUS WITH PERIODONTAL 
COMPLICATION 
E13.63 OTHER SPECIFIED DIABETES 
MELLITUS WITH HYPOGLYCAEMIA 
E13.64 OTHER SPECIFIED DIABETES 
MELLITUS WITH POOR CONTROL, SO 
DESCRIBED 
E13.68 OTHER SPECIFIED DIABETES 
MELLITUS WITH OTHER SPECIFIED 
COMPLICATION, NOT ELSEWHERE 
CLASSIFIED 
E13.7 OTHER SPECIFIED DIABETES 
MELLITUS WITH MULTIPLE 
COMPLICATIONS 
E13.70 OTHER SPECIFIED DIABETES 
MELLITUS WITH FOOT ULCER 
(ANGIOPATHIC) (NEUROPATHIC) 
E13.71 OTHER SPECIFIED DIABETES 
MELLITUS WITH FOOT ULCER 
(ANGIOPATHIC) (NEUROPATHIC) WITH 
GANGRENE 
E13.78 OTHER SPECIFIED DIABETES 
MELLITUS WITH MULTIPLE OTHER 
COMPLICATIONS 
E13.9 OTHER SPECIFIED DIABETES 
MELLITUS WITHOUT (MENTION OF) 
COMPLICATION 
E14 UNSPECIFIED DIABETES 
MELLITUS 
E14.0 UNSPECIFIED DIABETES 
MELLITUS WITH COMA 
E14.1 UNSPECIFIED DIABETES 
MELLITUS WITH ACIDOSIS 
E14.10 UNSPECIFIED DIABETES 
MELLITUS WITH KETOACIDOSIS 
E14.ll UNSPECIFIED DIABETES 
MELLITUS WITH LACTIC ACIDOSIS 
E14.12 UNSPECIFIED DIABETES 
MELLITUS WITH KETOACIDOSIS WITH 
LACTIC ACIDOSIS 
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E14.6 UNSPECIFIED DIABETES 
MELLITUS WITH OTHER SPECIFIED 
COMPLICATIONS 
E14.60 UNSPECIFIED DIABETES 
MELLITUS WITH MUSCULOSKELETAL 
AND CONNECTIVE TISSUE 
COMPLICATION 
E14.61 UNSPECIFIED DIABETES 
MELLITUS WITH SKIN AND 
SUBCUTANEOUS TISSUE 
COMPLICATION 
E14.62 UNSPECIFIED DIABETES 
MELLITUS WITH PERIODONTAL 
COMPLICATION 
E14.63 UNSPECIFIED DIABETES 
MELLITUS WITH HYPOGLYCAEMIA 
E14.64 UNSPECIFIED DIABETES 
MELLITUS WITH POOR CONTROL, SO 
DESCRIBED 
E14.68 UNSPECIFIED DIABETES 
MELLITUS WITH OTHER SPECIFIED 
COMPLICATION, NOT ELSEWHERE 
CLASSIFIED 
E14.7 UNSPECIFIED DIABETES 
MELLITUS WITH MULTIPLE 
COMPLICATIONS 
E14.70 UNSPECIFIED DIABETES 
MELLITUS WITH FOOT ULCER 
(ANGIOPATHIC) (NEUROPATHIC) 
E14.71 UNSPECIFIED DIABETES 
MELLITUS WITH FOOT ULCER 
(ANGIOPATHIC) (NEUROPATHIC) WITH 
GANGRENE 
E14.78 UNSPECIFIED DIABETES 
MELLITUS WITH MULTIPLE OTHER 
COMPLICATIONS 
E14.9 UNSPECIFIED DIABETES 
MELLITUS WITHOUT (MENTION OF) 
COMPLICATION 
HEART FAILURE AND 
PULMONARY EDEMA 
428 HEART FAILURE 
428.0 CONGESTIVE HEART 
FAILURE 
428.1 LEFT HEART FAILURE 
428.9 UNSPECIFIED 
518.4 ACUTE OEDEMA OF 
LUNG, UNSPECIFIED 
150 HEART FAILURE 
150.0 CONGESTIVE HEART FAILURE 
150.1 LEFT VENTRICULAR FAILURE 
150.9 HEART FAILURE, UNSPECIFIED 
J81 PULMONARY OEDEMA 
111.0 HYPERTENSIVE HEART DISEASE 
WITH (CONGESTIVE) HEART FAILURE 
HYPERTENSION 401 ESSENTIAL 
HYPERTENSION 
401.0 SPECIFIED AS 
MALIGNANT 
401.1 SPECIFIED AS BENIGN 
401.9 NOT SPECIFIED AS 
110 ESSENTIAL (PRIMARY) 
HYPERTENSION 
II 0.0 BENIGN HYPERTENSION 
110.1 MALIGNANT HYPERTENSION 
111 HYPERTENSIVE HEART DISEASE 
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PNEUMONIA 
MALIGNANT OR BENIGN 
402 HYPERTENSIVE HEART 
DISEASE 
402.0 SPECIFIED AS 
MALIGNANT 
402.1 SPECIFIED AS BENIGN 
402.9 NOT SPECIFIED AS 
MALIGNANT OR BENIGN 
403 HYPERTENSIVE RENAL 
DISEASE 
403.0 SPECIFIED AS 
MALIGNANT 
403.1 SPECIFIED AS BENIGN 
403.9 NOT SPECIFIED AS 
MALIGNANT OR BENIGN 
404 HYPERTENSIVE HEART 
AND RENAL DISEASE 
404.0 SPECIFIED AS 
MALIGNANT 
404.1 SPECIFIED AS BENIGN 
404.9 NOT SPECIFIED AS 
MALIGNANT OR BENIGN 
405 SECONDARY 
HYPERTENSION 
405.0 SPECIFIED AS 
MALIGNANT 
405.1 SPECIFIED AS BENIGN 
405.9 NOT SPECIFIED AS 
MALIGNANT OR BENIGN 
480 VIRAL PNEUMONIA 
480.0 PNEUMONIA DUE TO 
ADENOVIRUS 
480.1 PNEUMONIA DUE TO 
RESPIRATORY SYNCYTIAL 
VIRUS 
480.2 PNEUMONIA DUE TO 
PARAINFLUENZA VIRUS 
480.8 PNEUMONIA DUE TO 
OTHER VIRUS, NOT 
ELSEWHERE CLASSIFIED 
480.9 VIRAL PNEUMONIA, 
UNSPECIFIED 
481 PNEUMOCOCCAL 
PNEUMONIA 
482 OTHER BACTERIAL 
PNEUMONIA 
482.0 PNEUMONIA DUE TO 
KLEBSIELLA PNEUMONIAE 
482.1 PNEUMONIA DUE TO 
PSEUDOMONAS 
482.2 PNEUMONIA DUE TO 
HAEMOPHILUS INFLUENZAE 
(H.INFLUENZAE) 
J12 VIRAL PNEUMONIA, NOT 
ELSEWHERE CLASSIFIED 
J12.0 ADENOVIRAL PNEUMONIA 
J12.1 RESPIRATORY SYNCYTIAL 
VIRUS PNEUMONIA 
J12.2 PARAINFLUENZA VIRUS 
PNEUMONIA 
J12.3 HUMAN METAPNEUMOVIRUS 
PNEUMONIA 
J12.8 OTHER VIRAL PNEUMONIA 
J12.9 VIRAL PNEUMONIA, 
UNSPECIFIED 
J13 PNEUMONIA DUE TO 
STREPTOCOCCUS PNEUMONIA 
J14 PNEUMONIA DUE TO 
HAEMOPHILUS INFLUENZA 
J15 BACTERIAL PNEUMONIA, NOT 
ELSEWHERE CLASSIFIED 
J15.0 PNEUMONIA DUE TO 
KLEBSIELLA PNEUMONIA 
J15.1 PNEUMONIA DUE TO 
PSEUDOMONAS 
J15.2 PNEUMONIA DUE TO 
STAPHYLOCOCCUS 
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482.3 PNEUMONIA DUE TO 
STREPTOCOCCUS 
482.30 STREPTOCOCCUS, 
UNSPECIFIED 
482.31 GROUP A 
482.32 GROUP B 
J15.3 PNEUMONIA DUE TO 
STREPTOCOCCUS, GROUP B 
J15.4 PNEUMONIA DUE TO OTHER 
STREPTOCOCCI 
J15.5 PNEUMONIA DUE TO 
ESCHERICHIA COLI 
J15.6 PNEUMONIA DUE TO OTHER 
482.39 OTHER STREPTOCOCCU! AEROBIC GRAM-NEGATIVE BACTERIA 
482.4 PNEUMONIA DUE TO 
STAPHYLOCOCCUS 
482.40 PNEUMONIA DUE TO 
STAPHYLOCOCCUS, 
UNSPECIFIED 
482.41 METHICILLIN 
SUSCEPTIBLE PNEUMONIA 
DUE TO STAPHYLOCOCCUS 
AUREUS 
482.42 METHICILLIN 
RESISTANT PNEUMONIA DUE 
TO STAPHYLOCOCCUS 
AUREUS 
482.49 OTHER 
STAPHYLOCOCCUS 
PNEUMONIA 
482.8 PNEUMONIA DUE TO 
OTHER SPECIFIED BACTERIA 
482.81 ANAEROBES 
482.82 ESCHERICHIA COLI [E. C 
482.83 OTHER GRAM-
NEGATIVE BACTERIA 
482.84 LEGIONNAIRES' 
DISEASE 
482.89 OTHER SPECIFIED 
BACTERIA 
482.9 BACTERIAL 
PNEUMONIA, UNSPECIFIED 
483 PNEUMONIA DUE TO 
OTHER SPECIFIED ORGANISM 
483.0 MYCOPLASMA 
PNEUMONIAE 
483.1 CHLAMYDIA 
483.8 OTHER SPECIFIED 
ORGANISM 
484 PNEUMONIA IN 
INFECTIOUS DISEASES 
CLASSIFIED ELSEWHERE 
484.0 MEASLES 
484.1 CYTOMEGALIC 
INCLUSION DISEASE 
J15.7 PNEUMONIA DUE TO 
MYCOPLASMA PNEUMONIA 
J15.8 OTHER BACTERIAL PNEUMONIA 
J15.9 BACTERIAL PNEUMONIA, 
UNSPECIFIED 
J16 PNEUMONIA DUE TO OTHER 
INFECTIOUS ORGANISMS, NOT 
ELSEWHERE CLASSIFIED 
J16.0 CHLAMYDIAL PNEUMONIA 
J16.8 PNEUMONIA DUE TO OTHER 
SPECIFIED INFECTIOUS ORGANISMS 
J18 PNEUMONIA, ORGANISM 
UNSPECIFIED 
J18.0 BRONCHOPNEUMONIA, 
UNSPECIFIED 
J18.1 LOBAR PNEUMONIA, 
UNSPECIFIED 
J18.2 HYPOSTATIC PNEUMONIA, 
UNSPECIFIED 
J18.8 OTHER PNEUMONIA, ORGANISM 
UNSPECIFIED 
J18.9 PNEUMONIA, UNSPECIFIED 
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Vaccine 
Preventable 
Conditions 
DIPTHERIA 
HEMOPHILUS 
INFLUENZA TYPE B 
HEPATITIS A 
HEPATITIS B 
484.2 ORNITHOSIS 
484.3 WHOOPING COUGH 
484.4 TULARAEMIA 
484.5 ANTHRAX 
484.6 ASPERGILLOSIS 
484.7 PNEUMONIA IN OTHER 
SYSTEMIC MYCOSES 
484.8 PNEUMONIA IN OTHER 
INFECTIOUS DISEASES 
485 BRONCHOPNEUMONIA, 
ORGANISM UNSPECIFIED 
486 PNEUMONIA, ORGANISM 
UNSPECIFIED 
032 DIPHTHERIA 
032.0 FAUCIAL DIPHTHERIA 
032.1 NASOPHARYNGEAL 
DIPHTHERIA 
032.2 ANTERIOR NASAL 
DIPHTHERIA 
032.3 LARYNGEAL 
DIPHTHERIA 
032.8 OTHER 
032.81 CONIUNCTIVAL 
DIPHTHERIA 
032.82 DIPHTHERITIC 
MYOCARDITIS 
032.83 DIPHTHERITIC PERITON 
032.84 DIPHTHERITIC CYSTITIS 
032.85 CUTANEOUS DIPHTHERJ 
032.89 OTHER 
032.9 DIPHTHERIA, 
UNSPECIFIED 
320.0 HEMOPHILUS 
MENINGITIS 
070.0 VIRAL HEPATITIS A 
WITH HEPATIC COMA 
070.1 VIRAL HEPATITIS A 
WITHOUT MENTION OF 
HEPATIC COMA 
070.2 VIRAL HEPATITIS B 
A36 DIPHTHERIA 
A36.0 PHARYNGEAL DIPHTHERIA 
A36.1 NASOPHARYNGEAL 
DIPHTHERIA 
A36.2 LARYNGEAL DIPHTHERIA 
A36.3 CUTANEOUS DIPHTHERIA 
A36.8 OTHER DIPHTHERIA 
A36.9 DIPHTHERIA, UNSPECIFIED 
GOO BACTERIAL MENINGITIS, NOT 
ELSEWHERE CLASSIFIED 
GOO.O HAEMOPHILUS MENINGITIS 
B15 ACUTE HEPATITIS A 
B15.0 HEPATITIS A WITH HEPATIC 
COMA 
B15.9 HEPATITIS A WITHOUT HEPATIC 
COMA 
B16 ACUTE HEPATITIS B 
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WITH HEPATIC COMA 
070.3 VIRAL HEPATITIS B 
WITHOUT MENTION OF 
HEPATIC COMA 
B16.0 ACUTE HEPATITIS B WITH 
DELTA-AGENT (COINFECTION) WITH 
HEPATIC COMA 
B16.1 ACUTE HEPATITIS B WITH 
DELTA-AGENT (COINFECTION) 
WITHOUT HEPATIC COMA 
B16.2 ACUTE HEPATITIS B WITHOUT 
DELTA-AGENT WITH HEPATIC COMA 
B16.9 ACUTE HEPATITIS B WITHOUT 
DELTA-AGENT AND WITHOUT 
HEPATIC COMA 
INFLUENZA 487 INFLUENZA 
487.0 WITH PNEUMONIA 
487.1 WITH OTHER 
RESPIRATORY 
MANIFESTATIONS 
487.8 WITH OTHER 
MANIFESTATIONS 
J10 INFLUENZA DUE TO OTHER 
IDENTIFIED INFLUENZA VIRUS 
J10.0 INFLUENZA WITH PNEUMONIA, 
OTHER INFLUENZA VIRUS IDENTIFIED 
J10.1 INFLUENZA WITH OTHER 
RESPIRATORY MANIFESTATIONS, 
OTHER INFLUENZA VIRUS IDENTIFIED 
J10.8 INFLUENZA WITH OTHER 
MANIFESTATIONS, OTHER 
INFLUENZA VIRUS IDENTIFIED 
J l l INFLUENZA, VIRUS NOT 
IDENTIFIED 
J11.0 INFLUENZA WITH PNEUMONIA, 
VIRUS NOT IDENTIFIED 
J l l . l INFLUENZA WITH OTHER 
RESPIRATORY MANIFESTATIONS, 
VIRUS NOT IDENTIFIED 
J11.8 INFLUENZA WITH OTHER 
MANIFESTATIONS, VIRUS NOT 
IDENTIFIED 
MEASLES 055 MEASLES 
055.0 POSTMEASLES 
ENCEPHALITIS 
055.1 POSTMEASLES 
PNEUMONIA 
055.2 POSTMEASLES OTITIS 
055.7 WITH OTHER 
COMPLICATIONS 
055.71 
KERATOCONJUNCTIVITIES, 
MEASLES 
055.79 OTHER 
055.8 WITH UNSPECIFIED 
COMPLICATION 
055.9 MEASLES WITHOUT 
MENTION OF COMPLICATION 
B05 MEASLES 
B05.0 MEASLES COMPLICATED BY 
ENCEPHALITIS 
B05.1 MEASLES COMPLICATED BY 
MENINGITIS 
B05.2 MEASLES COMPLICATED BY 
PNEUMONIA 
B05.3 MEASLES COMPLICATED BY 
OTITIS MEDIA 
B05.4 MEASLES WITH INTESTINAL 
COMPLICATIONS 
B05.8 MEASLES WITH OTHER 
COMPLICATIONS 
B05.9 MEASLES WITHOUT 
COMPLICATION 
MENINGOCOCCAL 
DISEASE(MENINGITIS 
) 
036 MENINGOCOCCAL 
INFECTION 
036.0 MENINGOCOCCAL 
A39 MENINGOCOCCAL INFECTION 
A39.0 MENINGOCOCCAL MENINGITIS 
A39.1 WATERHOUSE-FRIDERICHSEN 
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MUMPS 
PERTUSSIS 
MENINGITIS 
036.1 MENINGOCOCCAL 
ENCEPHALITIS 
036.2 MENINGOCOCCAEMIA 
036.3 WATERHOUSE-
FRIDERICHSEN SYNDROME, 
MENINGOCOCCAL 
036.4 MENINGOCOCCAL 
CARDITIS 
036.40 MENINGOCOCCAL 
CARDITIS, UNSPECIFIED 
036.41 MENINGOCOCCAL 
PERICARDITIS 
036.42 MENINGOCOCCAL 
ENDOCARDITIS 
036.43 MENINGOCOCCAL 
MYOCARDITIS 
036.8 OTHER 
036.81 MENINGOCOCCAL 
OPTIC NEURITIS 
036.82 MENINGOCOCCAL 
ARTHROPATHY 
036.89 OTHER 
036.9 UNSPECIFIED 
072 MUMPS 
072.0 MUMPS ORCHITIS 
072.1 MUMPS MENINGITIS 
072.2 MUMPS ENCEPHALITIS 
072.3 MUMPS PANCREATITIS 
072.71 MUMPS HEPATITIS 
072.72 MUMPS POLYNEUROPAr 
072.79 OTHER 
072.8 MUMPS WITH UNSPECIFI 
COMPLICATION 
072.9 MUMPS WITHOUT MENTI 
OF COMPLICATION 
033 WHOOPING COUGH 
033.0 BORDETELLA PERTUSSIS 
(B.PERTUSSIS) 
033.1 BORDETELLA 
PARAPERTUSSIS 
(B.PARAPERTUSSIS) 
033.8 OTHER SPECIFIED 
ORGANISM 
033.9 WHOOPING COUGH, 
SYNDROME 
A39.2 ACUTE MENINGOCOCCAEMIA 
A39.3 CHRONIC MENINGOCOCCAEMIA 
A39.4 MENINGOCOCCAEMIA, 
UNSPECIFIED 
A39.5 MENINGOCOCCAL HEART 
DISEASE 
A39.8 OTHER MENINGOCOCCAL 
INFECTIONS 
A39.9 MENINGOCOCCAL INFECTION, 
UNSPECIFIED 
B26 MUMPS 
B26.0 MUMPS ORCHITIS 
B26.1 MUMPS MENINGITIS 
B26.2 MUMPS ENCEPHALITIS 
B26.3 MUMPS PANCREATITIS 
B26.8 MUMPS WITH OTHER 
COMPLICATIONS 
B26.9 MUMPS WITHOUT 
COMPLICATION 
A37 WHOOPING COUGH 
A37.0 WHOOPING COUGH DUE TO 
BORDETELLA PERTUSSIS 
A37.1 WHOOPING COUGH DUE TO 
BORDETELLA PARAPERTUSSIS 
A37.8 WHOOPING COUGH DUE TO 
OTHER BORDETELLA SPECIES 
A37.9 WHOOPING COUGH, 
UNSPECIFIED 
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UNSPECIFIED ORGANISM 
PNEUMOCOCCAL 
POLIOMYELITIS 
TUBERCULOSIS 
038.2 PNEUMOCOCCAL 
SEPTICAEMIA 
041.2 PNEUMOCOCCUS 
320.1 PNEUMOCOCCAL 
MENINGITIS 
481 PNEUMOCOCCAL 
PNEUMONIA 
[STREPTOCOCCUS 
PNEUMONIAE PNEUMONIA] 
567.1 PNEUMOCOCCAL 
PERITONITIS 
711.0 PYOGENIC ARTHRITIS 
045 ACUTE POLIOMYELITIS 
045.0 ACUTE PARALYTIC 
POLIOMYELITIS SPECIFIED AS 
BULBAR 
045.1 ACUTE POLIOMYELITIS 
WITH OTHER PARALYSIS 
045.2 ACUTE NONPARALYTIC 
POLIOMYELITIS 
045.9 ACUTE POLIOMYELITIS, 
UNSPECIFIED 
010 PRIMARY TUBERCULOUS 
INFECTION 
010.0 PRIMARY 
TUBERCULOUS COMPLEX 
010.1 TUBERCULOUS 
PLEURISY IN PRIMARY 
PROGRESSIVE TUBERCULOSIS 
010.8 OTHER PRIMARY 
PROGRESSIVE TUBERCULOSIS 
010.9 UNSPECIFIED 
011 PULMONARY 
TUBERCULOSIS 
011.0 TUBERCULOSIS OF 
LUNG, INFILTRATIVE 
011.1 TUBERCULOSIS OF 
LUNG, NODULAR 
011.2 TUBERCULOSIS OF 
LUNG WITH CAVITATION 
011.3 TUBERCULOSIS OF 
BRONCHUS 
GOO BACTERIAL MENINGITIS, NOT 
ELSEWHERE CLASSIFIED 
G00.1 PNEUMOCOCCAL MENINGITIS 
A40.3 SEPSIS DUE TO 
STREPTOCOCCUS PNEUMONIA 
J13 PNEUMONIA DUE TO 
STREPTOCOCCUS PNEUMONIA 
A80 ACUTE POLIOMYELITIS 
A80.0 ACUTE PARALYTIC 
POLIOMYELITIS, VACCINE-
ASSOCIATED 
A80.1 ACUTE PARALYTIC 
POLIOMYELITIS, WILD VIRUS, 
IMPORTED 
A80.2 ACUTE PARALYTIC 
POLIOMYELITIS, WILD VIRUS, 
INDIGENOUS 
A80.3 ACUTE PARALYTIC 
POLIOMYELITIS, OTHER AND 
UNSPECIFIED 
A80.4 ACUTE NONPARALYTIC 
POLIOMYELITIS 
A80.9 ACUTE POLIOMYELITIS, 
UNSPECIFIED 
A15 RESPIRATORY TUBERCULOSIS, 
BACTERIOLOGICALLY AND 
HISTOLOGICALLY CONFIRMED 
A15.0 TUBERCULOSIS OF LUNG, 
CONFIRMED BY SPUTUM 
MICROSCOPY WITH OR WITHOUT 
CULTURE 
A15.00 TUBERCULOSIS OF LUNG, 
CONFIRMED BY SPUTUM 
MICROSCOPY WITH OR WITHOUT 
CULTURE, WITH 
A15.01 TUBERCULOSIS OF LUNG, 
CONFIRMED BY SPUTUM 
MICROSCOPY WITH OR WITHOUT 
CULTURE, WITHOUT 
A15.1 TUBERCULOSIS OF LUNG, 
CONFIRMED BY CULTURE ONLY 
A15.2 TUBERCULOSIS OF LUNG, 
CONFIRMED HISTOLOGICALLY 
A15.20 TUBERCULOSIS OF LUNG, 
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011.4 TUBERCULOUS FIBROSIS 
OF LUNG 
011.5 TUBERCULOUS 
BRONCHIECTASIS 
011.6 TUBERCULOUS 
PNEUMONIA (ANY FORM) 
011.7 TUBERCULOUS 
PNEUMOTHORAX 
011.8 OTHER PULMONARY 
TUBERCULOSIS 
011.9 UNSPECIFIED 
012 OTHER RESPIRATORY 
TUBERCULOSIS 
012.0 TUBERCULOUS 
PLEURISY 
012.1 TUBERCULOSIS OF 
INTRATHORACIC LYMPH 
NODES 
012.2 ISOLATED TRACHEAL 
OR BRONCHIAL 
TUBERCULOSIS 
012.3 TUBERCULOUS 
LARYNGITIS 
012.8 OTHER 
013 TUBERCULOSIS OF 
MENINGES AND CENTRAL 
NERVOUS SYSTEM 
013.0 TUBERCULOUS 
MENINGITIS 
013.1 TUBERCULOMA OF 
MENINGES 
013.2 TUBERCULOMA OF 
BRAIN 
013.3 TUBERCULOUS ABSCESS 
OF BRAIN 
013.4 TUBERCULOMA OF 
SPINAL CORD 
013.5 TUBERCULOUS ABSCESS 
OF SPINAL CORD 
013.6 TUBERCULOUS 
ENCEPHALITIS OR MYELITIS 
013.8 OTHER 
013.9 UNSPECIFIED 
014 TUBERCULOSIS OF 
INTESTINES, PERITONEUM 
AND MESENTERIC GLANDS 
014.0 TUBERCULOUS 
PERITONITIS 
014.8 OTHER 
015 TUBERCULOSIS OF BONES 
AND JOINTS 
015.0 VERTEBRAL COLUMN 
015.1 HIP 
CONFIRMED HISTOLOGICALLY, WITH 
CAVITATION 
A15.21 TUBERCULOSIS OF LUNG, 
CONFIRMED HISTOLOGICALLY, 
WITHOUT CAVITATION OR 
UNSPECIFIED 
A15.3 TUBERCULOSIS OF LUNG, 
CONFIRMED BY UNSPECIFIED MEANS 
A15.30 TUBERCULOSIS OF LUNG, 
CONFIRMED BY UNSPECIFIED MEANS, 
WITH CAVITATION 
A15.31 TUBERCULOSIS OF LUNG, 
CONFIRMED BY UNSPECIFIED MEANS, 
WITHOUT CAVITATION OR 
UNSPECIFIED 
A15.4 TUBERCULOSIS OF 
INTRATHORACIC LYMPH NODES, 
CONFIRMED BACTERIOLOGICALLY 
AND HISTOLOGICALLY 
A15.5 TUBERCULOSIS OF LARYNX, 
TRACHEA AND BRONCHUS 
CONFIRMED BACTERIOLOGICALLY 
AND HISTOLOGICALLY16.210 
A15.6 TUBERCULOUS PLEURISY, 
CONFIRMED BACTERIOLOGICALLY 
AND HISTOLOGICALLY 
A15.7 PRIMARY RESPIRATORY 
TUBERCULOSIS, CONFIRMED 
BACTERIOLOGICALLY AND 
HISTOLOGICALLY 
A15.8 OTHER RESPIRATORY 
TUBERCULOSIS, CONFIRMED 
BACTERIOLOGICALLY AND 
HISTOLOGICALLY 
A15.9 RESPIRATORY TUBERCULOSIS 
UNSPECIFIED, CONFIRMED 
BACTERIOLOGICALLY AND 
HISTOLOGICALLY 
A15.90 RESPIRATORY TUBERCULOSIS 
UNSPECIFIED, CONFIRMED 
BACTERIOLOGICALLY AND 
HISTOLOGICALLY WITH 
CAVITATION 
A15.91 RESPIRATORY TUBERCULOSIS 
UNSPECIFIED, CONFIRMED 
BACTERIOLOGICALLY AND 
HISTOLOGICALLY, WITHOUT 
CAVITATION OR UNSPECIFIED 
A16 RESPIRATORY TUBERCULOSIS, 
NOT CONFIRMED 
BACTERIOLOGICALLY OR 
HISTOLOGICALLY 
A16.0 TUBERCULOSIS OF LUNG, 
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015.2 KNEE 
015.7 OTHER BONE 
015.8 OTHER JOINT 
015.9 UNSPECIFIED 
016 TUBERCULOSIS OF 
GENITOURINARY SYSTEM 
016.0 KIDNEY 
016.1 BLADDER 
016.2 URETER 
016.3 OTHER URINARY 
ORGANS 
016.4 EPIDIDYMIS 
016.5 OTHER MALE GENITAL 
ORGANS 
016.6 TUBERCULOUS 
OOPHORITIS AND 
SALPINGITIS 
016.7 FEMALE GENITAL 
ORGANS 
016.9 UNSPECIFIED 
017 TUBERCULOSIS OF OTHER 
ORGANS 
017.0 SKIN AND 
SUBCUTANEOUS CELLULAR 
TISSUE 
017.1 ERYTHEMA NODOSUM 
WITH HYPERSENSITIVITY 
REACTION IN TUBERCULOSIS 
017.2 PERIPHERAL LYMPH 
NODES 
017.3 EYE 
017.4 EAR 
017.5 THYROID GLAND 
017.6 ADRENAL GLANDS 
017.7 SPLEEN 
017.8 ESOPHAGUS 
017.9OTHER 
018 MILIARY TUBERCULOSIS 
018.0 ACUTE 
018.8 OTHER 
018.9 UNSPECIFIED 
BACTERIOLOGICALLY AND 
HISTOLOGICALLY NEGATIVE 
A16.1 TUBERCULOSIS OF LUNG, 
BACTERIOLOGICAL AND 
HISTOLOGICAL EXAMINATION NOT 
DONE 
A16.10 TUBERCULOSIS OF LUNG, 
BACTERIOLOGICAL AND 
HISTOLOGICAL EXAMINATION NOT 
DONE, WITH CAVITATION 
A16.ll TUBERCULOSIS OF LUNG, 
BACTERIOLOGICAL AND 
HISTOLOGICAL EXAMINATION NOT 
DONE, WITHOUT 
CAVITATION OR UNSPECIFIED 
A16.2 TUBERCULOSIS OF LUNG, 
WITHOUT MENTION OF 
BACTERIOLOGICAL OR 
HISTOLOGICAL CONFIRMATION 
A16.20 TUBERCULOSIS OF LUNG, 
WITHOUT MENTION OF 
BACTERIOLOGICAL OR 
HISTOLOGICAL CONFIRMATION, 
WITH 
CAVITATION 
A16.21 TUBERCULOSIS OF LUNG, 
WITHOUT MENTION OF 
BACTERIOLOGICAL OR 
HISTOLOGICAL CONFIRMATION, 
WITHOUT 
CAVITATION OR UNSPECIFIED3 
A16.3 TUBERCULOSIS OF 
INTRATHORACIC LYMPH NODES, 
WITHOUT MENTION OF 
BACTERIOLOGICAL OR 
HISTOLOGICAL 
CONFIRMATION 
A16.4 TUBERCULOSIS OF LARYNX, 
TRACHEA AND BRONCHUS, WITHOUT 
MENTION OF BACTERIOLOGICAL OR 
HISTOLOGICAL CONFIRMATION 
A16.5 TUBERCULOUS PLEURISY, 
WITHOUT MENTION OF 
BACTERIOLOGICAL OR 
HISTOLOGICAL CONFIRMATION 
A16.7 PRIMARY RESPIRATORY 
TUBERCULOSIS WITHOUT MENTION 
OF BACTERIOLOGICAL OR 
HISTOLOGICAL 
CONFIRMATION 
A16.8 OTHER RESPIRATORY 
TUBERCULOSIS, WITHOUT MENTION 
OF BACTERIOLOGICAL OR 
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HISTOLOGICAL CONFIRMATION 
A16.9 RESPIRATORY TUBERCULOSIS 
UNSPECIFIED, WITHOUT MENTION OF 
BACTERIOLOGICAL OR 
HISTOLOGICAL 
CONFIRMATION 
A16.90 RESPIRATORY TUBERCULOSIS 
UNSPECIFIED, WITHOUT MENTION OF 
BACTERIOLOGICAL OR 
HISTOLOGICAL 
CONFIRMATION, WITH CAVITATION 
A16.91 RESPIRATORY TUBERCULOSIS 
UNSPECIFIED, WITHOUT MENTION OF 
BACTERIOLOGICAL OR 
HISTOLOGICAL 
CONFIRMATION, WITHOUT 
CAVITATION OR UNSPECIFIEDA18.3 
A17 TUBERCULOSIS OF NERVOUS 
SYSTEM 
A17.0 TUBERCULOUS MENINGITIS 
A17.1 MENINGEAL TUBERCULOMA 
A17.8 OTHER TUBERCULOSIS OF 
NERVOUS SYSTEM 
A17.9 TUBERCULOSIS OF NERVOUS 
SYSTEM, UNSPECIFIED 
A18 TUBERCULOSIS OF OTHER 
ORGANS 
A18.0 TUBERCULOSIS OF BONES AND 
JOINTS 
A18.1 TUBERCULOSIS OF 
GENITOURINARY SYSTEM 
A18.2 TUBERCULOUS PERIPHERAL 
LYMPHADENOPATHY 
A18.3 TUBERCULOSIS OF INTESTINES, 
PERITONEUM AND MESENTERIC 
LYMPH NODES8.4 
A18.4 TUBERCULOSIS OF SKIN AND 
SUBCUTANEOUS TISSUE 
A18.5 TUBERCULOSIS OF EYE 
A18.6 TUBERCULOSIS OF EAR 
A18.7 TUBERCULOSIS OF ADRENAL 
GLANDS 
A18.8 TUBERCULOSIS OF OTHER 
SPECIFIED ORGANS 
A19 MILIARY TUBERCULOSIS 
A19.0 ACUTE MILIARY TUBERCULOSIS 
OF A SINGLE SPECIFIED SITE 
A19.1 ACUTE MILIARY TUBERCULOSIS 
OF MULTIPLE SITES 
A19.2 ACUTE MILIARY 
TUBERCULOSIS, UNSPECIFIED 
A19.8 OTHER MILIARY TUBERCULOSIS 
A19.9 MILIARY TUBERCULOSIS, 
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UNSPECIFIED 
RUBELLA 056.0 WITH NEUROLOGICAL 
COMPLICATIONS 
056.00 WITH UNSPECIFIED 
NEUROLOGICAL 
COMPLICATION 
056.01 ENCEPHALOMYELITIS 
DUE TO RUBELLA 
056.09 OTHER 
056.7 WITH OTHER SPECIFIED 
COMPLICATIONS 
056.71 ARTHRITIS DUE 
TO RUBELLA 
056.79 OTHER 
056.8 WITH UNSPECIFIED 
COMPLICATIONS 
056.9 RUBELLA 
WITHOUT MENTION OF 
COMPLICATION 
TETANUS 037 TETANUS A34 OBSTETRICAL TETANUS 
A35 OTHER TETANUS 
Acute Conditions 
DENTAL CONDITIONS 521 DISEASES OF HARD 
TISSUES OF TEETH 
521.0 DENTAL CARIES 
521.00 DENTAL CARIES, 
UNSPECIFIED 
521.01 DENTAL CARIES 
LIMITED TO ENAMEL 
521.02 DENTAL CARIES 
EXTENDING INTO DENTINE 
521.03 DENTAL CARIES 
EXTENDING INTO PULP 
521.04 ARRESTED DENTAL 
CARIES 
521.05 ODONTOCLASIA 
521.06 DENTAL CARIES PIT 
AND FISSURE 
521.07 DENTAL CARIES OF 
SMOOTH SURFACE 
521.08 DENTAL CARIES OF 
ROOT SURFACE 
521.09 OTHER DENTAL CARIES 
521.1 EXCESSIVE ATTRITION 
521.10 EXCESSIVE ATTRITION, 
UNSPECIFIED 
521.11 EXCESSIVE ATTRITION, 
K02 DENTAL CARIES 
K02.0 CARIES LIMITED TO ENAMEL 
K02.1 CARIES OF DENTINE 
K02.2 CARIES OF CEMENTUM 
K02.3 ARRESTED DENTAL CARIES 
K02.4 ODONTOCLASIA 
K02.8 OTHER DENTAL CARIES 
K02.9 DENTAL CARIES, UNSPECIFIED 
K03 OTHER DISEASES OF HARD 
TISSUES OF TEETH 
K03.0 EXCESSIVE ATTRITION OF 
TEETH 
K03.1 ABRASION OF TEETH 
K03.2 EROSION OF TEETH 
K03.3 PATHOLOGICAL RESORPTION 
OF TEETH 
K03.4 HYPERCEMENTOSIS 
K03.5 ANKYLOSIS OF TEETH 
K03.6 DEPOSITS [ACCRETIONS] ON 
TEETH 
K03.7 POSTERUPTIVE COLOUR 
CHANGES OF DENTAL HARD TISSUES 
K03.8 OTHER SPECIFIED DISEASES OF 
HARD TISSUES OF TEETH 
K03.9 DISEASE OF HARD TISSUES OF 
TEETH, UNSPECIFIED 
B06 RUBELLA [GERMAN MEASLES] 
B06.0 RUBELLA WITH NEUROLOGICAL 
COMPLICATIONS 
B06.8 RUBELLA WITH OTHER 
COMPLICATIONS 
B06.9 RUBELLA WITHOUT 
COMPLICATION 
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LIMITED TO ENAMEL 
521.12 EXCESSIVE ATTRITION, 
EXTENDING INTO DENTINE 
521.13 EXCESSIVE ATTRITION, 
EXTENDING INTO PULP 
521.14 EXCESSIVE ATTRITION, 
LOCALIZED 
521.15 EXCESSIVE ATTRITION, 
GENERALIZED 
521.2 ABRASION 
521.20 ABRASION, UNSPECIFIE1 
521.21 ABRASION, LIMITED TO 
ENAMEL 
521.22 ABRASION, EXTENDING 
INTO DENTINE 
521.23 ABRASION, EXTENDING 
INTO PULP 
521.24 ABRASION, LOCALIZED 
521.25 ABRASION, GENERALIZI 
521.3 EROSION 
521.30 EROSION, UNSPECIFIED 
521.31 EROSION, LIMITED TO 
ENAMEL 
521.32 EROSION, EXTENDING IT 
DENTINE 
521.33 EROSION, EXTENDING IT 
PULP 
521.34 EROSION, LOCALIZED 
521.35 EROSION, GENERALIZE! 
521.4 PATHOLOGICAL 
RESORPTION 
521.40 PATHOLOGICAL 
RESORPTION, UNSPECIFIED 
521.41 PATHOLOGICAL 
RESORPTION, INTERNAL 
521.42 PATHOLOGICAL 
RESORPTION, EXTERNAL 
521.49 OTHER PATHOLOGICAL 
RESORPTION 
K04 DISEASES OF PULP AND 
PERIAPICAL TISSUES 
K04.0 PULPITIS 
K04.1 NECROSIS OF PULP 
K04.2 PULP DEGENERATION 
K04.3 ABNORMAL HARD TISSUE 
FORMATION IN PULP 
K04.4 ACUTE APICAL PERIODONTITIS 
OF PULPAL ORIGIN 
K04.5 CHRONIC APICAL 
PERIODONTITIS 
K04.6 PERIAPICAL ABSCESS WITH 
SINUS 
K04.7 PERIAPICAL ABSCESS WITHOUT 
SINUS 
K04.8 RADICULAR CYST 
K04.9 OTHER AND UNSPECIFIED 
DISEASES OF PULP AND PERIAPICAL 
TISSUES 
K05 GINGIVITIS AND PERIODONTAL 
DISEASES 
K05.0 ACUTE GINGIVITIS 
K05.1 CHRONIC GINGIVITIS5.2 
K05.2 ACUTE PERIODONTITIS 
K05.3 CHRONIC PERIODONTITIS 
K05.4 PERIODONTOSIS 
K05.5 OTHER PERIODONTAL DISEASES 
K05.6 PERIODONTAL DISEASE, 
UNSPECIFIED 
K06 OTHER DISORDERS OF GINGIVA 
AND EDENTULOUS ALVEOLAR RIDGE 
K06.0 GINGIVAL RECESSION 
K06.1 GINGIVAL ENLARGEMENT 
K06.2 GINGIVAL AND EDENTULOUS 
ALVEOLAR RIDGE LESIONS 
ASSOCIATED WITH TRAUMA 
K06.8 OTHER SPECIFIED DISORDERS 
OF GINGIVA AND EDENTULOUS 
ALVEOLAR RIDGE 
K06.9 DISORDER OF GINGIVA AND 
EDENTULOUS ALVEOLAR RIDGE, 
UNSPECIFIED7.6 
K08 OTHER DISORDERS OF TEETH 
AND SUPPORTING STRUCTURES 
K08.0 EXFOLIATION OF TEETH DUE TO 
SYSTEMIC CAUSES 
K08.1 LOSS OF TEETH DUE TO 
ACCIDENT, EXTRACTION OR LOCAL 
PERIODONTAL DISEASE 
K08.2 ATROPHY OF EDENTULOUS 
ALVEOLAR RIDGE 
K08.3 RETAINED DENTAL ROOT 
K08.8 OTHER SPECIFIED DISORDERS 
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521.5 HYPERCEMENTOSIS 
521.6 ANKYLOSIS OF TEETH 
521.7 POSTERUPTIVE COLOUR 
CHANGES 
521.8 OTHER DISEASES OF 
HARD TISSUES OF TEETH 
521.81 CRACKED TOOTH 
521.89 OTHER SPECIFIED 
DISEASES OF HARD TISSUES 
OF TEETH 
521.9 UNSPECIFIED 
522 DISEASES OF PULP AND 
PERIAPICAL TISSUES 
522.0 PULPITIS 
522.1 NECROSIS OF THE PULP 
522.2 PULP DEGENERATION 
522.3 ABNORMAL HARD 
TISSUE FORMATION IN PULP 
522.4 ACUTE APICAL 
PERIODONTITIS OF PULPAL 
ORIGIN 
522.5 PERIAPICAL ABSCESS 
WITHOUT SINUS 
522.6 CHRONIC APICAL 
PERIODONTITIS 
522.7 PERIAPICAL ABSCESS 
WITH SINUS 
522.8 RADICULAR CYST 
522.9 OTHER AND 
UNSPECIFIED 
523 GINGIVAL AND 
PERIODONTAL DISEASES 
523.0 ACUTE GINGIVITIS 
523.00 ACUTE GINGIVITIS, 
PLAQUE INDUCED 
523.01 ACUTE GINGIVITIS, 
NON-PLAQUE INDUCED 
523.1 CHRONIC GINGIVITIS 
523.10 CHRONIC GINGIVITIS, 
PLAQUE INDUCED 
523.11 CHRONIC GINGIVITIS, 
NON-PLAQUE INDUCED 
523.2 GINGIVAL RECESSION 
523.20 GINGIVAL RECESSION, 
UNSPECIFIED 
523.21 GINGIVAL RECESSION, 
MINIMAL 
523.22 GINGIVAL RECESSION, 
MODERATE 
OF TEETH AND SUPPORTING 
STRUCTURES 
K08.80 MAXILLARY ALVEOLAR RIDGE 
HYPERPLASIA 
K08.81 MANDIBULAR ALVEOLAR 
RIDGE HYPERPLASIA 
K08.82 MAXILLARY ALVEOLAR RIDGE 
HYPOPLASIA10.1 
K08.83 MANDIBULAR ALVEOLAR 
RIDGE HYPOPLASIA 
K08.87 TOOTHACHE NOS 
K08.88 OTHER SPECIFIED DISORDERS 
OF TEETH AND SUPPORTING 
STRUCTURES 
K08.9 DISORDER OF TEETH AND 
SUPPORTING STRUCTURES, 
UNSPECIFIED 
K09.8 OTHER CYSTS OF ORAL REGION, 
NOT ELSEWHERE CLASSIFIED 
K09.9 CYST OF ORAL REGION, 
UNSPECIFIED 
K12 STOMATITIS AND RELATED 
LESIONS 
K12.0 RECURRENT ORAL APHTHAE 
K12.1 OTHER FORMS OF STOMATITIS 
K12.2 CELLULITIS AND ABSCESS OF 
MOUTH 
K12.3 ORAL MUCOSITIS (ULCERATIVE) 
K13 OTHER DISEASES OF LIP AND 
ORAL MUCOSA 
K13.0 DISEASES OF LIPS 
K13.1 CHEEK AND LIP BITING 
K13.2 LEUKOPLAKIA AND OTHER 
DISTURBANCES OF ORAL 
EPITHELIUM, INCLUDING TONGUE 
K13.3 HAIRY LEUKOPLAKIA 
K13.4 GRANULOMA AND 
GRANULOMA-LIKE LESIONS OF ORAL 
MUCOSA 
K13.5 ORAL SUBMUCOUS FIBROSIS 
K13.6 IRRITATIVE HYPERPLASIA OF 
ORAL MUCOSA 
K13.7 OTHER AND UNSPECIFIED 
LESIONS OF ORAL MUCOSA 
523.23 GINGIVAL RECESSION, 
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SEVERE 
523.24 GINGIVAL RECESSION, 
LOCALIZED 
523.25 GINGIVAL RECESSION, 
GENERALIZED 
523.3 ACUTE PERIODONTITIS 
523.30 AGGRESSIVE 
PERIODONTITIS, UNSPECIFIED 
523.31 AGGRESSIVE 
PERIODONTITIS, LOCALIZED 
523.32 AGGRESSIVE 
PERIODONTITIS, GENERALIZEI 
523.33 ACUTE PERIODONTITIS 
523.4 CHRONIC 
PERIODONTITIS 
523.40 CHRONIC PERIODONTIT 
UNSPECIFIED 
523.41 CHRONIC PERIODONTIT 
LOCALIZED 
523.42 CHRONIC PERIODONTIT 
GENERALIZED 
523.5 PERIODONTOSIS 
523.6 ACCRETIONS ON TEETH 
523.8 OTHER PERIODONTAL 
DISEASES 
523.9 UNSPECIFIED 
525 OTHER DISEASES AND 
CONDITIONS OF THE TEETH 
AND SUPPORTING 
STRUCTURES 
525.0 EXFOLIATION OF TEETH 
DUE TO SYSTEMIC CAUSES 
525.1 LOSS OF TEETH DUE TO 
ACCIDENT, EXTRACTION OR 
LOCAL PERIODONTAL 
DISEASE 
525.10 ACQUIRED ABSENCE 
OF TEETH, UNSPECIFIED 
525.11 LOSS OF TEETH DUE TO 
TRAUMA 
525.12 LOSS OF TEETH DUE TO 
PERIODONTAL DISEASE 
525.13 LOSS OF TEETH DUE TO 
CARIES 
525.19 OTHER LOSS OF TEETH 
525.2 ATROPHY OF 
EDENTULOUS ALVEOLAR 
RIDGE 
525.20 UNSPECIFIED ATROPHY 
OF EDENTULOUS ALVEOLAR 
RIDGE 
525.21 MINIMAL ATROPHY OF r 
MANDIBLE 
525.22 MODERATE ATROPHY O 
THE MANDIBLE 
525.23 SEVERE ATROPHY OF TI 
MANDIBLE 
525.24 MINIMAL ATROPHY OF : 
MAXILLA 
525.25 MODERATE ATROPHY O 
THE MAXILLA 
525.26 SEVERE ATROPHY OF TI 
MAXILLA 
525.3 RETAINED DENTAL 
ROOT 
525.4 COMPLETE EDENTULISM 
525.40 COMPLETE 
EDENTULISM, UNSPECIFIED 
525.41 COMPLETE EDENTULISM 
CLASS I 
525.42 COMPLETE EDENTULISM 
CLASS II 
525.43 COMPLETE EDENTULISM 
CLASS III 
525.44 COMPLETE EDENTULISM 
CLASS IV 
525.5 PARTIAL EDENTULISM 
525.50 PARTIAL EDENTULISM, 
UNSPECIFIED 
525.51 PARTIAL EDENTULISM, 
CLASS I 
525.52 PARTIAL EDENTULISM, 
CLASS II 
525.53 PARTIAL EDENTULISM, 
CLASS III 
525.54 PARTIAL EDENTULISM, 
CLASS IV 
525.6 UNSATISFACTORY 
RESTORATION OF TOOTH 
525.60 UNSPECIFIED 
UNSATISFACTORY RESTORATION 
OF TOOTH 
525.61 OPEN RESTORATION 
MARGINS 
525.62 UNREPAIRABLE 
OVERHANGING OF DENTAL 
RESTORATIVE MATERIALS 
525.63 FRACTURED DENTAL 
RESTORATIVE MATERIAL 
WITHOUT LOSS OF MATERIAL 
525.64 FRACTURED DENTAL 
RESTORATIVE MATERIAL WITH 
LOSS OF MATERIAL 
525.65 CONTOUR OF EXISTING 
RESTORATION OF TOOTH 
BIOLOGICALLY INCOMPATIBLE 
WITH ORAL HEALTH 
525.66 ALLERGY TO EXISTING 
DENTAL RESTORATIVE 
MATERIAL 
525.67 POOR AESTHETICS OF 
EXISTING RESTORATION 
525.69 OTHER UNSATISFACTORY 
RESTORATION OF EXISTING 
TOOTH 
525.7 ENDOSSEOUS DENTAL 
IMPLANT FAILURE 
525.71 OSSEOINTEGRATION 
FAILURE OF DENTAL IMPLANT 
525.72 POST-OSSEOINTEGRATION 
BIOLOGICAL FAILURE OF DENTAL 
IMPLANT 
525.73 POST-OSSEOINTEGRATION 
MECHANICAL FAILURE OF 
DENTAL IMPLANT 
525.79 OTHER ENDOSSEOUS 
DENTAL IMPLANT FAILURE 
525.8 OTHER 
525.9 UNSPECIFIED 
528 DISEASES OF THE ORAL 
SOFT TISSUES, EXCLUDING 
LESIONS SPECIFIC FOR 
GINGIVA AND TONGUE 
528.0 STOMATITIS 
528.00 STOMATITIS AND 
MUCOSITIS, UNSPECIFIED 
528.01 MUCOSITIS 
(ULCERATIVE) DUE TO 
ANTINEOPLASTIC THERAPY 
528.02 MUCOSITIS 
(ULCERATIVE) DUE TO OTHER 
DRUGS 
528.09 OTHER STOMATITIS 
AND MUCOSITIS 
(ULCERATIVE) 
528.1 CANCRUM ORIS 
528.2 ORAL APHTHAE 
528.3 CELLULITIS AND 
ABSCESS 
528.4 CYSTS 
528.5 DISEASES OF LIPS 
528.6 LEUKOPLAKIA OF ORAL 
MUCOSA, INCLUDING 
TONGUE 
528.7 OTHER DISTURBANCES 
OF ORAL EPITHELIUM, 
INCLUDING TONGUE 
528.71 MINIMAL KERATINIZED 
RESIDUAL RIDGE MUCOSA 
528.72 EXCESSIVE 
KERATINIZED RESIDUAL 
RIDGE MUCOSA 
528.79 OTHER DISTURBANCES 
OF ORAL EPITHELIUM, 
INCLUDING TONGUE 
528.8 ORAL SUBMUCOUS 
FIBROSIS, INCLUDING OF 
TONGUE 
528.9 OTHER AND 
UNSPECIFIED 
L03 CELLULITIS 
L03.0 CELLULITIS OF FINGER AND TOE 
L03.00 CELLULITIS OF FINGER 
L03.01 CELLULITIS OF TOE 
L03.1 CELLULITIS OF OTHER PARTS OF 
LIMB 
L03.10 CELLULITIS OF UPPER 
LIMBL03.11O 
L03.ll CELLULITIS OF LOWER LIMB 
L03.2 CELLULITIS OF FACE 
L03.3 CELLULITIS OF TRUNK 
L03.30 CELLULITIS OF CHEST WALL 
L03.31 CELLULITIS OF ABDOMINAL 
WALL 
L03.32 CELLULITIS OF UMBILICUS 
L03.33 CELLULITIS OF GROIN 
L03.34 CELLULITIS OF BACK [ANY 
PART EXCEPT BUTTOCK] 
L03.35 CELLULITIS OF BUTTOCK 
L03.36 CELLULITIS OF PERINEUM 
L03.39 CELLULITIS OF TRUNK, 
UNSPECIFIED 
L03.8 CELLULITIS OF OTHER SITES 
L03.9 CELLULITIS, UNSPECIFIED 
L04 ACUTE LYMPHADENITIS 
CELLULITIS 681 CELLULITIS AND ABSCESS 
OF FINGER AND TOE 
681.0 FINGER 
681.00 CELLULITIS AND 
ABSCESS, UNSPECIFIED 
681.01 FELON 
681.02 ONYCHIA AND 
PARONYCHIA OF FINGER 
681.1 TOE 
681.10 CELLULITIS AND 
ABSCESS, UNSPECIFIED 
681.11 ONYCHIA AND 
PARONYCHIA OF TOE 
681.9 CELLULITIS AND 
ABSCESS OF UNSPECIFIED 
DIGIT 
682 OTHER CELLULITIS AND 
ABSCESS 
682.0 FACE 
682.1 NECK 
682.2 TRUNK 
682.3 UPPER ARM AND 
FOREARM 
682.4 HAND, EXCEPT FINGERS 
682.5 BUTTOCK 
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682.6 LEG, EXCEPT FOOT 
682.7 FOOT, EXCEPT TOES 
682.8 OTHER SPECIFIED SITE 
682.9 UNSPECIFIED SITE 
683 ACUTE LYMPHADENITIS 
686 OTHER LOCAL 
INFECTIONS OF SKIN AND 
SUBCUTANEOUS TISSUE 
686.0 PYODERMA 
686.00 PYODERMA, 
UNSPECIFIED 
686.01 PYODERMA 
GANGRENOSUM 
686.09 OTHER PYODERMA 
686.1 PYOGENIC GRANULOMA 
686.8 OTHER LOCAL 
INFECTIONS OF SKIN AND 
SUBCUTANEOUS TISSUE 
686.9 UNSPECIFIED LOCAL 
INFECTIONS OF SKIN AND 
SUBCUTANEOUS TISSUE 
L04.0 ACUTE LYMPHADENITIS OF 
FACE, HEAD AND NECK 
L04.1 ACUTE LYMPHADENITIS OF 
TRUNK 
L04.2 ACUTE LYMPHADENITIS OF 
UPPER LIMB 
L04.3 ACUTE LYMPHADENITIS OF 
LOWER LIMB 
L04.8 ACUTE LYMPHADENITIS OF 
OTHER SITES 
L04.9 ACUTE LYMPHADENITIS, 
UNSPECIFIED 
L08 OTHER LOCAL INFECTIONS OF 
SKIN AND SUBCUTANEOUS TISSUE 
L08.0 PYODERMA 
L08.1 ERYTHRASMA 
L08.8 OTHER SPECIFIED LOCAL 
INFECTIONS OF SKIN AND 
SUBCUTANEOUS TISSUE 
L08.9 LOCAL INFECTION OF SKIN AND 
SUBCUTANEOUS TISSUE, 
UNSPECIFIED 
L44.4 INFANTILE PAPULAR 
ACRODERMATITIS [GIANNOTTI-
CROSTI] 
L88 PYODERMA GANGRENOSUM 
L92.2 GRANULOMA FACIALE 
[EOSINOPHILIC GRANULOMA OF 
SKIN] 
L98.0 PYOGENIC GRANULOMA 
L98.3 EOSINOPHILIC CELLULITIS 
[WELLS] 
PELVIC 
INFLAMMATORY 
DISEASE 
614 INFLAMMATORY DISEASE 
OF OVARY, FALLOPIAN TUBE, 
PELVIC CELLULAR TISSUE 
AND PERITONEUM 
614.0 ACUTE SALPINGITIS 
AND OOPHORITIS 
614.1 CHRONIC SALPINGITIS 
AND OOPHORITIS 
614.2 SALPINGITIS AND 
OOPHORITIS, NOT SPECIFIED 
AS ACUTE, SUBACUTE OR 
CHRONIC 
614.3 ACUTE PARAMETRITIS 
AND PELVIC CELLULITIS 
614.4 CHRONIC OR 
UNSPECIFIED PARAMETRITIS 
AND PELVIC CELLULITIS 
614.5 ACUTE OR UNSPECIFIED 
PELVIC PERITONITIS, FEMALE 
614.6 PELVIC PERITONEAL 
ADHESIONS, FEMALE 
N70 SALPINGITIS AND OOPHORITIS 
N70.0 ACUTE SALPINGITIS AND 
OOPHORITIS 
N70.1 CHRONIC SALPINGITIS AND 
OOPHORITIS 
N70.9 SALPINGITIS AND OOPHORITIS, 
UNSPECIFIED 
N73 OTHER FEMALE PELVIC 
INFLAMMATORY DISEASES 
N73.0 ACUTE PARAMETRITIS AND 
PELVIC CELLULITIS 
N73.1 CHRONIC PARAMETRITIS AND 
PELVIC CELLULITIS 
N73.2 UNSPECIFIED PARAMETRITIS 
AND PELVIC CELLULITIS 
N73.3 FEMALE ACUTE PELVIC 
PERITONITIS 
N73.4 FEMALE CHRONIC PELVIC 
PERITONITIS 
N73.5 FEMALE PELVIC PERITONITIS, 
UNSPECIFIED 
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614.7 OTHER CHRONIC PELVIC 
PERITONITIS, FEMALE 
614.8 OTHER SPECIFIED 
INFLAMMATORY DISEASE OF 
FEMALE PELVIC ORGANS 
AND TISSUES 
614.9 UNSPECIFIED 
INFLAMMATORY DISEASE OF 
FEMALE PELVIC ORGANS 
AND TISSUES 
N73.6 FEMALE PELVIC PERITONEAL 
ADHESIONS 
N73.8 OTHER SPECIFIED FEMALE 
PELVIC INFLAMMATORY DISEASES 
N73.9 FEMALE PELVIC 
INFLAMMATORY DISEASE, 
UNSPECIFIED 
N99.4 POSTPROCEDURAL PELVIC 
PERITONEAL ADHESIONS 
SEVERE EAR, NOSE 
AND THROAT (ENT) 
INFECTIONS 
382 SUPPURATIVE AND 
UNSPECIFIED OTITIS MEDIA 
382.0 ACUTE SUPPURATIVE 
OTITIS MEDIA 
382.00 ACUTE SUPPURATIVE 
OTITIS MEDIA WITHOUT 
SPONTANEOUS RUPTURE OF 
EAR DRUM 
382.01 ACUTE SUPPURATIVE 
OTITIS MEDIA WITH 
SPONTANEOUS RUPTURE OF 
EAR DRUM 
382.02 ACUTE SUPPURATIVE 
OTITIS MEDIA IN DISEASES 
CLASSIFIED ELSEWHERE 
382.1 CHRONIC 
TUBOTYMPANIC 
SUPPURATIVE OTITIS MEDIA 
382.2 CHRONIC 
ATTICOANTRAL 
SUPPURATIVE OTITIS MEDIA 
382.3 UNSPECIFIED CHRONIC 
SUPPURATIVE OTITIS MEDIA 
382.4 UNSPECIFIED 
SUPPURATIVE OTITIS MEDIA 
382.9 UNSPECIFIED OTITIS 
MEDIA 
462 ACUTE PHARYNGITIS 
463 ACUTE TONSILLITIS 
465 ACUTE UPPER 
RESPIRATORY INFECTIONS OF 
MULTIPLE OR UNSPECIFIED 
SITE 
465.0 ACUTE 
LARYNGOPHARYNGITIS 
465.8 OTHER MULTIPLE SITES 
465.9 UNSPECIFIED SITE 
472.1 CHRONIC PHARYNGITIS 
H66 SUPPURATIVE AND UNSPECIFIED 
OTITIS MEDIA 
H66.0 ACUTE SUPPURATIVE OTITIS 
MEDIA 
H66.1 CHRONIC TUBOTYMPANIC 
SUPPURATIVE OTITIS MEDIA 
H66.2 CHRONIC ATTICOANTRAL 
SUPPURATIVE OTITIS MEDIA 
H66.3 OTHER CHRONIC SUPPURATIVE 
OTITIS MEDIA 
H66.4 SUPPURATIVE OTITIS MEDIA, 
UNSPECIFIED 
H66.9 OTITIS MEDIA, UNSPECIFIED 
H67 OTITIS MEDIA IN DISEASES 
CLASSIFIED ELSEWHERE 
H67.0 OTITIS MEDIA IN BACTERIAL 
DISEASES CLASSIFIED ELSEWHERE 
H67.1 OTITIS MEDIA IN VIRAL 
DISEASES CLASSIFIED ELSEWHERE 
H67.8 OTITIS MEDIA IN OTHER 
DISEASES CLASSIFIED ELSEWHERE 
J02 ACUTE PHARYNGITIS 
J02.0 STREPTOCOCCAL PHARYNGITIS 
J02.8 ACUTE PHARYNGITIS DUE TO 
OTHER SPECIFIED ORGANISMS 
J02.9 ACUTE PHARYNGITIS, 
UNSPECIFIED 
J03 ACUTE TONSILLITIS 
J03.0 STREPTOCOCCAL TONSILLITIS 
J03.8 ACUTE TONSILLITIS DUE TO 
OTHER SPECIFIED ORGANISMS 
J03.9 ACUTE TONSILLITIS, 
UNSPECIFIED 
J06 ACUTE UPPER RESPIRATORY 
INFECTIONS OF MULTIPLE AND 
UNSPECIFIED SITES 
J06.0 ACUTE LARYNGOPHARYNGITIS 
J06.8 OTHER ACUTE UPPER 
RESPIRATORY INFECTIONS OF 
MULTIPLE SITES 
J06.9 ACUTE UPPER RESPIRATORY 
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GASTROENTERITIS & 
DEHYDRATION 
558.9 OTHER AND 
UNSPECIFIED 
NONINFECTIOUS 
GASTROENTERITIS AND 
COLITIS 
276.5 VOLUME DEPLETION 
276.50 VOLUME DEPLETION, 
UNSPECIFIED 
276.51 DEHYDRATION 
276.52 HYPOVOLEMIA 
INFECTION, UNSPECIFIED 
J31.2 CHRONIC PHARYNGITIS 
K52.2 ALLERGIC AND DIETETIC 
GASTROENTERITIS AND COLITIS 
K52.8 OTHER SPECIFIED 
NONINFECTIVE GASTROENTERITIS 
AND COLITIS 
K52.9 NONINFECTrVE 
GASTROENTERITIS AND COLITIS, 
UNSPECIFIED 
E86 VOLUME DEPLETION 
E86.0 DEHYDRATION 
E86.8 OTHER VOLUME DEPLETION 
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Appendix B: APP and FFS Communities, and Flags 
Alternative Payment Plan (APP) Communities 
McBride 
Dunster 
Fraser Lake 
Valemount 
Robson 
Haida Gwaii (Queen Charlotte) 
Sandspit 
Stewart 
Fee for Service (FFS) Communities 
Prince Rupert 
Tumbler Ridge 
Smithers 
Telkwa 
3. Other 
Postal Codes NOT listed above 
Postal Codes 
VOJ 2E0 
VOJ 1J0 
VOJ ISO 
VOE 2Z0 
VOG 1X0 
VOT ISO, VOT 1S1; 
VOT 1T0 
VOT 1W0 
Postal Codes 
V8J0A1-V8J4S4 
VOC 2W0 
VOJ 2N0 - VOJ 2N7 
VOJ 2X0 - VOJ 2X3 
Flag 
APP 
APP 
APP 
APP 
APP 
APP 
APP 
APP 
Flag 
FFS 
FFS 
FFS 
FFS 
Flag 
N/A 
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